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Abstract
Impairment in cognitive functioning is a core component of opioid dependence
due to its importance in the course of addiction and its role in treatment, but the effect of
opioid use on cognition in individuals undergoing early stages of treatment is under
examined, particularly in the Australian population. Although existing pharmacological
options have demonstrated some efficacy in treating opioid dependence, they are limited
in their ability to treat the cognitive dysfunction present in opioid dependent individuals.
Hence, there is a need for novel treatment options that address these limitations. The
commensal gut microbiota can engage in bidirectional communication with the brain
and thus influence brain function, including cognition. Dysbiosis of the microbiota has
been reported in several areas of addiction and concomitant cognitive impairment, and
may serve as a target for potential future novel treatments. The effect of opioid use on
the gut microbiota is inconclusive, however. The present thesis aimed to: a) investigate
cognition in individuals with a history of chronic opioid use during the early stages of
rehabilitation treatment in an Australian setting; b) examine the effect of opioid use on
the gut microbiota, and; c) outline the functional potential of the gut microbiota in
opioid use and how it may relate to key signalling pathways of the microbiota-gut-brain
axis. In Chapter 2, Australian participants at early stages of community-based
rehabilitative treatment (including treatment with methadone or buprenorphinenaloxone, BNX) underwent neurocognitive testing. Results demonstrated impaired
cognitive functioning compared to the general population, but no significant differences
between performance in BNX compared to methadone-treated participants. BNX
treatment was associated with a longer length of stay, which could indicate greater
treatment adherence. The potential influence of treatment and non-treatment related
parameters were also examined. Treatment related factors (e.g., time since last dose,
ii

life-time length of treatment) had a significant relationship with cognitive performance
in BNX-treated participants, but not methadone treated participants. Neurocognitive
performance was also significantly influenced by non-treatment related demographics
factors, such as age and BMI. Together, these findings demonstrate cognitive
impairment in people undergoing residential rehabilitation for opioid addiction and
highlight treatment and demographics parameters that could potentially influence
cognitive outcomes and should be considered in future studies.
In Chapter 3, a systematic literature review was conducted to investigate the
effect of opioids on the gut microbiota. Results demonstrated that opioid use resulted in
dysbiosis of the gut microbiota, and identified specific microbes that were repeatedly
dysbiotic across clinical and preclinical studies for the first time. Opioid use also
resulted in alterations to key signalling pathways of the microbiota-gut-brain axis,
suggesting the potential for opioid induced dysbiosis of the gut microbiota to influence
cognition. These results may have significant implications for future research aiming to
better understand the pathology of opioid dependence, and may inform the development
of future novel treatments that improve the lives of people with opioid dependence.
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Chapter 1

1.1

Introduction

1.1.1

Overview of Opioid Use
Chronic opioid use, including Opioid Use Disorder and Opioid Misuse, is a potentially

fatal practice that is occurring at epidemic levels, and as such is an issue requiring greater
attention and understanding. Opioid use disorder (OUD) is a Diagnostic and Statistical Manual
(DSM)-5 substance use disorder (SUD) characterized by chronic, relapsing use of drugs such
as morphine, hydrocodone and fentanyl, in spite of the severe negative cognitive, physical,
social and economic consequences they may incur. OUD is a spectrum SUD (Strang et al.,
2020), the severity of which depends on the number of criteria (Table 1) that an individual
presents with, with diagnoses ranging from mild (2-3), moderate (4-5), to severe (6-7). Apart
from the DSM-5, the DSM-IV and ICD-10 can used to diagnose opioid addiction. Unlike the
DSM-5, the DSM-IV considers opioid abuse and dependence to be two distinct disorders (Peer
et al., 2013). Similarly, the ICD-10 also considers abuse and dependence to be two separate
disorders (Strang et al., 2020), though it uses many of the same diagnostic criteria (Table 1.1).
Opioid misuse is the administration of prescribed opioid medications (such as codeine) not in
line with prescriber direction, such as using higher doses than is recommended or more
frequently than directed (Tetrault and Butner, 2015). Chronic opioid use commonly involves
opiates and opioids. Opiates refer to substances of natural origin derived from the poppy plant,
such as morphine. Opioids refer to substances that act on opioid receptors in the body more
broadly, and can include semi-synthetic compounds such as hydrocodone, and synthetic
compounds such as fentanyl and heroin (Strang et al., 2020). While technically incorrect, the
two terms will be used interchangeably for the remainder of this thesis.
1

Table 1.1 Diagnostic criteria for chronic opioid use, including DSM-IV and DSM-5
criteria for Opioid Use Disorder and ICD-10 criteria for Opioid Dependence
DSM-IV
Persistent use despite negative
health consequences
Failure to meet work, school or
social obligations due to opioid
use
Persistent use of opioids despite
recurring social issues resulting
from or exacerbated by effects of
opioids

DSM-5
Persistent use despite negative
health consequences
Failure to meet work, school or
social obligations due to opioid
use
Persistent use of opioids despite
recurring social issues resulting
from or exacerbated by effects of
opioids
Craving for opioids

Taken in larger amounts or for
longer than intended

Taken in larger amounts or for
longer than intended

Persistent, but unsuccessful desire
to reduce or control use

Persistent, but unsuccessful desire
to reduce or control use

Spending large amounts of time
trying to obtain, use, or recover
from use
Reduced or failure to uphold
social, work, or recreational
activities due to use
Continued use despite awareness
of physical or psychological issues
onset from or exacerbated by drug
Tolerance defined as either, a)
diminished effects with continued
use of same dose or, b) need for
higher doses to achieve
intoxication or desired effect
Withdrawal upon cessation of use,
evidenced by either, a)
characteristic withdrawal
syndrome, or b) use of opioids for
purpose of relieving or avoiding
withdrawal

Spending large amounts of time
trying to obtain, use, or recover
from use
Reduced or failure to uphold
social, work, or recreational
activities due to use
Continued use despite awareness
of physical or psychological issues
onset from or exacerbated by drug
Tolerance defined as either, a)
diminished effects with continued
use of same dose or, b) need for
higher doses to achieve
intoxication or desired effect
Withdrawal upon cessation of use,
evidenced by either, a)
characteristic withdrawal
syndrome, or b) use of opioids for
purpose of relieving or avoiding
withdrawal

ICD-10
Strong desire to use opioids
Difficulty controlling use of
opioids
Development of tolerance (i.e.,
higher doses are needed to achieve
desired effects
Persistent use despite negative
consequences (i.e. impaired
cognition
Neglecting other interests to spend
greater time pursuing opioids or
recover from their impact
Withdrawal upon cessation of use,
evidenced by either, a)
characteristic withdrawal
syndrome, or b) use of opioids for
purpose of relieving or avoiding
withdrawal

Notes: Diagnostic and Statistical Manual (DSM) IV allows for diagnosis of abuse or dependence, whereas DSM-5 only
diagnoses OUD. DSM-IV criteria for abuse include the first three criteria as well as substance-related legal issues (not
listed). Dependence involves meeting three or more italicised symptoms in a concurrent 12-month period. DSM-5 added the
criteria of craving and severity of OUD, not included in DSM-IV.

The prevalence of harmful opioid use is immense and is on the rise. OUD is occurring
at an epidemic level with an estimated 40.5 million individuals presenting with the disorder
globally in 2017 (Degenhardt et al., 2019, James et al., 2018), and an estimated 2 million adults
2

qualifying for a DSM-IV diagnosis of OUD in the United States alone (Han et al., 2017). In
addition to this, an increasing rate of mortality has been linked to these drugs, rising 292%
from 2001 to 2016 in the United States (Gomes et al., 2018). Globally, opioids contributed to
approximately one-third of drug related deaths in 2015 (Nolan, Socias and Wood, 2018), with
approximately 40 000 deaths related to opioids and 24 000 deaths related to heroin or synthetic
opioids (Ruhm, 2018). Prescription opioids serve a unique problem as, whilst they are a vital
option for pain management, they are often misused (used in higher doses or for longer than
directed), and are a risk factor for the development of a full OUD (Brummett et al., 2017,
Cicero and Ellis, 2017, Deyo et al., 2017). While cases are more concentrated in the US, there
is a need for further investigation into Australian cohorts.

Misuse of opioids is exceedingly high, with an estimated 11.5 million U.S. adults
reporting misuse of prescription opioids in 2015 (Han et al., 2017). Use of hydrocodone and
oxycodone, commonly prescribed pain management drugs, has increased two- and five-fold
respectively over the last fifteen years (Kolodny et al., 2015). Several other comorbidities often
result from harmful opioid use including: increased risk of infection with blood borne diseases
such as Human Immunodeficiency Virus (HIV) and Hepatitis C (HCV); development of other
comorbid diseases (Strang et al., 2020); progression to use of stronger opioids such as heroin
and riskier drug use practises (Cicero and Ellis, 2017, Strang et al., 2020); greater risk of
involvement in the criminal justice system (Pryor, Boman and Hemez, 2021), and an increased
risk of mortality. Additionally, the societal costs of OUD and misuse are immense, with
approximately a trillion dollars lost through the health care system, criminal justice system and
lost work hours in the United States alone (Florence, Luo and Rice, 2021). Hence, misuse of
opioids is occurring at an epidemic rate, in part due to increasing use of synthetic and
prescription opioids, leading to severe health, social and economic consequences.
3

1.1.2

Opioid Use and Cognition

While definitions vary, cognition most commonly refers to the processes involved in the
acquisition, processing, storage and retrieval of information (Lyon et al., 2021). More recently,
Lyon (2020) put forward a new definition, suggesting cognition can be referred to as “…the
sensory and other information-processing-mechanisms an organism has for becoming familiar
with, valuing, and interacting productively with features of its environment […] in order to
meet existential needs…”. Cognitive processes are classified by domains (Harvey, 2019) and
are usually defined by the processes involved. These domains are hierarchical in nature; more
general domains, such as attention, contain subdomains, such as selective attention (Table 1.2).
Domains are not independent as processes in some domains may rely on the functioning of
others. Performance in these domains is assessed through the use of neurocognitive tests.
Poorer performance in these tests reflects impairments in cognition, and is frequently reported
in patients engaging in chronic use of substances such as opioids (discussed in detail below).
For example, Darke et al. (2012) reported poorer performance in tests measuring the domains
of executive function, processing speed, verbal learning and non-verbal learning in patients
engaging in either methadone and buprenorphine use compared to healthy controls not using
opioids. Mechanisms by which these impairments may occur are also discussed below.
Addiction is also conceptualised as a form of maladaptive learning, suggesting even a role for
intact processes in the development and maintenance of addiction (Belin et al., 2013, Gould,
2010, Milton and Everitt, 2012). The effect of medications for opioid treatment on cognitive
performance remains is the subject of much contemporary research; however, it is unclear
whether treatment improves or further impairs cognition.

4

Table 1.2 A brief list of general cognitive domains and their subdomains, as well as some
neurocognitive tests used to assess performance in those domains
General Cognitive
Domain
Executive Function
Processing Speed
Motor Skills
Attention
Memory

Subdomain
Reasoning and problem
solving
Coding and tracking
Drawing
Copying
Selective attention
Vigilance
Working memory
Episodic/Declarative

Language and Verbal
Skills

Further
Subdomains

Verbal
Non-verbal
Verbal
Non-verbal

Naming and fluency

Example Neurocognitive Tests
used for Assessment
WCTS, NAB-Mazes
TMT-A and B, BACS-Symbol
Coding
MCoA-Clock Drawing
BVMT-R
Dual processing
CPT
LNS
WMS III-SS
HVLT-R
CF-Animal Naming

Notes: This is not an exhaustive list, and there is much debate over the categorisation and classification of the various
cognitive domains. For example, reasoning and problem solving are considered two distinct subdomains by (Harvey, 2019),
but are assessed as one domain by the MATRICS Consensus Cognitive Battery. This table was adapted from HARVEY, P.
D. 2019. Domains of cognition and their assessment. Dialogues in Clinical Neuroscience, 21, 227-237.

1.1.3

Existing Treatments for OUD and their Limitations
While the existing treatment options of OUD have some efficacy, medication options

have several clinically significant limitations (Table 1.3). Pharmacological treatments for
opioid addiction include methadone, buprenorphine, buprenorphine-naloxone (BNX, a mixture
of buprenorphine and the µ-opioid receptor antagonist naloxone) and naltrexone (Volkow and
Blanco, 2020). Although there are three types of opioid receptors (µ, δ, and κ), literature
suggests that µ-opioid receptors have the greatest involvement in OUD and addiction (Fields
and Margolis, 2015), and as such, are the primary target for medication assisted therapies.
Methadone is a full µ-opioid-receptor (µ-OR) agonist with an extended
pharmacodynamic profile. Treatment with methadone can control withdrawal symptoms and
its long-lasting effects are able to reduce craving and diminish the rewarding effects of illicit
opioids (Lobmaier et al., 2010). While methadone has the highest efficacy out of all available
treatment options, treatment programmes using methadone have high rates of drop out and

5

Table 1.3 Summary of existing treatment options for opioid addiction, their receptors
and their limitations
Overview

Limitations

Methadone
µ-OR agonist

Buprenorphine
Partial µ-OR
agonist, full κ-OR
antagonist

BNX
Sublingual mixture
of buprenorphine
and naloxone

Abuse
potential, may
cause neonatal
abstinence
syndrome

Can precipitate
withdrawal,
efficacy is dose
dependent

Potentially harmful
during pregnancy,
lower treatment
adherence
compared to other
treatments

Naloxone
µ-OR
antagonist
IV
injection,
IM
injection
Can
precipitate
withdrawal

Naltrexone
µ-OR antagonist

High dropout
especially in
early treatment
periods, can
precipitate
withdrawal

relapse, especially within the first twelve months of treatment (Salsitz and Wiegand, 2016,
Nosyk et al., 2010, Cao et al., 2014). Risk factors for early methadone treatment dropout
include inadequate dosing and prior treatment dropout (Durand et al., 2021). Buprenorphine is
a partial µ-OR agonist and κ-opioid receptor (κ-OR) antagonist. While higher doses are needed
to match the efficacy of methadone, it is safer to administer during overdose due to its reduced
potency (Lobmaier et al., 2010). A more recent formulation using buprenorphine is
buprenorphine-naloxone (BNX). BNX, generally delivered sublingually, has less abuse
potential than buprenorphine and has lower risk of diversion (channelling of prescription
medications to unintended users) due to an extended pharmacological profile and lower
bioavailability, and precipitation of withdrawal if injected (Doran, 2005). In spite of its varied
benefits, lower treatment adherence has been observed in patients administered these options
compared to patients undergoing treatment with methadone (Gryczynski et al., 2013, Mattick
et al., 2014). Naltrexone, unlike methadone and buprenorphine, is a µ-opioid receptor
antagonist. Treatment with naltrexone can result in precipitated withdrawal if a patient has not
undergone detoxification to ensure a prior lack of drugs in their system. To reduce the risk of
precipitated withdrawal, treatment with naltrexone often requires stepped escalation in dosage
over the course of treatment, is used later in the course of treatment for opioid addiction and is
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often reserved to maintain abstinence in patients following treatment exit (Blanco and Volkow,
2019). Finally, behavioural therapies may confer some benefits when combined with
pharmacological treatments, but results are mixed. For example, a study by Pan et al. (2015),
reported a greater number of opioid-negative urine tests in patients treated with cognitive
behavioural therapy (CBT) and methadone maintenance therapy (MMT) compared to patients
treated with MMT alone, but did not report any difference in retention rates. Conversely, in
their review of the literature, Amato et al. (2011) did not find a significant improvement in
therapy retention, abstinence or therapy attendance for patients undergoing combined
psychosocial and pharmacological treatment compared to those undergoing pharmacological
treatment alone. Hence, results regarding the benefits of psychobehavioural treatments are
mixed. In short, while there is some efficacy with the existing treatments for opioid addiction,
these treatments have several limitations, and new treatment options that address these gaps
are needed to further improve patient outcomes.
1.1.4

Summary
Chronic opioid use is occurring at epidemic rates, and are continuing to rise,

contributing to an alarming rate of mortality as well as other health, social and economic
consequences. The literature suggests that existing pharmacological treatments for OUD have
greater efficacy than psychobehavioural treatments, but fails to demonstrate a significant
improvement of combined (pharmacological and psychobehavioural) therapy programmes on
treatment outcomes. In addition to this, pharmacological treatments such as methadone,
buprenorphine and naltrexone have several clinically significant limitations. These include
high rates of dropout in treatment programmes, especially early in the treatment course, high
rates of relapse, significant abuse potential, and poorer efficacy with incorrect dosing. As such,
there is a need to address the shortcomings of existing treatments, and determine the factors
that may contribute to poorer clinical outcomes in order to improve these treatments.
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Considering chronic opioid use through a neuropsychological framework is helpful in
highlighting the factors that may contribute to poorer treatment outcomes in patients
undergoing chronic opioid use. A growing body of literature has described cognitive
impairments, underpinned by drug-induced alterations in brain structures and neurocircuitry,
as major contributing factors to the pathology of opioid addiction.

1.2

The Three-Stage Model of Addiction, Neurobiology and
Cognition in Chronic Opioid Use
OUD can be considered a neuropsychological disorder involving maladaptive learning,

impaired cognitive functioning and behaviour, underpinned by drug-induced adaptations in
brain regions and signalling pathways related to motivation and reward processing (Strang et
al., 2020). The current three-stage model of addiction is useful in explaining how these
psychological and neurological adaptations may develop and further contribute to the
maintenance of OUD (Koob and Volkow, 2010). The three-stage cycle consists of a
binge/intoxication stage, a withdrawal/negative affect stage, and a preoccupation/anticipation
stage (Figure 1.1), each of which is mediated by different brain structures and signalling
between structures (Table 1.4), leading to impaired cognition. Cognition (the input, processing,
storage and retrieval of information) involves executive functions, such as attentional control,
working memory, inhibitory control and attention shifting (Bickel et al., 2012). Compared to
healthy individuals, patients with addiction disorders have impaired functioning in these
processes (i.e., poorer performance in tests sensitive to these processes) which may further
contribute to the course of the disorder. The theoretical model of addiction, the allostatic
(compensatory) neurobiological changes that occur as a result of addiction and OUD, and the
cognitive impairments of OUD will now be reviewed below.
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Figure 1.1 The three-stage model of addiction. While this model is proposed as being
ubiquitous in addiction, the model outlines the brain structures and processes involved in
chronic opioid use. Not included in the figure are the psychological processes that underlie
the three stages. The Binge/Intoxication stage is mediated in part by the psychological
attribute of Incentive Salience, where a cue is attributed motivation properties, for example.
Incentive Salience orients an individual to cues that reliably predict opioids (e.g., a needle).
The Withdrawal/Negative Affect stage involves hyperkatifeia and hyperalgesia, factors that
contribute to relapse and further drug seeking. Finally, the Preoccupation/Anticipation stage
is mediated by failures in cognition and executive processes. This stage characterises
addiction as a cyclical process by contributing to relapse. Adapted from VOLKOW, N. D.,
KOOB, G. F. & MCLELLAN, A. T. 2016. Neurobiologic Advances from the Brain Disease
Model of Addiction. N Engl J Med, 374, 363-71.
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Table 1.4 Overview of the brain structures and mechanisms involved in the three stages
of opioid addiction and their role in the stage

Binge/Intoxication
VTA, NAcc, Amyg, Hipp, VP,
Hypo, DSt, PFC

Withdrawal/Negative Affect
VTA, NAcc, PaG, DTh,
eAmyg, Sh. of NAcc, VSt, DSt

Preoccupation/Anticipation
PFC, VTA, NAcc, Sh. of
NAcc, eAmyg, Insula, Hipp

Mechanisms
Involved

Role in Addiction

Dopamine, D1
receptors
GABAergic
interneurons

Opioids inhibit GABAergic neurons causing
disinhibition of dopaminergic neurons. Dopaminergic
signalling facilitates rewarding effects of drugs and
reinforces drug seeking behaviour

Dopamine, D2
receptors, GABA,
Glutamate, CRT,
Dynorphin

Continued opioid use results in diminishing returns as
tolerance and withdrawal occurs. At the cellular and
molecular level this is mediated through the
development of allostatic adaptations. Allostatic
adaptations include receptor internalisation and
desensitization. Hyperkatifeia (negative affect) occurs
as a result of brain stress system activation which
contributes to withdrawal as does activation of the
pain pathway

CRF, glutamate,
GABA

Failures in executive processes (seated in the PFC)
contribute to relapse. Mechanisms at the cellular and
molecular level that may facilitate this includes CRF
signalling and disruption of glutamatergic
homeostasis. Drug associated-cues and stress may
contribute to relapse through these mechanisms.

Notes: This table serves as a brief overview outlining the key structures and mechanisms involved in the three stages of
opioid addiction (it is not a comprehensive list). Abbreviations: Amyg=Amygdala, eAmyg=Extended Amygdala,
CRF=Corticotropin-Releasing Factor, DSt=Dorsal Striatum, VSt=Ventral Striatum, GABA=γ-aminobutyric acid,
Hipp=Hippocampus, Hypo=Hypothalamus, PaG=Periaqueductal Grey, PFC=Prefrontal Cortex, NAcc=Nucleus
Accumbens, Sh. Of NAcc=Shell of the NAcc, VP=Ventral Pallidum, VTA=Ventral Tegmental Area

1.2.1

Binge/Intoxication Stage
In the binge/intoxication phase, the use of opioids activates reward related

neurocircuitry that positively reinforces drug-seeking and administration by inducing feelings
of euphoria or sedation (Koob and Volkow, 2010, Moningka et al., 2019). Concurrently,
maladaptive learning occurs wherein an individual becomes sensitized to drug-associated cues
that further motivates drug-seeking and administration – the motivational property of these
cues is known as incentive salience. At the neurobiological level, drug use induces an influx of
the reward related neurotransmitter dopamine into the mesocorticolimbic system, including the
ventral tegmental area (VTA), ventral striatum, nucleus accumbens (NAc), and the prefrontal
cortex (PFC). Neurotransmitters other than dopamine suggested to be involved in the
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binge/intoxication phase include GABA, serotonin and opioid peptides (Koob and Volkow,
2016). Additionally, glutamate is reported to mediate dopaminergic signalling, suggesting a
role of this neurotransmitter in reward learning (Wise and Robble, 2020). With prolonged use
of opioids, allostatic adaptations develop at the neurobiological level leading to tolerance of
the drug (Williams, Christie and Manzoni, 2001). At the cellular level, these allostatic
adaptations include rapid recycling of µ-OR, which may drive increasing dosage as patients
receive diminishing returns from current doses.
Other mechanisms at the cellular level that may potentially contribute to opioid
tolerance include pro-inflammatory signalling leading to neuronal sensitization (Latremoliere
and Woolf, 2009, Eidson and Murphy, 2019). In their study, Ikeda, Kiritoshi and Murase
(2012) report that astrocytes contribute to central sensitization through hyperexcitability in rats
subjects to inflammatory pain. Elsewhere, studies report that microglial release of cytokines
such as TNFα, IL-1β and Il-6 may contribute to neuronal sensitization (Basbaum et al., 2009),
which may contribute to tolerance (Hutchinson et al., 2011). In their preclinical study,
Kawasaki et al. (2008) evidenced a potential link between these pro-inflammatory cytokines
and altered synaptic transmission; IL-1β and TNFα enhanced excitatory signalling, whereas
IL-1β and IL-6 reduced inhibitory synaptic signalling in spinal neurons. Further, microglia
express TLR4 which can be activated by morphine, fentanyl and oxycodone (as well as
bacterial components, as discussed throughout this thesis) – hence these substances have the
potential to directly induce the release of proinflammatory cytokines (Eidson and Murphy,
2019). Finally, recent evidence suggests such central sensitization may be an integral
component of opioid dependence (Cahill and Taylor, 2017, Hall et al., 2022), potentially
through inflammatory mechanisms.
These neurobiological changes may drive the cognitive processes that cause a shift from
voluntary drug use to addiction (Koob and Volkow, 2010). The cognitive processes that
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facilitate this shift include maladaptive learning and the attribution of incentive salience to
drug-associated cues. A cue is a stimulus that frequently occurs with, and reliably predicts the
drug. For example, a needle may be a cue the reliably predicts the presence of heroin. With
prolonged drug use, the cue develops the motivational attribute of incentive salience, and may
illicit craving and expectation of the drug, stimulating further drug seeking as a result. In fact,
cues themselves can activate reward related circuitry. Evidence for this can be found in a nondrug primate study that demonstrated a shift in dopaminergic neuron signalling from
presentation of a reward to a cue (Schultz, Dayan and Montague, 1997). Initially, dopaminergic
neuron signalling was observed when animals were presented with a reward (i.e., food). Over
extended presentations, when the reward was paired with a cue, and the cue could reliably
predict the reward, reward-related dopaminergic signalling occurred in response to the cue
itself and not the reward (Schultz et al., 1997). Similarly, in the context of drug addiction, a
cue (for example, a needle) that is associated with, and reliably predicts, a reward (for example,
heroin) may induce drug-seeking as the reward is expected in the context of the cue.

1.2.2

Withdrawal/Negative Affect Stage
By the withdrawal/negative affect stage, allostatic adaptations have developed as a

result of chronic drug administration. These adaptations increase the reward threshold for
opioid drugs (meaning higher doses of drugs are needed to achieve the desired effects) leading
to tolerance. Opponent processes result in a decreased pain threshold (hyperalgesia) and the
development of negative affect (hyperkatifeia) wherein a patient may feel dysphoria, malaise
and irritability (Koob, 2020). Normally, the presence of opioids in the system keeps these
opponent processes in balance. Cessation of opioid use, or even an inadequate dosage, results
in an emphasised effect of these negative processes, resulting in symptoms of withdrawal and
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craving. These withdrawal symptoms negatively reinforce opioid use (Moningka et al., 2019).
At the neurobiological level, areas associated with the withdrawal/negative affect stage include
the ventral striatum extended amygdala, the nucleus accumbens, and ventral tegmental area
(Koob, 2020, Koob and Volkow, 2010).

1.2.3

Preoccupation/Anticipation Stage
The preoccupation/anticipation stage characterises the chronic, relapsing nature of

substance addiction, facilitated by failures in executive functions. At the neurobiological level,
this stage of the addiction cycle involves the prefrontal cortex and neurotransmitters such as
dopamine and serotonin which together underlie the executive functions that are impaired in
addiction (Logue and Gould, 2014). Deficits in executive functions are associated with
negative treatment outcomes, such as poor treatment retention and relapse back into drug use,
making them critical to the course of addiction (Mahoney, 2019, Ramey and Regier, 2019,
Sampedro-Piquero et al., 2019). Cognitive impairment may also predict treatment adherence.
For example, a study by Aharonovich, Nunes and Hasin (2003) investigating a cohort of
patients with cocaine use disorder found poorer attention and reasoning performance at
baseline in patients who dropped out of a treatment programme compared to those who
completed treatment. The finding that cognitive impairment predicts poorer treatment
adherence has also been observed in patients engaging in abuse of alcohol (Copersino et al.,
2012, Teichner et al., 2002, Manning, Verdejo-Garcia and Lubman, 2017), and in heroin users
(Katz et al., 2005). There is a lack of research in other substances, but cognitive impairment in
nicotine, methamphetamine, cannabis and opiates may also predict worse treatment outcomes
(Stevens et al., 2014). In short, cognitive impairment is a central component of several forms
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of substance use disorders due to its relevance to treatment outcomes, and as such, these
impairments need to be addresses and treated.
Research has highlighted several domains that are impaired in OUD (Wollman et al.,
2019). For example, a meta-analysis by Baldacchino et al. (2012) reported that patients
engaging in chronic opioid use performed worse on tasks measuring verbal working memory,
verbal fluency and impulsivity/inhibition compared to opioid free controls. Additionally,
chronic opioid users had poorer performance in tasks measuring attention and long-term
memory compared to controls, although these deficits were not statistically significant. A
separate meta-analysis reported impaired performance in tasks measuring impulsivity,
cognitive flexibility, short-term memory and long-term memory in chronic methadone users
(as part of Methadone Maintenance Treatment; MMT) compared to healthy controls
(Baldacchino et al., 2017). Abstinence from opioid use appears to recover cognitive functioning
as short-, and long-term memory performance was greater in abstinent patients compared to
chronic methadone users (Baldacchino et al., 2017). While the research demonstrates cognitive
impairment in chronic opioid use, studies often use different neurocognitive batteries to assess
performance, which themselves have vastly different methods of classifying cognitive
domains. This is a limitation that makes it difficult to standardise results and determine patterns
across the literature. Regardless, a brief summary by of the findings by Wollman et al. (2019)
are included in this thesis as a general overview of the impairments observed in the literature
(Table 1.5).
While impairments in cognitive functioning are a component of OUD, existing
treatment options are unproven in their ability to recover them. In fact, medication assisted
therapy for opioid use disorder (MOUD) may result in further impairments in cognitive
functioning (Pujol et al., 2018). For example, patients undergoing methadone maintenance
treatment (MMT) perform worse on tasks measuring impulsivity, processing speed, social
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Table 1.5 Neurocognitive domains identified as being impaired in patients with OUD
Cognitive Domain
Simple Attention
Decision Making
Immediate Visual Memory
Immediate Verbal Memory
Delayed Verbal Memory
Working Memory
Visuospatial Ability
Complex Psychomotor
Processing
Planning
Verbal Fluency
Inhibition
Cognitive Flexibility

Tests Used for Assessment
Digit Span Forward
Iowa Gambling Test
Benton Visual, Retention Test,
Rey Auditory Verbal, Learning, Logical Memory
Rey Auditory Verbal, Learning, Logical Memory
WAIS-Digit Span-Backwards, WAIS-Letter Number Sequencing, 2
Back test
Block Design
Digit Symbol, Substitution Test, Symbol Digit, Modality Test
Tower of London, Porteus Maze
Phonemic Fluency, Semantic Fluency
Stroop Task, Go/No Go Test
Trail-Making Test-B, WCST Perseverative Error

Notes: This is not a comprehensive list. The ability to collate impaired domains is limited due to studies utilising different
neurocognitive batteries and a lack of consistency in defining cognitive domains. Adapted from WOLLMAN, S. C.,
HAUSON, A. O., HALL, M. G., CONNORS, E. J., ALLEN, K. E., STERN, M. J., . . . FLORA-TOSTADO, C. 2019.
Neuropsychological functioning in opioid use disorder: A research synthesis and meta-analysis. American Journal of Drug
and Alcohol Abuse, 45, 11-25.

cognition, cognitive flexibility and working memory, compared to healthy, opioid free
controls. Other recent studies conversely suggest a beneficial effect of methadone treatment on
cognitive performance. The first study by Wong et al. (2021) reported an improvement in
cognitive functioning as a result of methadone treatment after a four-week period, measured
by the Montreal Cognitive Assessment, though this study did not compared patients to an
opioid free control group. The second study by Li et al. (2021) also reported improvements in
some measures of impulsivity but not others (delayed discounting task) in patients undergoing
MMT, compared to controls. Finally, a study by Nikraftar et al. (2021a) reported some
beneficial effect of MMT and buprenorphine treatment on cognition compared to current users,
though patients in treatment still performed worse than healthy controls on some tasks.
Compared to controls, buprenorphine treated patients performed worse on tasks measuring
memory, but were not significantly different in tasks measuring set shifting and attention.
Compared to controls, methadone patients performed worse on tasks measuring set shifting
and attention, but were not significantly impaired on tasks measuring memory (Nikraftar et al.
(2021a). Therefore, while there is some evidence for a therapeutic effect of MOUD on
cognitive impairment in chronic opioid users, studies appear conflicting. The limited efficacy
15

of existing treatments in addressing these cognitive impairments needs to be addressed due the
clinical significance of these deficits.

1.2.4

Summary
Neurobiological alterations and psychological impairments occur at the various stages

of chronic opioid use. Initial hijacking of the dopaminergic reward pathway by opioids leads
to the development of addiction. This process occurs in concert with maladaptive cognitive
processes that sensitize an individual to drug associated cues, further motivating drug seeking.
Adaptations at the neurobiological level result in diminishing returns from opioids,
contributing to tolerance. In addition, symptoms of withdrawal such as hyperkatifeia and
hyperalgesia negatively reinforce drug seeking. Finally, the chronicity of addiction is facilitated
by failures in cognitive functioning, especially executive functions such as attention and
impulse control. Performance in these executive functions is clinically significant as they can
predict treatment retention and dropout. Existing treatments for OUD do not adequately address
these cognitive impairments, and may even exacerbate them, potentially driving the cycles of
addiction forward. As such, addressing the limited ability of existing therapies to target these
cognitive impairments should be a central concern for future treatments. First, a greater
understanding of the pathology of OUD is required, especially with regards to the development
and maintenance of these cognitive impairments. Recent research has suggested dysbiosis of
the gut microbiota in patients with chronic opioid use, but the contribution of this dysbiosis to
neurobiology and cognitive aspects of opioid addiction are not fully understood.
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1.3

Overview of the Gut Microbiota
Accumulating evidence implicates the gut microbiota, i.e., the complex and dynamic

community of bacteria that inhabits the gastrointestinal tract in host health, and in brain
development and cognition (Diaz Heijtz et al., 2011). This community of bacteria outnumbers
both the cell and gene count of humans and, locally, are vital in nutrition extraction, vitamin
synthesis and overall gastrointestinal health (Wang and Wang, 2016). A growing body of
research implicates the gut microbiota in brain functioning, as the gut microbiota and brain can
engage in bidirectional communication through several, often overlapping pathways,
collectively known as the microbiota-gut-brain (MGB) axis (Figure 1.2). These pathways
include the immune system (Fung, Olson and Hsiao, 2017), nervous system (Carabotti et al.,
2015), neuroendocrine system (Cussotto et al., 2018), metabolic products including short chain
fatty acids (Dalile et al., 2019, Silva, Bernardi and Frozza, 2020) and bile acids (MonteiroCardoso, Corliano and Singaraja, 2021), and production and modulation of neurotransmitters
(Strandwitz, 2018, Liu and Huang, 2019).
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Figure 1.2 An overview of the microbiota-gut-brain (MGB) axis. Adapted from LIANG, S., WU, X. & JIN, F. 2018. GutBrain Psychology: Rethinking Psychology From the Microbiota-Gut-Brain Axis. Front Integr Neurosci, 12, 33.
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1.3.1

Gut Microbiota and the Immune System
Within the immune system the gut microbiota can influence microglia, which are CNS

localised immune cells that are crucial in synaptic pruning and, neuronal development and
homeostasis (Lannes et al., 2017). Evidence has shown that microglia development and
function is impaired in animals that do not possess a gut microbiota (known as germ free
animals), compared to animals with an intact microbiota (Erny et al., 2015). The same study
also observed recovery of microglia morphology and activity upon colonisation of the
gastrointestinal tract in germ-free animals, further evidencing the role of the microbiota in CNS
immune system functioning. Elsewhere, the potential significance of microglia in cognition
has been demonstrated in a rodent model of Parkinson’s disease, where microglial activation
was associated with cognitive impairment in this model (Zhang et al., 2021a). Interestingly, an
altered gut microbiota has been observed in patients with this neurodegenerative disease
(Scheperjans et al., 2015). The microbiota is critically important in immune system
development and functioning, and may have less direct influence on the brain through other
mechanisms, such as influencing the differentiation of immune cells and regulating
inflammatory responses (Brown, Kenny and Xavier, 2019).

1.3.2

Gut Microbiota and the Nervous System
Nervous system and gut microbiota interactions primarily involve the vagus nerve and

the enteric nervous system. The vagus nerve serves as an interface between the enteric nervous
system (ENS) and the central nervous system (Breit et al., 2018), primarily receiving input
from the ENS; however, neither are in direct contact with the microbiota (Hyland and Cryan,
2016). Instead, communication between the microbiota, gut and brain involves intermediary
mechanisms such as Toll-Like Receptors (TLR), which are expressed in the ENS (Barajon et
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al., 2009), and vagus nerve activation by microbially-derived products (such as endotoxins and
short-chain fatty acids (SCFAs). The vagus nerve serves as a primary mediator of interoceptive
cues, from sites such as the gut (Paciorek and Skora, 2020, Weng et al., 2021), thereby serving
as a mechanism by which the microbiota can influence the brain.

1.3.3

Gut Microbiota and the Endocrine/Neuroendocrine System
Another pathway through which the gut microbiota can influence the brain involves the

neuroendocrine system. The neuroendocrine pathway includes the hypothalamic-pituitaryadrenal (HPA) axis (a system involved in the regulation of a number of processes, including
mood (Bao and Swaab, 2019) and memory (Wolf, 2003)), which is regulated by corticotrophin
releasing factor (CRF) signalling, but also includes components of the immune and nervous
system pathways (Cussotto et al., 2018). In the gut, the neuroendocrine system includes cells
such as enteroendocrine and enterochromaffin cells (EEC; ECC) secrete hormones (such as
glucagon-like peptide 1 and 2, GLP-1, GLP2; and peptide YY, PYY) and neuropeptides (Toni,
2004, Holzer and Farzi, 2014, Farzi, Frohlich and Holzer, 2018), allowing them to influence
appetite and gut barrier homeostasis. More importantly, the activity of these cells can be
influenced by the gut microbiota and their metabolic products. For example, a study by Cani
et al. (2009) reported an increase in the production of the EEC-derived hormone GLP-2
following prebiotic supplementation in a model of obesity, compared to mice without a
prebiotic supplemented diet. The hormone GLP-2 improves gut barrier integrity, possibly
through upregulating tight junction proteins (Cani, Everard and Duparc, 2013, Kuwahara et al.,
2020). As such, the literature suggests a role for the microbiota in influencing various actions
of EECs, such as hormone secretion, which may directly or indirectly influence host behaviour.
The activity of EECs can reach the brain by way of the vagus nerve (Dockray, 2013), thereby
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allowing for a path of communication between the gut microbiota and the brain. In addition to
influencing the activity of EECs, the microbiota exerts a measure of control over colonic ECCs,
which synthesize the majority of serotonin in the body. For example, a study by Yano et al.
(2015) reported deficient serum and plasma serotonin concentrations in germ-free (GF) mice
compared to specific pathogen free (SPF) control mice, a finding attributed to ECCs. Hence, it
appears that the gut microbiota influences neuroendocrine cells such as EECs and ECCs, which
serve as intermediaries in the MGB axis.

1.3.4

Gut Microbiota and Neurotransmitters
In addition to modulating synthesis of neurotransmitters by the host, the gut microbiota

possesses the ability to produce and metabolise neurotransmitters (Strandwitz, 2018,
Strandwitz et al., 2019). Neurotransmitters linked to the gut microbiota include dopamine,
serotonin, tryptamine, glutamate and GABA, all of which are implicated in cognition and
addiction. Evidence for the link between neurotransmitters and the gut microbiota comes
primarily from preclinical studies. For example, a study by Asano et al. (2012) reported lower
levels of catecholamines (including dopamine) in GF animals compared to SPF animals, albeit
the majority of these catecholamines existed in a biologically inactive form. Exposing GF mice
to Clostridia genus bacteria possessing GUS (β-glucuronidase) resulted in an increase in lumen
levels of dopamine. Elsewhere, the gut microbiota has been linked to dopamine receptor
expression in the brain, and to addiction related behaviours. For example, in their preclinical
study, Jadhav et al. (2018) examined the relationship between vulnerability to alcohol
addiction, dopamine receptor availability in the dorsal striatum and the gut microbiota. Animals
with an increased vulnerability to addiction reportedly had increased alpha diversity (i.e.,
within site diversity) compared to more resilient animals, increased D 1, and decreased D2

21

dopamine receptor expression in the dorsal striatum (Jadhav et al. (2018). Together these
papers suggest a role of the gut microbiota in dopamine production, and a link between the gut
microbiota and dopamine receptor expression in the context of addiction. In addition to
dopamine, the gut microbiota has been linked to production and regulation of serotonin. As
mentioned above, the gut microbiota is able to control the production of serotonin through
interactions with ECC cells (Yano et al., 2015), potentially through their upregulation of
tryptophan hydroxylase by SCFAs (Reigstad et al., 2015) and tryptamine production (Williams
et al., 2014), but various strains have been identified serotonin-producing (O’Mahony et al.,
2015). In addition to these neurotransmitters, certain bacteria are able to produce glutamate,
though strains capable of this are yet to be identified in the gut (Baj et al., 2019) and gut bacteria
possess the ability to produce GABA (Barrett et al., 2012, Pokusaeva et al., 2017). Therefore,
gut bacteria may play a role in modulating major inhibitory and excitatory neurotransmitter
signalling pathways. Finally, addictive behaviour may also modulate neurotransmitter
production and metabolism by microbiota. Therefore, further research to understand the role
of the gut microbiota in addiction is required.

1.3.5

Gut Microbiota and Metabolic Products
Finally, gut microbiota derived products (such as SCFAs and secondary bile acids), as

well as their constituents (such as lipopolysaccharides (LPS) and peptidoglycans (PGN)), have
the potential to directly and indirectly influence the brain. SCFAs, including acetate, propionate
and butyrate, are produced by the gut microbiota through fermentation of dietary fibres
(Macfarlane and Macfarlane, 2003) and serve several important roles. For example, SCFAs
serve as a source of energy, protect from inflammation, maintain blood brain barrier (BBB)
and gastrointestinal barrier integrity, promote mucous production in the gastrointestinal tract
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and protect from inflammation (Dalile et al., 2019). In addition to regulating BBB integrity,
SCFAs can cross the BBB through via monocarboxylate transporters where they exhibit
histone deacetylase inhibitor (HDACi) properties on various genes relevant to cognition, such
as brain derived neurotrophic factor (BDNF). Other products of the gut microbiota that may
influence the brain include secondary bile acids, which are involved in gut barrier homeostasis
and inflammation (Lajczak-McGinley et al., 2020, Liu et al., 2018). Studies also report links
between altered bile acids profiles and cognitive impairment in Alzheimer’s disease
(MahmoudianDehkordi et al., 2019b, Nho et al., 2019). In short, these studies outline a link
between microbially-derived products and the brain, with potential influence on cognition.
Bacterial cell components (such as LPSs and PGNs) may also influence brain function. LPS
are toxic components of the outer membrane of microbes (Raetz and Whitfield, 2002) that can
activate TLR-4 (part of the innate immune system) and initiate immune responses, leading to
inflammation (Hoshino et al., 2016, Park and Lee, 2013). A study by Zhao et al. (2019) reported
cognitive impairment in measures of memory in mice as a result of LPS induced neuroinflammation. PGN also are a component of bacterial cell walls (Tosoni, Conti and Heijtz,
2019) that are able to cross the blood brain barrier. Within the CNS, PGN can activate part of
the innate immune system, and furthermore, research suggests a role of PGN in the
development of the brain (Arentsen et al., 2018). In short, microbial products and components
serve as another pathways enabling communication between the gut and the brain.

1.4

Studying the Gut Microbiota

1.4.1

Profiling the Gut Microbiota
Profiling the gut microbiota provides insight into how the composition and functional

potential of a bacterial community is altered in normal and pathological states. Following
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collection of faecal samples from subjects, gene sequences are extracted and analysed. The
majority of studies utilise 16S rRNA gene sequences, though an increasing number of studies
are beginning to utilise whole genome sequencing (WGS). Sequences extracted are amplified
by polymerase chain reaction (PCR) and grouped into operational taxonomic units (OTUs).
OTUs are cross referenced to databases to then identify which microbes they represent. This is
accomplished by determining which genes present in an OTU also occur in identified microbes.
Following identification of the bacteria present, the alpha (α) and beta (β) diversity of the gut
microbiota can be determined, outlining the structure of a community (Figure 1.3).

1.4.1.1 α-Diversity
Alpha diversity is a measure of within sample diversity, and can be broken down
further into richness and evenness (Kim et al., 2017). Richness considers the number of distinct
species present in a community, but is not concerned with what the species actually are.
Evenness considers the relative abundance of the individual species – that is, it considers the
differences in the number of the individual species present, and how much of a community
they occupy. To explain these concepts, consider three farms. One farm may have three species
present – cows, goats, and pigs. This site has a richness of three. The second farm may have
four species – cows, sheep, chickens and ducks. The second farm has a greater richness, due to
the greater number of species occupying the site. Within this second farm there may be two
cows, four sheep, seven pigs and eleven ducks. The third farm may have the same number of
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a)

b)

c)

Figure 1.3 Alpha and Beta Diversity. Alpha Diversity refers to the within-sample structure of
a community, whereas beta diversity refers to the differences in community structure between
samples. Alpha diversity can be further broken down in richness and evenness. Richness is the
number of different species present in a sample. In the figure, sample a) and sample c) have the
same richness (both have 3 species present, but sample a) and b) have a different richness.
Evenness (or, relative abundance) is the distribution of the species present. While sample a) and
c) have the same richness, the evenness is different as sample a) has an equal distribution of
species, whereas sample c) does not. Finally, beta diversity is different between all three sample
as they do not all possess the same species.

species but may have an equal number of each. In this case, the richness is the same, but there
is a disparity in evenness. Numerous indices exist that can be used to measure alpha diversity,
and include Chao1, Simpson’s Index, Shannon’s Index and Observed OTUs.
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1.4.1.2 β-Diversity
Beta diversity considers the similarity and dissimilarity (or overlap) of two or more
different sites by considering the number of shared species between sites (Lozupone et al.,
2011). In the example of the farms, the first two farms share only one species, cows, and
therefore have little overlap i.e., there is a difference in beta diversity. Conversely, the second
and third farm have complete overlap as they share all species i.e., there is no difference in beta
diversity. Indices for measuring beta diversity include Bray-Curtis and UniFrac (Wong, Wu
and Gloor, 2016), the latter of which can be Weighted (considering repeat counts of bacterial
strains) or Unweighted (not considering repeat counts of bacterial strains).

1.5

Converging Evidence of Gut Microbiota in Cognition and
SUD
Dysbiosis of the gut microbiota has been reported in several neuropsychiatric disorders

such as autism (Strati et al., 2017a), bipolar disorder (Sublette et al., 2021), schizophrenia (Li
et al., 2020b, Yuan et al., 2019), depression (Cheung et al., 2019) and anxiety (Simpson et al.,
2021), all of which present with impairments in cognitive ability (Alabdali, Al-Ayadhi and ElAnsary, 2014, Bora and Ozerdem, 2017, Castaneda et al., 2008, Perini et al., 2019).
Additionally, disruption of the commensal gut microbiota has been reported in patients
misusing cocaine, opioids, alcohol and methamphetamine, cohorts which also frequently
present with cognitive impairment (discussed earlier). For example, a clinical study by Volpe
et al. (2014) reported increased abundance of Bacteroidetes in cocaine users compared to nonusers. While the results regarding alpha diversity are inconclusive, preclinical studies reliably
show alterations in beta diversity in pre-clinical models chronically exposed to cocaine
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(Chivero et al., 2019, Scorza et al., 2019). Interestingly, studies are suggesting a potential link
between microbiota and addiction-related behaviours in preclinical models. For example, a
study by Suess et al. (2021) found certain bacteria (such as the genera Allobaculum,
Ruminococcus and Turicibacter) to have increased abundance at baseline in rats with higher
sensitivity to cocaine compared to rats with lower sensitivity. In another study, Kiraly et al.
(2016) reported that mice with their microbiota depleted through exposure to antibiotics
develop conditioned place preference at lower doses than mice not exposed to antibiotics. The
development of conditioned place preference is an indication of the rewarding effects of the
drug (Huston et al., 2013), and as such, this study suggests that the microbiota may be involved
in cognitive processing of the rewarding effects of a drug. Dysbiosis of the gut microbiota has
also been reported in cohorts engaging in chronic opioid use, though the pattern of dysbiosis is
inconclusive (discussed in Chapter 3). For example, clinical studies have found dysbiosis in
the gut microbiota and enrichment of bacteria such as Bifidobacterium (Acharya et al., 2017,
Barengolts et al., 2018); however, the effect of opioids on specific microbes is inconclusive.
Similarly, preclinical studies report inconsistent findings when examining the effect of opioids
on diversity and specific microbes (Sharma et al., 2020a, Simpson et al., 2020).
As dysbiosis of the gut microbiota has been reported in addiction, which is associated
with cognitive impairment, and given that research demonstrates communication between
microbiota and the brain, it is possible that microbiota may influence addiction-related
behaviours. Therefore, it is important to examine the effect of opioids on the gut microbiota
and seek to understand how the microbiota may influence cognition. Elucidating the nature of
this relationship may provide new insights aiding in the development of novel treatments for
opioid addiction and associated brain dysfunction.
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1.6

Summary
The harmful use of opioids is occurring at an epidemic rate, resulting is severe health,

social and economic outcomes. Impairment in cognitive functioning is a core component of
OUD, and these impairments can exacerbate and perpetuate the state of addiction. While there
is some efficacy of current medications available for chronic opioid use, these treatments have
several clinically significant limitations such as their inability to treat the cognitive
impairments resulting from opioid addiction. As such there is need to address the limitations
of these existing treatments.
Research shows that the gut microbiota is disrupted in several neuropsychiatric diseases
that present with impairments in cognitive functioning, suggesting that the two may be linked.
Such findings have been reported in patients with autism (Strati et al., 2017a), schizophrenia
(Li et al., 2020b, Yuan et al., 2019), bipolar disorder (Sublette et al., 2021) and depression
(Cheung et al., 2019). In addition, the gut microbiota is disrupted in patients addicted to various
substances of abuse – including alcohol, cocaine, methamphetamine and opioids – and further
evidence shows a link to drug-related learning in preclinical models, further supporting this
link. A growing body of literature demonstrates that the gut microbiota is able to communicate
with the brain along a number of distinct but often overlapping pathways. Therefore, disruption
of the microbiota with opioid use may impact the brain and contribute to the cognitive
impairment. While this link is plausible, the effect of opioid use on the gut microbiota is
inconclusive as studies provide confounding evidence. Furthermore, the link between the gut
microbiota and cognition in opioid use disorder has not yet been examined in the literature.
Addressing these gaps may provide novel insight into the pathology of addiction in opioid
users, and may aid in treating the cognitive sequalae that contributes to the chronic nature of
this disorder; however, further research is needed.
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1.7

Thesis Aims

1.7.1

General Aims
The general aim of this thesis was to examine cognition in chronic opioid users,

investigate changes to the gut microbiota with opioid use, and identify whether changes to the
microbiota by opioids may be related to cognition. Given the role of gut microbiota in brain
function, including cognition and addiction, understanding changes in microbiota may provide
clues that could underpin the development of novel therapeutics to improve the treatment of
opioid dependence and associated cognitive decline. This thesis was significantly impacted by
COVID and required alteration to the project design (as detailed in COVID Impact Statements*
under the Specific Aims, below).

1.7.2

Specific Aims

The specific aims of this thesis were to:
1. Investigate the effect of opioid use on cognition through clinical testing of participants
undergoing treatment for opioid dependence in a residential care setting;
*COVID Impact Statement Aim 1: due to COVID, participant testing for the
control group could not be completed and data sets were incomplete resulting
in a smaller sample size.
2. Investigate the influence of opioids on specific strains of the gut microbiota;
*COVID Impact Statement Aim 2: microbiota analyses was to be conducted in
opioid vs control participants via Whole Genome Sequencing (WGS); however,
analyses could not be conducted due to incomplete data sets. Instead, this aim
was addressed through extraction of existing data during a systematic literature
review.
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3. Outline the potential functional outcomes of altered gut microbiota and metabolites in
relation to brain function and cognition.
*COVID Impact Statement Aim 3: Cognitive data sets collected from opioid vs
control participants were to be correlated with WGS data (which yields
functional information) from participant gut microbiota samples; however, this
could no longer occur. Instead, functional outcomes of microbiota alterations
during opioid use were inferred from data extracted during the systematic
literature review, where available, and further literature investigations were
conducted to identify their potential role in signalling pathways of the
microbiota-brain-gut axis
1.7.3

Hypotheses

1. Cognition will be impaired in patients undergoing chronic opioid use compared to the
control cohort
2. Opioid use will result in a dysbiosis of the microbiota and will result in alterations in
specific strains
3. Opioid use will result in changes in the functional potential of the gut microbiota in
pathways relevant to the microbiota-gut-brain axis that may in turn influence cognition

1.7.4

Significance
Chronic opioid use is occurring at an alarming rate, and whilst existing treatments have

proven efficacy, there are several inherent limitations. Addiction to opioids may be considered
a neuropsychological disorder, presenting with a varied range of cognitive deficits. Existing
treatments do not address these deficits and may even result in further impairments, thus
contributing to poorer treatment outcomes.
In order to address the limitations of the existing treatment options, a greater
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understanding of the nature of chronic opioid use is needed. The gut microbiota is increasingly
being implicated in host health and brain function. Further, research has reported alterations in
the gut microbiota in cohorts engaging in chronic use of other substances and in
neuropsychological disorders. Investigating the gut microbiota in individuals with a history of
chronic opioid use may provide novel insights into our understanding of the nature of the
disorder and inform the development of novel therapies that may better address the limitations
of current treatments.

1.8

General Methods
To address aim 1 listed in Section 1.7.2 of this thesis, a cohort of patients undergoing

mandated treatment for opioid addiction in an Australian residential setting were tested.
Participants underwent testing with a neurocognitive battery to determine the effect of chronic
opioid use on cognitive performance and to examine how various treatment related factors (i.e.,
dosage, length of stay, length of treatment, time since last opioid treatment dose) might
influence test performance, as well as non-treatment-related demographic factors (age, BMI
and years of education) (Chapter 2). To address aims 2 and 3 listed in Section 1.7.2 of this
thesis, a systematic literature review in line with PRISMA guidelines was conducted. The
systematic literature identified studies from three major scientific databases to determine how
chronic opioid use effects specific strains of the gut microbiota and how the functional potential
of the gut microbiota may be affected (Chapter 3).
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Chapter 2
The Effect of Chronic Opioid Use on Cognition in a Residential Care
Setting

2.1

Abstract

Impaired cognitive functioning is a core component of addiction; however, it is unclear
whether cognitive dysfunction occurs with opioid use due to confounding results in the
literature. Pharmacological options for opioid addiction can negatively affect cognitive
performance; however, the mechanisms are unknown. The present study aimed to investigate
the effect of opioid-based pharmacological treatments for opioid dependence (methadone and
BNX), treatment-factors (i.e., dosage, lifetime duration of treatment, length of stay, time since
last treatment), and non-treatment related factors (age, years of education and BMI) on multiple
cognitive domains. Participants who recently entered residential rehabilitation, receiving daily
methadone (n=15) or BNX (n=7), underwent testing to assess multiple cognitive domains. Raw
test scores were converted to T-scores and percentiles as an indicator of performance compared
to the general population. Below-average to average test performance was found in both
groups, with no difference between groups (all p > .05). The BNX (not methadone) group
showed a significant positive correlation between time since last treatment and verbal learning
performance (r = .770, p = .043); and between lifetime history of treatment and non-verbal
working memory (r = .920, p = .027). Non-treatment (demographic)-related factors including
age positively correlated to processing speed (r = .631, p = .002) across both groups, and BMI
negatively correlated to problem solving (r = -.857, p = .014) in the BNX group. BNX resulted in
a longer length of stay, suggesting greater treatment adherence compared to methadone. This
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study demonstrated cognitive impairment in individuals undergoing treatment for chronic
opioid addiction in an Australian rehabilitation setting, and identified several treatment and
demographic-related parameters influenced cognition. While there were no differences in
cognitive performance between methadone and BNX-treated participants overall, BNX
appeared to confer several treatment benefits. Further research using adequate sample sizes and
an opioid-naïve control group is required.
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2.2

Introduction

As discussed in Chapter 1, chronic opioid use is associated with impaired
neurocognitive functioning which can have a significant influence on daily functioning and
may also impact the course of the addiction cycle, as well as treatment outcomes (Aharonovich
et al., 2006, Copersino et al., 2012, Katz et al., 2005). While there have been consistent reports
of impairment in patients exhibiting chronic opioid use, the existing literature appears to be
confounding and the specific domains impaired differs between studies. In a meta-analysis by
Baldacchino et al. (2012), verbal working memory, cognitive impulsivity and verbal fluency
were consistently impaired in chronic opioid users compared to opioid naïve controls, whereas
visual working memory, long-term memory, attention and cognitive flexibility did not differ
significantly. A subsequent meta-analysis by the same group (Baldacchino et al., 2017)
reported impaired cognitive flexibility, attention, short- and long-term memory, and
impulsivity in chronic methadone users compared to healthy controls. Wollman et al. (2019)
reported impairments in complex psychomotor functioning, attention, memory and working
memory, visuospatial memory, verbal fluency and executive functioning, but not motor and
processing speed in patients with OUD compared to controls. Hence, it appears that certain
domains might be more readily affected by chronic opioid use compared to others.
Inconsistencies may be explained by methodological differences and heterogeneity of
participants (particularly age and body mass index that are negatively correlated with cognitive
function (Drag and Bieliauskas, 2010, Gunstad et al., 2010, Prickett, Brennan and Stolwyk,
2015, Smith et al., 2011).
Methadone and buprenorphine are two-well studied opioid medications utilised for the
pharmacological treatment of opioid dependence. These drugs have distinct receptor binding
profiles; the former is a µ-OR (µ-OR) agonist, whereas the latter is a high-affinity, partial µ-
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OR binding agonist, but a κ-opioid receptor (κ-OR) antagonist. Furthermore, contemporary
therapeutic regimes utilise naloxone, a µ-OR antagonist in conjunction with buprenorphine in
a formulation known as buprenorphine-naloxone (BNX), further changing the binding profile.
These differences in pharmacology may contribute to variability in cognitive performance;
however, little is known about the cognitive effects of BNX. Indeed, the literature often reports
poorer cognitive functioning in patients treated with methadone compared to those
administered buprenorphine, though these results are only limited to several domains such as
attention (Loeber et al., 2008, Nikraftar et al., 2021b, Rapeli et al., 2011). Data reveals that
methadone users also had poorer short-term memory compared to short-term abstinent
individuals (Baldacchino et al., 2017). Regardless, individuals undergoing pharmacological
treatment for opioid use seem to outperform active chronic opioid users (Baldacchino, Balfour
and Matthews, 2015), suggesting some benefit of treatment; however, unfortunately these
levels appear to remain lower compared to healthy controls (Rapeli et al., 2011, Soyka et al.,
2008).
Elsewhere, the literature suggests that other clinical factors relating to opioid addiction
medications, such as dose, duration of treatment and time since administration (i.e., considering
peaks and troughs in circulating drug levels), may influence cognition in patients; however,
findings appear to be conflicting. For example, Rass et al. (2014) reported a negative effect of
increasing methadone dosage on neurocognitive performance, a finding not replicated by other
studies investigating patients undergoing methadone or buprenorphine treatment (Soyka et al.,
2008, Haight et al., 2019). In addition, the cross-sectional study by Rass et al. (2014) reported
a positive correlation between length of treatment and a select number of cognitive domains,
such as working memory in a cohort of patients undergoing methadone maintenance therapy
(MMT). Conversely, other cross-sectional studies such as those by Li et al. (2021) and
Motazedian et al. (2021) failed to replicate these findings in cohorts undergoing MMT. Time
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since treatment administration could influence cognitive function as peak levels of methadone
and buprenorphine occur from approximately one- to one and a half hours after administration
(Baewert et al., 2007, Bullingham et al., 1981). For example, patients maintained on
buprenorphine exhibited poorer neurocognitive functioning in the domains of verbal fluency
and set shifting (a subdomain of cognitive flexibility) when tested during peak levels of
buprenorphine compared to trough levels (Singh et al., 2021). In individuals undergoing
methadone treatment, peak level testing sessions were also associated with poorer performance
in psychomotor speed, working memory and divided attention compared to trough level testing
sessions (Rass et al., 2014). However, to date, no study has compared cognitive performance
in patients administered methadone compared to BNX-treated patients. Overall, the gaps and
apparent inconsistencies in the literature demonstrate a need for further research examining
cognition in individuals undergoing treatment for opioid misuse, and the potential influence of
treatment related factors (i.e., dosage, length of treatment, time since dosage). Furthermore,
there is limited investigation in this field in the Australian population, particularly in people
who have recently entered rehabilitation and commencing pharmacological treatment with
opioid-based therapies, especially BNX.
The overall aim of the present study was to examine cognition in individuals undergoing
treatment for opioid dependence. Specifically, this study aimed to examine the effect of; (1)
opioid-based pharmacological treatment for opioid dependence (methadone vs BNX), (2)
clinical parameters pertaining to treatment (dosage, time since last dose, length of treatment
and length of stay), (3) non-treatment related demographic parameters (such as age, BMI and
years of education) on multiple domains of cognitive function. It was hypothesised that: a) the
cognitive performance of patients undergoing treatment with either intervention (methadone or
BNX) would not be equal, b) neurocognitive functioning would be influenced by clinical
parameters pertaining to treatment (i.e. patients with longer durations of treatment and length
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of stay would have more intact cognitive functioning; and neurocognitive functioning would
be different based on dosage and time since administration), c) non-treatment related
parameters would influence cognition with a negative relationship between increasing age
and/or BMI, and reduced cognitive functioning.
COVID IMPACT STATEMENT: This study originally aimed to examine alterations in
the gut microbiota and cognitive function of 2 groups: 1) individuals undergoing treatment for
chronic opioid use disorder, 2) matched (age, sex, BMI and education) drug-naïve controls
without a history of substance use. Differences between groups in relation to gut microbiota
profiles and functioning in specific cognitive domains were to be investigated, as well as
correlational analyses between these factors. As a result of COVID, this clinical research could
not be continued and complete data sets could not be collected within the timeframe of this 1
year Master’s degree. At the point of lock-down, the cognitive data had been collected for a
smaller sample of a patient cohort (individuals undergoing treatment for opioid misuse),
without controls, and, due to missing data, microbiota analyses also could not proceed at this
time. In order to fulfil the research component of this Master’s thesis, the aim was altered to
investigate the cognitive data for the cohort containing individuals undergoing treatment for
opioid use disorder, converted to percentiles to infer cognitive performance of this participant
group compared to the general population (and specific aims above).

2.3

Methods

2.3.1

Participants
A single site cohort study was conducted to examine cognitive function in individuals

undergoing treatment for opioid dependence. The population consisted of participants (n=22)
receiving treatment for chronic opioid misuse at a residential rehabilitation clinic in NSW,
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Australia. A standard requirement for admission to the facility was a history of chronic opioid
misuse. The opioid treatment program included pharmacological intervention (methadone or
BNX treatment (see Table 2.1 for dose range), administered daily at 10am) in addition to
therapeutic community-based treatment. The goal of treatment in the facility was to attain
stabilised methadone or BNX treatment, which patients are encouraged to achieve within 90
days (this population was recruited to the present study). After this, participants progress to a
different part of the facility where the goal of treatment is to reduce methadone or BNX use
(but did not form part of the present study). While participants in the present study were new
to the rehabilitation program, they may have been undergoing methadone or BNX use prior to
admission, therefore length of treatment (days) representing the self-reported lifetime length of
treatment with either BNX or methadone was collected. To be eligible for inclusion,
participants were required to be: (1) able to give Informed Consent; (2) proficient in English
reading, writing and speaking, (3) be able to participate in neurocognitive tests and surveys,
and (4) 18 years or older. Participants with a history of poly substance use, and past history of
mental illness were included in this study.

2.3.2

Procedure
Participants were recruited through flyers placed in the rehabilitation clinic by staff.

Participants provided two sets of informed consent: 1) consent for the researcher to visit and
discuss the project, 2) informed consent to participate in the project following a briefing and
question/answer session with the researchers. Demographics data were collected from
participants including age, gender, BMI, handedness, years in education, parent’s years of
education, life-time length of treatment (methadone or BNX). Participants then underwent
testing with a neurocognitive battery. The total testing period took approximately two hours,
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with breaks as needed, and were conducted on the clinic premises. Participants were provided
with compensation in the form of a $20 gift voucher at the end of the sessions. This project
was approved by the Joint University of Wollongong and Illawarra Shoalhaven Local Health
District Health and Medical Human Research Ethics Committee (2019/ETH03695).

2.3.3

Apparatus

The neuropsychological tests conducted were:


Trail-Making Test A (TMT-A): TMT-A measures speed of processing. Participants are
presented with a sheet of paper containing randomly positioned numbered circles (1 to
25) and are requested to rapidly draw a line connecting the circles in consecutive order.
Time taken to connect the lines was recorded in seconds (Bowie and Harvey, 2006).



Brief Assessment of Cognition-Symbol Coding (BACS-SC): BACS-SC measures speed of
processing. In this test, participants are presented with a range of symbols, and numbers
that correspond to each symbol (i.e., a code). Participants are then provided with a set of
symbols and are requested to match each symbol with its corresponding number within 90
seconds. The number of correct matches were recorded (Keefe et al., 2008).



Hopkins Verbal Learning Test-Revised (HVLT-R): HVLT-R measures verbal learning. In
this test, participants are orally presented a list of 12 nouns derived from three semantic
categories that they are asked to recite. Participants are presented the list three times and
asked to recite as many words as possible. The number of correct recalls were recorded
after each of the three trials and a total score was calculated (Benedict et al., 1998).



Wechsler Memory Scale III (WMS-III) Spatial Span (WMS-III SS): WMS-III SS measures
non-verbal working memory. The participant is requested to reproduce a sequence pattern
that was demonstrated by the test administrator on an array of 10 blocks using their pointer
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finger. The first trial begins with a sequence pattern length of two blocks, and one additional
block is added with each successful trial. The trials are discontinued when the participant
cannot successfully reproduce the pattern sequence. The participant is then requested to
perform trials involving reproducing the sequence pattern in reverse order to the
administrator. The number of correct trials was recorded (Wiechmann, Hall and O'Bryant,
2011).


Letter-Number Span (LNS): LNS measures verbal working memory. Participants are orally
presented with a mixed sequence of letters and numbers and are requested to verbally repeat
a reordered sequence with letters presented first in alphabetical order, followed by numbers
in sequential order. The sequence length begins at two symbols, with an additional symbol
added with each trial. Every trial consists of four tests. The test ends upon completion of
all trials or until participants are unable to complete any of the four tests of a given trial.
The number of correct tests was recorded (Mielicki et al., 2018).



Neuropsychological Assessment Battery (NAB-Mazes): NAB-Mazes measures reasoning
and problem-solving. Participants are presented a series of seven mazes of escalating
complexity and are requested to complete them in the shortest period of time possible.
Participants cannot cross lines and must correct mistakes to adequately complete a maze.
Testing is concluded if participants complete the mazes within a 3-minute period, or if
completion was unable to be reached. Scores were awarded for each based on time to
completion (i.e., shorter time to completion is awarded a larger score) and the total score
across the completed mazes was calculated (Pietrzak, Sprague and Snyder, 2008).



Brief Visuospatial Memory Test-Revised (BVMT-R): BVMT-R measures visual learning.
In this test, participants are presented with an array of six figures on a page for 10 seconds,
and are required reproduce them exactly as they appear on the page. Three attempts are
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given. A score for each correct figure and its positioning was awarded and a total of the
three attempted was calculated (Tam and Schmitter-Edgecombe, 2013).


Category Fluency-Animals (CF-Animals): CF-Animals measures speed of processing.
Participants are required to name as many animals as possible with a 60 second period. The
number of unique animals named was calculated (Gladsjo et al., 1999).

2.3.4

Statistical Analyses
Statistical analyses were performed using IBM SPSS Statistics 27. For cognitive data,

T-scores and percentiles (%ile) were calculated from the participant’s raw scores for each test.
This was done by determining which T-score and %ile the raw scores corresponded to
according to published normative data, corrected for age and gender. In this way, participant’s
performance could be compared to the general population in the absence of a control cohort
(as per COVID impact statement above). One-Way ANOVAs were used to examine treatment
(methadone or BNX) effects on neurocognitive test performance and demographic parameters.
Pearson’s Correlation tests were used to investigate the relationship between test scores and
treatment-related parameters (dosage, time since last treatment, life-time length of
pharmacological treatment, length of stay) and non-treatment demographic parameters (age,
BMI, years of education). In the event that data did not meet the assumption of normality,
Spearman’s rho tests were used for correlation analyses. Correlation analyses were conducted
on the cohort as a whole, and for the methadone and BNX groups individually. Significant
differences were accepted when p < .05; however, non-significant trends in the data (p = .05 to
.07) were also noted.
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2.4 Results
2.4.1

Demographics
Demographics are outlined in Table 2.1. The cohort included 22 subjects, with 15

undergoing methadone treatment (11 male), and 7 undergoing BNX treatment (2 male). The
mean age was 37.32 ± 1.40 years for the whole cohort, 37.60 ± 1.59 years for the methadone
group and 36.71 ± 2.80 years for the BNX group with no significant difference between the
groups (F(1, 20) = .087, p = .771) (Table 2.1). The mean BMI for the whole cohort was 27.67
± 1.49, including 28.49 ± 1.40 for the methadone group and 25.92 ± 3.70 for the BNX group
that were not significantly different between groups (F(1, 20) = .637, p = .434) (Table 2.1).
Mean years of education was 11.36 ± 0.45 years for the whole cohort, and when
analysed based on treatment group, the methadone group had 10.67 ± 0.42 years of education
while the BNX group had 12.86 ± 0.91. A one-way ANOVA revealed a statistically significant
difference in years in education (F(1, 20) = 6.344, p = .020) between these groups (Table 2.1).
There was no significant difference in total years of education for the father (F(1, 20) = .408,
p = .536), or mother (F(1, 20) = .232, p = .638) in the methadone compared to the BNX
treatment groups (Table 2.1).
Mean length of treatment (life-time treatment with methadone or BNX) for the whole
cohort was 1097 ± 403.20 days, and there were no significant differences between the length
of treatment in the BNX- compared to the methadone-treated group (F(1, 15) = 2.695, p = .121)
(Table 2.1). When considering length of stay within the treatment facility, the average number
of days was 60.68 ± 10.94 for the cohort as a whole, 44.07 ± 9.67 days for the methadonetreated group whereas the BNX-treatment group exhibited a significantly longer stary
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Table 2.1 Cohort demographics
Whole Cohort
N
Sex

22

(Methadone
Group)
15

Male
Female
Age (x̄ ± SEM)

13
9
37.32 ± 1.40

11
4
37.60 ± 1.59

2
5
36.71 ±
2.80

Handedness
Right
Left
BMI (x̄ ± SEM)

22
0
27.67 ± 1.49

15
0
28.49 ± 1.40

Education (Years, x̄ ± SEM)

11.36 ± 0.45

10.67 ± 0.42

7
0
25.92 ±
3.70
12.86 ±
0.91

10.81 ± 1.22
11.10 ± .99

11.44 ± 1.00
11.50 ± 0.62

1097.12 ±
403.20
60.68 ± 10.94

1503.42 ±
532.81
44.08 ± 9.67

246.73 ± 29.64

242.40 ± 37.96

-

30 - 135
95.36 ± 7.89

16
17
3
2
1
7
2
3
2

10
12
3
1
2
5
2
2
1

6
5
0
1
0
3
0
1
1

3
16
11
11
14
5
6
7

3
10
6
7
9
4
5
3

6
5
4
5
1
1
4

Parent’s Education (Years, x̄ ±
SEM)
Father
Mother
Length of Treatment (Days, x̄ ±
SEM)
Length of Stay (Days, x̄ ± SEM)
Time since last Treatment
(Minutes, x̄ ± SEM)
Dosage (Range, mg)
(mg, x̄ ± SEM)
Self-Reported Psychiatric Illness
Depression
Anxiety
Bipolar
Schizophrenia
Panic Disorder
PTSD
Psychosis
Personality/Behavioural
Other
Self-Reported Substance Use in
Past 6 Months
Alcohol
Cigarettes
Cannabis
Ice (Crystal Meth)
Heroin
Other Opioids
Other (Cocaine,
Methamphetamine, MDMA,
GHB, LSD, etc.)

(BNX
Group)
7

9.80 ± 2.89
10.50 ±
2.40
122.00 ±
23.96
96.67 ±
22.35
256.00 ±
49.39
6 - 32
19.71 ±
3.10

F

p

.087

.771

.637

.434

6.344

.020

.408
.232

.536
.638

2.695

.121

6.529

.020

.044

.837

Abbreviations: BNX=buprenorphine and naloxone, MDMA=3, 4-Methylenedioxymethamphetamine or, Ecstasy,
GHB=Gamma-hydroxybutyrate
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of 96.67 ± 22.35 days (F(1, 20) = 6.529, p = .020) (Table 2.1). The mean time since last
treatment (i.e. most recent dose of methadone or BNX) for the whole cohort was 246.73 ±
29.64 minutes and there was no statistically significant difference in the time since last
treatment (F(1, 20) = .044, p = .837) between the treatment groups (Table 2.1). Self-reported
psychiatric illnesses and substance use over the past 6 months are shown in Table in 2.1, with
each participant reporting use of at least one substance; however, given that participants enter
the facility due to opioid dependence, opioid misuse was underreported (Table 2.1).

2.4.2

Neurocognitive Test Scores of Participants: Whole Cohort and Pharmacological
(Methadone or BNX) Treatment Groups
The mean neurocognitive test T-scores and percentiles are shown in Table 2.2. In the

absence of a control group, the ability to examine the scores of the participants undergoing
treatment compared to non-treated subjects was not possible; however, examination of the
percentiles identified average-low cognitive performance across the cohort as a whole. Scores
in the highest percentile were apparent in the CF-Animal Naming test (52.85 ± 5.25 percentile),
and lowest performance was observed in the HVLT-R test (19.85 ± 3.65 percentile) (Table
2.2). A one-way ANOVA was conducted to investigate the effect of treatment on
neurocognitive test performance; however, there were no significant differences between
scores in the methadone or BNX treatment groups for any of the tests conducted (TMT-A, F(1,
20) = .046, p = .832; BACS-SC, F(1, 20) = 1.283, p = .271; HVLT-R, F(1, 20) = .158, p =
.696; WMS III-SS F(1, 20) = 1.205, p = .285; LNS, F(1, 20) = .001, p = .971; NAB Mazes,
F(1, 20) = .529, p = .476; BVMT-R, F(1, 20) = .174, p = .681; and CF Animal Naming, F(1,
20) = 1.291, p = .269) (Table 2.2).
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Table 2.2 Mean neurocognitive test T-scores and percentiles by treatment groups
Test Scores (x̄ ± SEM)
TMT-A
T-score
%ile
BACS-SC
T-score
%ile
HVLT-R
T-score
%ile
WMS III-SS
T-score
%ile
LNS
T-score
%ile
NAB Mazes
T-score
%ile
BVMT-R
T-score
%ile
CF-Animal Naming
T-score
%ile

Whole Cohort

(Methadone Group)

(BNX Group)

45.23 ± 1.88
35.95 ± 5.76

44.87 ± 2.36
35.08 ± 7.21

46.00 ± 3.27
37.80 ± 10.19

40.64 ± 2.45
27.46 ± 6.22

38.13 ± 3.18
22.68 ± 7.87

46.00 ± 2.90
37.71 ± 9.55

38.96 ± 1.52
19.85 ± 3.65

38.53 ± 2.09
20.86 ± 5.23

39.86 ± 1.88
17.69 ± 2.96

40.91 ± 2.06
26.53 ± 5.06

39.73 ± 2.34
22.75 ± 5.66

43.43 ± 4.22
34.61 ± 10.25

40.18 ± 2.34
25.59 ± 5.22

40.20 ± 2.71
25.45 ± 5.95

40.14 ± 4.86
25.87 ± 11.11

46.32 ± 1.83
38.00 ± 5.96

45.40 ± 2.09
35.00 ± 6.64

48.29 ± 3.73
44.43 ± 12.64

45.09 ± 2.57
42.93 ± 7.29

45.33 ± 3.17
45.05 ± 9.05

44.57 ± 4.74
38.39 ± 13.08

51.45 ± 1.89
52.85 ± 5.25

49.73 ± 1.90
48.80 ± 6.01

55.14 ± 4.23
61.53 ± 10.22

No significant difference between the treatment groups (all p>0.05).
2.4.3

Correlation between Treatment Factors (Dosage, Time Since Last Dose, Length of
Treatment and Length of Stay) and Test Score
Correlation analyses were conducted to investigate the relationship between dosage and

neurocognitive test scores for each treatment group. Pearson’s correlation tests reveal no
significant relationship between dosage and neuropsychological test performance in the
methadone or BNX groups (all p>0.05) (Table 2.3).
Table 2.3 Correlation between Dosage (mg) and neurocognitive test performance (%ile)
Test
TMT-A
BACS-SC
HVLT-R
WMS III-SS
LNS
NAB Mazes
BVMT-R
CF-Animal Naming

Methadone Group
r = -.446, p = .110
r = .055, p = .853
r = -.148, p = .615
r = -.098, p = .740
r = -.090, p = .758
r = .171, p = .559
r = .136, p = .643
r = .387, p = .172

BNX Group
r = -.195, p = .676
r = -.110, p = .815
r = .066, p = .888
r = -.300, p = .514
r = .025, p = .957
r = .666, p = .103
r = -.388, p = .390
r = -.403, p = .370
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To investigate the relationship between time since last treatment dosage and
neurocognitive test performance Pearson’s correlation tests were conducted. No significant
correlations were identified between the variables when analysing the cohort as a whole (all p
> 0.05); however, a trend towards a positive correlation between time since last treatment and
NAB Mazes scores was identified when observing the data across the whole cohort (r = .374,
p = .068) (Table 2.4). When splitting the data based on treatment, there was a significant and
strong positive correlation between time since last treatment and HVLT-R test performance (r
= .770, p = .043) within the BNX treatment group (Figure 2.1), with no further significant
correlations noted in either treatment group (all p > .05) (Table 2.4).

Table 2.4 Correlation between Time since last Treatment (minutes) and neurocognitive
test performance (%ile)
Test
Whole Cohort
(Methadone Group)
TMT-A
r = .301, p = .174
r = .204, p = .466
BACS-SC
r = .197, p = .378
r = .075, p = .792
WMS III-SS
r = -.159, p = .478
r = -.215, p = .442
LNS
r = .251, p = .260
r = .108, p = .703
NAB Mazes
r = .374, p = .068^
r = .272, p = .326
BVMT-R
r = .033, p = .884
r = -.060, p = .831
CF-Animal Naming
r = .149, p = .509
r = -.024, p = .933
Notes: ^ results trended towards significance (p = .05 - .07)

(BNX Group)
r = .558, p = .193
r = .565, p = .187
r = -.100, p = .831
r = .557, p = .194
r = .592, p = .162
r = .298, p = .517
r = .519, p = .232

Spearman’s rho tests were utilised when examining the relationship between length of
treatment (i.e. self-reported life-time length of methadone or BNX treatment) and test
performance as the assumption of normality was not met; however, no significant correlations
were found across the cohort as a whole (all p > .05) (Table 2.5, Figure 2.2). When considering
data for each treatment group, a significant and strong positive correlation was found between
WMS III-SS performance and length of treatment for the BNX group (r = .920, p = 027), but
this was not significant for the methadone group (Figure 2.2) and no other correlations were
identified for length of treatment (all p > .05).
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Figure 2.1 Correlation between time since last treatment (minutes) and HVLT-R test
performance (%ile) for the whole cohort and by treatment. A significant and strong
positive correlation was found between time since last treatment and HVLT-R performance for
the BNX treatment (r = .770, p = .043). No significant correlation was found for the whole
cohort (r = .031, p = .891 or the methadone group (r = -.071, p = .801).

Table 2.5 Correlation between length of treatment (days) and neurocognitive test
performance (%ile)
Test
TMT-A
BACS-SC
HVLT-R
LNS
NAB Mazes
BVMT-R
CF-Animal Naming

Whole Cohort
r = -.022, p = .933
r = .310, p = .226
r = .221, p = .395
r = .031, p = .907
r = .278, p = .279
r = .400, p = .111
r = .076, p = .773

(Methadone Group)
r = .060, p = .853
r = .341, p = .278
r = .338, p = .283
r = .062, p = .849
r = .468, p = .125
r = .312 p = .323
r = .412, p = .183

(BNX Group)
r = -.214, p = .730
r = .781, p = .119
r = -.445, p = .453
r = .373, p = .536
r = -.194, p = .754
r = .214, p = .730
r = -.463, p = .433
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Figure 2.2 Correlation between life-time length of treatment (days) and WMS III-SS test
performance (%ile) for the whole cohort and by treatment. A significant and strong
positive correlation was found between life-time length of pharmacological treatment and
WMS III-SS performance for the BNX group, (r = .920, p = .027). No significant correlation
was found for the whole cohort (r = .111, p = .671) or the methadone group, (r = -.032, p =
.922).

To assess the statistical relationship between length of stay and neurocognitive test
performance for the whole cohort, bivariate correlation analyses were conducted. The
assumption of normality was not met so Spearman’s rho were used for the analyses. No
significant correlation was found between length of stay and performance in any cognitive test
(all p > .05) (Table 2.6); however, there was a non-significant trend towards a positive
relationship between length of stay and BACS-SC (r = .435, p = .062) and a negative
correlation with HVLT-R scores (r = -.455, p = .050) (Table 2.6). Further analyses were
conducted to examine the relationship between length of stay and test performance within each
treatment group. No significant correlation was found between length of stay and performance
in any test within the methadone treatment group (all p>0.05) (Table 2.6). Furthermore, there
were no significant correlations in the BNX group (all p > 0.05); however, a trend towards a
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positive correlation was observed in the WMS II-SS scores in the BNX group (r = .787, p =
.063) (Table 2.6).

Table 2.6 Correlation between Length of Stay (days) and neurocognitive test
performance (%ile)
Test
Whole Cohort
(Methadone Group)
TMT-A
r = .412, p = .080
r = .434, p = .138
BACS-SC
r = .435, p = .062^
r = .270, p = .372
HVLT-R
r = -.455, p = .050^
r = -.333, p = .266
WMS III-SS
r = .349, p = .143
r = .290, p = .336
LNS
r = -.005, p = .983
r = -.057, p = .854
NAB Mazes
r = -.043, p = .862
r = .149, p = .627
BVMT-R
r = .098, p = .689
r = .393, p = .184
CF-Animal Naming
r = -.153, p = .531
r = -.247, p = .416
Notes: ^ results trended towards significance (p = .05 - .07)

2.4.4

(BNX Group)
r = -.388, p = .447
r = .234, p = .644
r = -.745, p = .089
r = .787, p = .063^S
r = -.257, p = .623
r = -.695, p = .133
r = .006, p = .991
r = -.598, p = .210

Correlation between Non-Treatment Related Demographic Factors (Age, BMI and
Years of Education) and Test Score

To assess the statistical relationship between demographic factors (i.e. participant age, BMI
and years of education) and neurocognitive test performance, bivariate correlation analyses
were conducted. A Pearson’s correlation test was conducted to examine age and neurocognitive
test scores across the whole cohort as the assumption of normality was met. Analyses revealed
a significant and strong positive correlation between age and TMT-A performance (r = .631, p
= .002) (Figure 2.3); however, no further significant correlations with age were reported when
considering the cohort as a whole (Table 2.7). Further analyses were then conducted to
investigate correlations between age and neurocognitive test performance for each treatment
group. A significant and positive correlation was found between age and TMT-A performance
for both the methadone (r = .530, p = .042) and the BNX group (r = .859, p = .013) (Figure
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2.3), with no significant correlations reported between age and any other neurocognitive tests
across the treatment groups (Table 2.7).
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Figure 2.3 Correlation between age (years) and TMT-A test performance (%ile) for the
whole cohort and by treatment. A significant positive correlation was found between age and
TMT-A performance for the whole cohort (r = .631, p = .002), with a moderate correlation in
the methadone group, (r = .530, p = .042), and a strong correlation in the BNX group, (r = .859,
p = .013).

Table 2.7 Correlation between age (years) and neurocognitive test performance (%ile)
Test
BACS-SC
HVLT-R
WMS III-SS
LNS
NAB Mazes
BVMT-R
CF-Animal Naming

Whole Cohort
r = .317, p = .150
r = -.225, p = .314
r = -.108, p = .633
r = -.328, p = .136
r = .165, p = .464
r = .164, p = .467
r = .020, p = .928

(Methadone Group)
r = .325, p = .237
r = -.352, p = .198
r = -.205, p = .463
r = .093, p = .742
r = .161, p = .566
r = .115, p = .683
r = -.307, p = .266

(BNX Group)
r = .408, p = .363
r = .240, p = .605
r = .078, p = .869
r = .691, p = .086
r = .204, p = .661
r = .246, p = .596
r = .518, p = .233

Spearman’s rho tests were utilised when examining the relationship between BMI and
test performance as the assumption of normality was not met, with no significant correlations
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observed across the cohort as a whole (all p > .05) (Table 2.8, Figure 2.4). However, further
analyses examining these variables for each treatment group revealed a significant and strong
negative correlation between BMI and NAB-Mazes performance for the BNX group (r = -.817,
p = .014) (Figure 2.4), but no other correlations between test scores and BMI were noted in the
treatment groups (Table 2.8).

Table 2.8 Correlation between body mass index and neurocognitive test performance
(%ile)
Test
TMT-A
BACS-SC
HVLT-R
WMS III-SS
LNS
BVMT-R
CF-Animal Naming

Whole Cohort
r = -.167, p = .458
r = -.245, p = .272
r = -.264, p = .234
r = .020, p = .928
r = -.145, p = .518
r = .054, p = .812
r = -.049, p = .830

(Methadone Group)
r = -.362, p = .185
r = -.098, p = .727
r = -.080, p = .776
r = -.278, p = .315
r = -.350, p = .200
r = .137, p = .626
r = .305, p = .269

(BNX Group)
r = .324, p = .478
r = -.036, p = .939
r = -.546, p = .205
r = .468, p = .289
r = .378, p = .403
r = -.107, p = .819
r = .036, p = .939
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Figure 2.4 Correlation between body mass index and NAB-Mazes test performance (%ile)
for the whole cohort and by treatment. A significant and strong negative correlation was
found between body mass index and NAB-Mazes performance for the BNX group, (r = -.857, p
= .014). No significant correlation was found across the cohort as a whole (r = -.351, p = .109)
or for the methadone group, (r = -.019, p = .948).
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Finally, there were no significant correlations between years of education and
neurocognitive test scores across the cohort as a whole (all p > .05) (Table 2.9); however,
correlations between CF-Animal Naming score and years of education trended towards
significance for the whole cohort (r = .408, p = .059) and the BNX group (r = .741, p =.057),
as did BVMT-R and years of education for the BNX group (r = .741, p = .057), with no other
correlations observed (Table. 2.9).

Table 2.9 Correlation between education (years) and neurocognitive test performance
(%ile)
Test
Whole Cohort
(Methadone Group)
TMT-A
r = .143, p = .527
r = .141, p = .615
BACS-SC
r = .217, p = .332
r = -.030, p = .915
HVLT-R
r = .388, p = .075
r = .429, p = .111
WMS III-SS
r = .221, p = .323
r = .036, p = .898
LNS
r = -.085, p = .707
r = -.123, p = .662
NAB Mazes
r = .185, p = .410
r = .464, p = .081
BVMT-R
r = .329, p = .134
r = .405, p = .134
CF-Animal Naming
r = .408, p = .059^
r = .145, p = .607
Notes: ^ results trended towards significance (p = .05 - .07)

(BNX Group)
r = .278, p = .546
r = .330, p = .469
r = .215, p = .643
r = .241, p = .603
r = .259, p = .574
r = -.385, p = .393
r = .753, p = .051
r = .741, p = .057^
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2.5 Discussion
The present study aimed to investigate neurocognitive functioning in a cohort of
individuals following chronic opioid exposure (i.e., undergoing pharmacological treatment
using the opioid medications methadone and BNX, for chronic opioid dependence). Clinical
parameters relating to treatment, such as drug treatment administered, dosage, time since last
treatment, life-time length of pharmacological treatment and current length of stay in the
residential facility, as well as non-treatment related parameters including age, years of
education and BMI were examined using correlational analyses to infer the major factors
influencing cognitive function in specific domains. In the present population-based study, there
were no significant differences in cognitive test scores between methadone and BNX-treated
individuals; however, overall test scores were below-average to average across all tests utilised
when assessing percentiles as an indicator of performance compared to the general population.
Individuals undergoing BNX treatment had a higher self-reported number of years in
education; however, correlational analyses did not identify a significant relationship between
years of education and cognitive performance in either of the treatment groups or the cohort as
a whole. Participants undergoing BNX treatment also had a longer length of stay compared to
the methadone group, indicating greater compliance to the rehabilitation therapy program;
however, length of stay within the facility did not appear to significantly impact cognitive
performance in either group. This differed to the self-reported lifetime history of treatment with
either methadone or BNX, as this study revealed a strong positive relationship between the
length of BNX treatment and non-verbal working memory (WMS III-SS). Treatment dosage
did not correlate to cognitive performance but timing between the last dose and the start of
cognitive testing was a factor following BNX treatment, as there was a strong positive
correlation with verbal learning (i.e., HVLT-R performance) in the BNX group that was not
apparent in the methadone group. Non-treatment related demographics factors, such as age and
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BMI, impacted cognition with an unexpected significant improvement in processing speed
(TMT-A scores) with increasing age in the cohort as a whole and across both treatment groups,
and a negative correlation between BMI and reasoning / problem solving (NAB-Mazes) in the
BNX group that was not apparent in the methadone group.
The finding that the two treatment groups did not significantly differ in cognitive
performance is in agreement with a finding by Rapeli et al. (2011), who reported no significant
difference in verbal memory performance (Logical Memory subtest from the WMS III) in
participants treated with either methadone, buprenorphine or BNX (also known as suboxone).
However, several other studies that reported superior performance in the domains of verbal
memory, as well as impulsivity, cognitive flexibility, executive function and attention in
patients undergoing buprenorphine treatment compared to methadone-treated patients (Hill,
Garner and Baldacchino, 2018, Nikraftar et al., 2021b, Rapeli et al., 2007). For example, a
study by Rapeli et al., (2011) examined patients treated with buprenorphine or
buprenorphine/naloxone and revealed improvements in the LNS task from 6 – 9 months posttreatment to 12 – 17 months post-treatment, a finding that was not replicated in methadonetreated patients or controls. Although there was no control group included in the present study,
results revealed below-average to average cognitive performance in participants treated with
either methadone or BNX compared to the general population when utilising percentiles as an
indicator of test performance. Other studies report mixed results when comparing cognitive
performance to drug naïve patients. For example, our findings are in line with prior reports of
impairments in speed of processing, verbal fluency, working memory as well as attention and
impulsivity in cohorts undergoing treatment with methadone compared to non-treated controls
(Li et al., 2021, Mintzer and Stitzer, 2002, Sant, Camilleri and Dimech, 2020). Motazedian et
al. (2021) also reported impairments in executive functioning, short-term memory and attention
in a cohort of MMT patients compared to abstinent opioid users, suggesting that cognitive
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function could recover following cessation of opioid intake. However, other studies have also
reported no significant impairment in certain domains, such as non-verbal memory and
visuospatial skills, as well as attention and executive function in participants undergoing
methadone treatment compared to healthy controls (Elkana et al., 2019, Sant et al., 2020).
Interestingly, the results of the present study showed that CF-Animal Naming performance was
slightly higher than average in the present cohort compared to the general population
(particularly in the BNX-treated group), which also seems converse to the established research.
For example, impaired performance in similar paradigms have been reported in patients
undergoing methadone (Elkana et al., 2019, Mazhari et al., 2015) and buprenorphine treatment
(Messinis et al., 2009, Soyka et al., 2008). However, the present study appears to be the first to
reveal cognitive improvements in processing speed linked to increased length of treatment with
BNX. Overall, the contrasts between findings across studies may be due to the use of different
neurocognitive tests. For example, the present study tested verbal memory performance with
the Letter Number Span paradigm, whereas the Logical Memory subtest of the WMS III was
utilised in other studies (Rapeli et al., 2007, Rapeli et al., 2011). Inconsistencies may also be
due to differences in drug treatments (most studies have focussed on methadone or
buprenorphine alone), dosage, the populations studied, and also due to the small sample size
used in the present study. These inconsistencies highlight the need to utilise a standard testing
battery to investigate the effects of opioid on cognitive performance in research going forward.
The inconsistences also demonstrate the need to further investigate how cognitive performance
varies in BNX-treated cohorts compared to other opioids and controls (using adequately
powered study designs), as this is under investigated in the literature.
The present study did not find any significant correlations between dosage and test
performance for either treatment. This finding was unexpected, as we hypothesised that dosage
would impact cognition. Indeed, higher methadone dosage has been reported to impair
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performance in episodic memory (Curran et al., 2001), attention and working memory (Rass et
al., 2014), but improve performance in executive functioning (Rass et al., 2014). The dosage
range of methadone administered in our cohort was 30-135mg, lower than the range of 40 –
200mg administered in the study conducted by Rass et al. (2014). However, much like the
present study, no significant correlation was found between test performance and
buprenorphine dosage by Saroj et al. (2020); or between test performance and either
buprenorphine or methadone dosage by Soyka et al. (2008). Therefore, further studies are
required to clarify the effects of dosage on cognitive performance during treatment. On the
other hand, the present study identified a significant and strong positive correlation between
self-reported lifetime history of BNX treatment and working memory (WMS III-SS), and
between time since last treatment and verbal learning in the BNX treatment group (not in the
methadone treatment group). These results suggest that increased BNX adherence could
improve aspects of cognitive function and that timing between dosing and testing should be a
consideration in future studies. However, it is also important to note the limitations of
correlational analyses and that controlled longitudinal studies would be helpful in
understanding whether cognitive benefits exist during BNX treatment over time. Nevertheless,
a positive correlation between verbal working memory (Sternberg task) and length of
methadone treatment was also reported by Rass et al. (2014), who also demonstrated a positive
correlation between length of treatment, and episodic memory and meta-memory. However,
while the present study found that increased time since last treatment correlated to improved
verbal working memory performance, Rass et al. (2014) found that increasing time since last
treatment resulted in poorer reaction times during a working memory task (n-back task). Other
research has demonstrated a negative correlation between time since last treatment and
performance in psychomotor function, attention and episodic memory (Rass et al., 2014) and
cognitive flexibility (Barahmand et al., 2016), while Elkana et al. (2019) did not find a
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significant correlation between duration of methadone use and cognitive performance, or time
since last treatment and cognitive performance. Taken together, the results of the present study
and others could reflect methodological differences between studies (i.e., the present study
included participants with self-reported mental illness, whereas others excluded patients with
psychiatric illnesses (Rass et al. (2014), Curran et al. (2001)), and drug treatment examined
(i.e., other studies examine methadone while the present study found significance in the BNX
treatment group which was not administered to participants in these prior studies).
Alternatively, it is possible that cognitive performance follows an inverted U-shaped curve in
the time following treatment, where scores are lower immediately following treatment (i.e. a
possible sedative/euphoric effect), improving within the hours after the dose, then lowering
over time prior to the need for the next dose; however, longitudinal studies are required to
confirm this suggestion.
In the present study, although the BNX group had a significantly longer length of stay
compared to the methadone-treated group, no significant correlation was found between
performance in any test and this factor. As with our study, Elkana et al. (2019) did not find a
correlation between length of methadone maintenance treatment on verbal and non-verbal
memory, attention and executive function or psychomotor functioning in methadone-treated
patients. Similarly, our findings are supported by Saroj et al. (2020) who did not find a
correlation between length of treatment and verbal learning, speed of processing, and verbalor non-verbal working memory, in patients undergoing buprenorphine treatment compared to
healthy controls. Conversely, Li et al. (2021) reported impairment in some tasks measuring
impulsivity (such as delayed discounting) but not others (such as the beads task) in patients
undergoing MMT compared to healthy controls. Also in contrast to our findings, Rass et al.
(2014) report a positive correlation between treatment duration and working memory, the free
recall component subtest measuring episodic memory and meta-memory, as well as increased
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false alarm rates during tasks measuring recognition memory. In the present study, while an
increased length of stay could reflect greater adherence to the rehabilitation program, we were
unable to determine whether the lower mean length of stay in the methadone group reflected
higher drop-out rates, or increased rate of progression through the rehabilitation program. The
literature does not suggest a significant difference in compliance in patients treated with
methadone compared to those treated with buprenorphine (Kinsky et al., 2019, Soyka et al.,
2008, Strain et al., 1994); however, this is the first report in BNX patients. It should also be
noted that inconsistencies between our findings and the literature may be explained by the large
standard error for length of days for the methadone group, but further research is needed to
validate these conclusions.
Non-treatment related demographic factors (age and BMI) were found to have a
significant influence on cognitive performance in some tests. The present study found that age
was positively correlated to speed of processing (TMT-A) in both treatments and when the
cohort was analysed as a whole. We hypothesised that increased age would negatively impact
cognitive function, similar to the findings of Waters and Caplan (2005), who reported a
negative correlation between age and speed of processing utilising a digit symbol substitution
task (a paradigm similar to the BACS-SC test used in the present study), and deficits in working
memory and executive functioning (Murman, 2015). However, the average age of the
population investigated in the present study was approximately 37 years; therefore, while
increasing age could be a factor contributing to cognitive impairment, it may not have been a
negative influence in the present study due to the younger age of the participants. Indeed,
Kennedy (1981) reported poorer TMT-A performance in participants aged 50 – 69 compared
to participants aged 20 – 49 from the general population. In addition to age, BMI was negatively
correlated to reasoning / problem-solving performance (NAB-Mazes) in the BNX group but
not the methadone treatment group. The established literature supports our finding that
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increased BMI negatively impacts cognitive performance (Smith et al., 2011). For example,
BMI was negatively correlated to reasoning / problem-solving and executive functioning in
children (Gray, Schvey and Tanofsky-Kraff (2020) and adults (Gunstad et al., 2007). Studies
by Gunstad et al. (2010) and Nilsson and Nilsson (2009) also reported a negative effect of
higher BMI on performance in prospective memory, verbal fluency (letter and category
fluency) and semantic memory in adults; however, Gunstad et al. (2010) also reported superior
visuospatial attention and processing speed in participants with a higher BMI compared to
lower BMI participants. While studies do report higher BMI in chronic opioid users (Diasso et
al., 2019), few studies have investigated how BMI and chronic opioid use may influence
cognition together. The average BMI in our cohort was 27.67, which is considered overweight
and having excess adiposity (Flegal et al., 2005, Okorodudu et al., 2010). A possible
mechanism by which BMI may lead to impaired cognition is through the inflammatory effect
of adipose tissue. For example, Cannavale et al. (2021) found that C-reactive protein (an
inflammatory marker) mediated the relationship between visceral adipose tissue and
impairments in performance in attentional inhibitory control as assessed by a modified flanker
task. Opioids similarly have a pro-inflammatory effect (Hofford, Russo and Kiraly, 2019),
inducing upregulation of cytokines such as TNF-α and IL-6 (Johnston et al., 2004) and altering
neuro-inflammation related pathways in the brains of chronic opioid users (Seney et al., 2021).
Hence, a high BMI in the context of chronic opioid use may further exacerbate cognitive
impairment through an inflammatory process; however, further research is required to confirm.
Interestingly, while age and BMI did affect cognitive performance, other demographic factors
such as years of education (which were significantly different between the treatment groups)
did not influence test performance. Given the results of the present study, future research
should consider the potential influence of demographic co-variates on cognitive performance.
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There are several shortcomings of the present study. Firstly, the present study utilised
a small population-based sample that may have impacted the results and larger, multi-site
studies are required. Secondly, the present study was not able include a drug-naïve control
group (see COVID Impact Statement), which is a limitation that should be addressed in future
research in order to determine whether cognitive function is reduced in people undergoing
opioid treatment compared to people without a history of opioid use, and to examine
differences between drug treatment groups. Importantly, correlational analyses can only infer
statistical relationships and may not represent cause or effect. In addition, the present study
included participants with a self-reported history of comorbid psychiatric illness, comorbid
substance use or history of psychiatric medication use, which could influence cognitive
outcomes. Furthermore, while each participant in this study was admitted to the residential
rehabilitation site for opioid misuse, few participants recalled a history of opioid use during the
collection of demographic data. Accurate demographic data should be incorporated as covariates in future studies. In addition, a consensus on the gold standard of tests to use when
assessing cognitive performance in individuals with chronic opioid misuse should be made in
order to assist comparison of results across studies.
In conclusion, the present study revealed cognitive deficits in individuals undergoing
methadone or BNX treatment for chronic opioid misuse in an Australian residential
rehabilitation setting, with no significant differences between treatment groups. Clinical
parameters pertaining to treatment, such as increased time since last dosage and length of
treatment with BNX was associated with improved cognition in key domains, while dosage
and length of stay did not alter test scores. None of the parameters examined influenced
cognition during methadone treatment. BNX treatment may increase adherence to the
residential rehabilitation program, evidenced through an increased length of stay compared to
the methadone treatment group. Non-treatment related demographic parameters, such as age
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and BMI influenced cognition, while years of education did not. This study is among the first
to investigate the effects of BNX treatment on cognitive functioning and examine other factors
that may affect neurocognitive performance. The results of this small-sample population study
demonstrate reason for further studies to investigate cognition and influencing factors in opioid
misuse, ideally employing longitudinal study designs. Understanding the factors that influence
cognitive performance in cohorts engaging in chronic opioid use may help to guide the
development of future novel treatments and improve the lives of people with opioid addiction.
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Chapter 3
Dysbiosis of the Commensal Gut Microbiota in Chronic Opioid Use

3.1

Abstract
Chronic opioid use is occurring at an epidemic rate, resulting in several severe

consequences such as impaired cognition. Existing medications for treating opioid addiction
have inherent limitations such as high abuse potential, relapse and dropout, the potential to
induce withdrawal symptoms and to further impair cognition. A growing body of literature has
demonstrated that the gut microbiota engages in bidirectional communication with the brain,
and is also altered (dysbiotic) in patients engaging in chronic alcohol and cocaine use compared
to healthy controls. Clinical and preclinical studies similarly report dysbiosis in cohorts
engaging in chronic opioid use, though the pattern of dysbiosis is inconclusive. Therefore, the
present study aimed to determine: a) what the effect of opioid use is on the gut microbiota, and
b) outline the changes in functional potential to the gut microbiota by opioid use and how they
may relate to the signalling pathways of the microbiota-gut-brain axis. A systematic literature
search of three databases (SCOPUS, PubMed, and Web of Science) was conducted for studies
investigating the effect of chronic opioid use on the gut microbiota. 20 articles were included
in the present review (4 clinical, 16 preclinical). Chronic opioid use consistently resulted in
alterations in beta, but not alpha, diversity. Seven genera were repeatedly dysbiotic in clinical
studies, as well as 36 microbes at various levels of taxonomy in preclinical studies. Four
bacteria (Dialister, Lachnospiraceae, Peptostreptococcaceae and Ruminococcaceae) had a
consistent pattern of dysbiosis across both clinical and preclinical studies. Four phyla
(Actinobacteria, Bacteroidetes, Cyanobacteria, Firmicutes), four families (Bacteroidaceae,
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Lachnospiraceae, Peptostreptococcaceae, Ruminococcaceae), and 13 genera (Alistipes,
Alloprevotella,

Anaerostipes,

Bacteroides,

Bifidobacterium,

Dialister,

Haemophilus,

Lactobacillus, Parabacteroides, Parasutterella, Prevotella, Roseburia, Ruminococcus) were
repeatedly dysbiotic as a result of opioid use, in addition to several metabolites (including short
chain fatty acids and bile acids) and metabolic pathways, all of which may contribute to brain
function. Future research would benefit from determining the relationship between these
microbes, their functional potential and cognition in the context of opioid addiction and
cognition.
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3.2

Introduction
Harmful use of opioids, opioid misuse and opioid use disorder (OUD) are growing

public health concerns that require treatment options facilitated by a deeper understanding of
the pathophysiology of the disorders. An alarming increase in prevalence of OUD and a high
rate of misuse of opioids have been reported, with an estimated 40.5 million individuals
misusing opioids globally in 2017 (Degenhardt et al., 2019, James et al., 2018). Major factors
contributing to this increase are the misuse of prescription opioids (such as codeine) (Han et
al., 2017, Han et al., 2015, Han, Sherman and Palamar, 2019), and synthetic opioids (such as
fentanyl) (Jones, Einstein and Compton, 2018, O'Donnell, Gladden and Seth, 2017), overprescription for minor pain, as well as a shift to stronger and longer acting opioids (such as
oxycodone and methadone) (Karanges et al., 2016, Gisev et al., 2018, Larance et al., 2018, Han
et al., 2017, Han et al., 2015, Han et al., 2019). Opioid misuse is defined as the use of opioids
outside of prescriber direction (Elliott and Jones, 2019), whereas OUD is a DSM-5 substance
use disorder characterised by the continued and harmful use of opioid drugs despite the
presence of detrimental outcomes (Blanco and Volkow, 2019, Strang et al., 2020). These
include greater likelihood for, and rates of, polysubstance misuse and dependence (Compton,
Valentino and DuPont, 2021, D'Amico et al., 2021), neonatal abstinence syndrome (Martins et
al., 2019), potential involvement with the criminal justice system (Pryor et al., 2021,
Subramaniam and Stitzer, 2009, Winkelman, Chang and Binswanger, 2018), negative
economic consequences (Oderda et al., 2015, Edwards et al., 2020, Florence et al., 2021) and
an increased risk of mortality (Gaither, Shabanova and Leventhal, 2018, Olfson et al., 2019,
Mattson et al., 2021). Existing treatments for opioid use disorders include pharmacological
interventions (methadone maintenance treatment, buprenorphine/naloxone treatment) and
psychobehavioural interventions (such as cognitive behavioural therapy, CBT), however these
treatments have limitations (Dugosh et al., 2016). Methadone is a µ-opioid receptor agonist
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useful in opioid detoxification and in opioid maintenance therapy programmes (Ayanga,
Shorter and Kosten, 2016). Whilst methadone has shown efficacy in treating opioid dependent
patients (Salsitz and Wiegand, 2016), treatment efficacy is dependent on early treatment
adherence (i.e., during first 12 months), which is when treatment dropout is highest (Salsitz
and Wiegand, 2016, Nosyk et al., 2010, Cao et al., 2014), and incorrect dosage can result in
relapse or poor treatment adherence (D'Aunno, Park and Pollack, 2019). Buprenorphine is a
partial µ-opioid receptor agonist also used in maintenance therapy, often in conjunction with
the opioid receptor antagonist naloxone (i.e., BNX) (Ayanga et al., 2016). Although
buprenorphine has many benefits over methadone, such as a decreased likelihood of being
misused (Ayanga et al., 2016), evidence indicates poorer retention (Burns et al., 2015,
Gryczynski et al., 2013, Hser et al., 2014), especially at lower or unfixed doses (Mattick et al.,
2014). In addition, high levels (up to 59%) of treatment drop-out have been reported during
early phases of buprenorphine treatment (Ponizovsky et al., 2010, Hakansson and Hallen,
2014). Psychobehavioural therapies (such as Cognitive Behavioural Therapy; CBT) alone
(Mayet et al., 2005, Veilleux et al., 2010), or in combination with pharmacotherapies (Amato
et al., 2011, Strang et al., 2020) also have limited efficacy. Therefore, novel treatments for
opioid dependence are required.
Poorer cognitive performance in several domains has been reported in patients engaging
in harmful opioid use (see Chapter 2). For example, performance in attention, executive
function, psychomotor speed, and working memory are reportedly below the levels of healthy
patients (Baldacchino et al., 2012, Wollman et al., 2019, Sanborn et al., 2020, Kroll et al.,
2018). This is an issue that requires more attention due to the potential importance of cognition
in the course of substance use disorders and their treatment. Indeed, research on other
commonly abused substances, such as alcohol and cocaine, demonstrate an inverse relationship
between cognitive performance and positive treatment outcomes including treatment adherence
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(Teichner et al., 2002, Aharonovich et al., 2006, Streeter et al., 2008, Copersino et al., 2012,
Manning et al., 2017, Mahoney, 2019, Caballeria et al., 2020). It is unclear whether existing
treatments for OUD improve the cognitive dysfunctions associated with the disorder, and some
evidence suggests that pharmacological treatments for opioid addiction may further worsen
cognitive outcomes (Pujol et al., 2018). Patients undergoing methadone maintenance treatment
(MMT) can present with poorer cognitive performance compared with both healthy controls
and abstinent patients (Baldacchino et al., 2017, Motazedian et al., 2021, Sanborn et al., 2020).
Buprenorphine-treated patients show poorer performance in tasks measuring cognitive
flexibility, set shifting, working memory and executive function (Soyka et al., 2008, Saroj et
al., 2020). A study by Rapeli et al. (2007) investigated the cognitive performance of patients
undergoing either methadone, or combined buprenorphine / naloxone treatment, compared to
untreated, non-addicted healthy controls. Results indicated poorer performance in working
memory in both the treatment groups compared to the controls, with lower attention and verbal
memory also reported in participants undergoing methadone treatment (Rapeli et al., 2007). In
a subsequent longitudinal study, neither methadone nor buprenorphine were able to recover
cognitive performance over the long term, as neither treatment group showed improvement in
working memory performance (Rapeli et al., 2009). Overall, there is a need to address the
shortcomings of these existing treatments in terms of efficacy for addiction and cognitive
impairments associated with OUD, and novel treatment options that may potentially target
these pathologies are required.
There has been a growing body of evidence in recent years to show that the commensal
microflora community inhabiting the gastrointestinal tract (known as the gut microbiota) plays
an integral role in host health, including brain function and cognition (Bienenstock, Kunze and
Forsythe, 2015, Liang, Wu and Jin, 2018, Cryan et al., 2019). A central part of microbiota
research involves characterising the structure of the gut microbiota, and generally utilises 16S
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rRNA gene sequencing (Bjorkhaug et al., 2019, Wang et al., 2018b) or shotgun (whole
genome) sequencing (Dubinkina et al., 2017), and considers many factors including alpha and
beta diversity. Alpha diversity (measured by indices such as Chao1, the Shannon index, the
Simpson index and the ACE index), considers the richness (number of species present) and
evenness (uniformity of the abundance of the species present) of the microbiota within a site.
On the other hand, beta diversity considers the differences and overlap in community structure
between distinct sites or individuals.
The microbiota engages in bidirectional communication with the body and brain along
the microbiota-gut-brain axis (MGB) through several pathways including the immune,
neuroendocrine and nervous systems (Carabotti et al., 2015), the ability of microbes to
produces neurotransmitters (Strandwitz, 2018), and their role in gastrointestinal tract health
(Aziz et al., 2013) and can thus influence brain function. For example, germ-free mice have
impaired microglia function (e.g., abnormal cell growth, and impaired activation) compared to
control animals, and reconstitution of the microbiota in germ-free animals is able to return
microglia to normal after several weeks (Cryan et al., 2019). Microglia, found exclusively in
the CNS, are important for healthy synaptic development and neuronal health (Morris et al.,
2013), while impaired microglia are associated with both neuropsychiatric diseases (Blank and
Prinz, 2013, Kato et al., 2013) and impaired hippocampal-dependent learning and memory
(Reshef et al., 2014). In addition, the gut microbiota can influence host health through
metabolites such as short chain fatty acids (Dalile et al., 2019, Silva et al., 2020), which are
able to influence the permeability of the blood brain barrier by regulating tight junction proteins
(Braniste et al., 2014), and can cross the blood brain barrier (Kim et al., 2013, Stilling et al.,
2016), where they may act as histone deacetylase (HDAC) inhibitors (Davie, 2003, Kim, Leeds
and Chuang, 2009). While the gut microbiota is associated with normal brain function and
behaviour (Diaz Heijtz et al., 2011, Stilling, Dinan and Cryan, 2014, Borre et al., 2014, Ceppa,
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Mancini and Tuohy, 2019) including neurodevelopment (Sampson and Mazmanian, 2015) and
cognitive function (Bajaj et al., 2012, Magnusson et al., 2015), an altered microbiota profile
(known as dysbiosis) is associated with negative health consequences, including
neuropsychiatric disorders such as autism (Strati et al., 2017b), schizophrenia (Nguyen et al.,
2021), bipolar disorder (Nguyen et al., 2018), anxiety (Crumeyrolle-Arias et al., 2014, Jiang et
al., 2018) depression (Li et al., 2019), and the severity symptoms (Madan et al., 2020, Li et al.,
2020b). A dysbiotic gut microbiota has also been associated with addiction as substance abuse
alters the gut microbiota. For example, alcohol (Dubinkina et al., 2017, Wang et al., 2018b,
Leclercq et al., 2019, Litwinowicz, Choroszy and Waszczuk, 2020), cocaine (Volpe et al.,
2014, Scorza et al., 2019) and methamphetamine (Forouzan, Hoffman and Kosten, 2020)
misuse result in dysbiosis of the microbiota. In addition to this, a study in alcohol dependence
found a link between severity of behavioural symptoms in alcohol dependent patients and an
increase in gut intestinal tract permeability, a finding which was associated with a dysbiotic
gut microbiota (Yang et al., 2019). These papers outline a relationship between the gut
microbiota and substance dependence, and the potential of the microbiota to contribute to the
cognitive impairments observed in these disorders.
Research suggests that opioid misuse also causes dysbiosis in the gut. For example, a
clinical study by Acharya et al. (2017) found beta diversity to be different between patients
engaging in opioid use compared to patients not engaging in opioid use in a cohort with hepatic
encephalitis, but did not report results regarding alpha diversity. Preclinical studies have also
found alterations in alpha and beta diversity as a result of morphine treatment as well as
enrichment in several strains (Wang et al., 2018a), however other studies do not observe any
patterns of dysbiosis in alpha diversity as a result of morphine treatment (Lee et al., 2018).
Therefore, results on the effect of opioid use on the gut microbiota remain unclear. Addressing
this gap may identify microbes that could serve as candidates for targets in succeeding research
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aiming to understand the pathology of opioid addiction and developing novel therapeutics for
opioid addiction and associated cognitive dysfunction. While thematic reviews have explored
opioid use and the gut microbiota (Wang and Roy, 2017, Ren and Lotfipour, 2020), to the
author’s knowledge, a systematic review investigating the gut microbiota and opioid use has
not yet been conducted. As such, the aim of the present systematic literature review was to: a)
determine the effect of opioids on specific strains of the gut microbiota; and, b) outline the
potential functional outcomes of altered gut microbiota and metabolites by investigating their
role in key signalling pathways of the microbiota-gut brain axis and how they may potentially
affect cognition.

3.3

Methods
A systematic review following PRISMA guidelines (Moher et al., 2009, Moher et al.,

2015) was conducted to examine research investigating the relationship between opioid use
and the commensal gut microbiota. Opioids were selected as the sole focus of this chapter as
these substances were consistently utilised by the cohort of patients investigated in Chapter 2.
An outline detailing the screening phases of this systematic review is provided in Figure 3.1.

3.3.1

Search Strategy
Three electronic databases (PubMed, SCOPUS and Web of Science; WOS) were

searched for relevant literature. Databases were searched for original articles, written in English
up to September, 2020. Search terms used to identify literature investigating opioid use and gut
microbiota

included

“heroin, opiate*,

opioid*”

paired

with

either

“gut

microbiota, microbiome, or microbiota”. As an example, WOS database searches for studies
examining heroin and microbiota were: “heroin AND gut microbiota”,
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310 articles identified
through database searches

80 articles after removing
duplicates

80 articles screened by
title and abstract

34 articles removed that did
not investigate the effects of
opioid use on gut microbiota;
23 articles removed that were
not research papers; 1 article
removed that was not written
in English

22 articles assessed for
eligibility through full text
screening

4 studies removed that
lacked an opioid-free
control group; 1 study
removed that investigated
endogenous opioids

17 articles retained after
second round of screening

20 studies included in
systematic literature
review

3 additional articles
identified through
reference lists

Fig. 3.1 PRISMA Flow Chart outlining process for identification of eligible studies for
inclusion into systematic literature review.

“heroin AND microbiome” and “heroin AND microbiota.” After removing duplicates, a first
round of screening was conducted based on title and abstract. The second round of screening
was a full text article screening against the eligibility criteria. Review articles were excluded
but reference lists were screened for further studies.
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3.3.2

Eligibility Criteria
To be eligible for inclusion in this systematic review, studies must have investigated

the relationship between opioid use and the gut microbiota. Studies were excluded if: 1) they
did not report the microbiota profiles of the cohorts being investigated, or 2) did not compare
opioid use compared to controls.

3.3.3

Data Extraction and Analysis
After screening, eligible studies were further reviewed for data extraction. The

following data were extracted from the articles: substance examined, cohort demographic data,
species and strain (for preclinical studies), study design including dosage of substances
administered, route of administration, treatment duration and timelines, cognitive and
behavioural tests used, methods of microbiota sampling and analyses, microbiota structure and
composition (i.e., alpha and beta diversity), dysbiotic strains and mechanistic data (where
available), as well as standard publication data (authors, year of publication, journal of
publication).

3.4 Results
3.4.1

Search Results
The literature search yielded 310 returns (SCOPUS: 193, WOS: 111, PubMed: 6).

Duplicates were removed, and 80 articles were retained for first round of screening by title and
abstract. After first round of screening, 58 articles were excluded; 34 articles were removed as
they did not investigate opioid use or did not report on the gut microbiota, 23 articles were
removed as they were not research papers (reviews, conference proceedings etc.), and one was
removed as it was not written in English. Twenty-two articles were retained for a second round
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of screening by full text screening. After a second round of screening, 5 articles were excluded;
four articles were removed because they lacked an opioid free control group (IglesiasSantamaria, 2020, Jackson et al., 2018, Pettigrew et al., 2019, Zaborin et al., 2014), and one
article was removed as it investigated endogenous opioids (Lee et al., 2017). Seventeen articles
were retained after full text screening. Three additional papers were sourced from references
(Li et al., 2020a, O'Sullivan et al., 2019, Xu et al., 2017). A total of 20 articles passed the
screening process and were included in this systematic literature review (outlined in Table 3.1
and Table 3.2). Four articles were clinical studies (Acharya et al., 2017, Barengolts et al., 2018,
Li et al., 2020a, Xu et al., 2017), and are outlined in Table 3.1. The remaining 16 were
preclinical studies, including one primate study (Sindberg et al., 2019), 12 mice studies
(Banerjee et al., 2016, Hakimian et al., 2019, Kang et al., 2017, Lee et al., 2018, Meng et al.,
2020, Meng, Sindberg and Roy, 2015, Sharma et al., 2020b, Touw et al., 2017, Wang et al.,
2018a, Wang et al., 2020a, Zhang et al., 2019a, Zhang et al., 2021b), and three rat studies
(O'Sullivan et al., 2019, Simpson et al., 2020, Zhang et al., 2020a), and are outlined in Table
3.2.

3.4.2

Alterations to the Microbiota by Opioid/Opiate Use

3.4.2.1 Alterations to the Microbiota by Opioid/Opiate Administration in Clinical Studies
Acharya et al. (2017) reported dysbiosis of the gut microbiota as a result of opioid use
in patients with cirrhosis (n=72, including patients with non-alcohol steatohepatitis (NASH)
and hepatic encephalopathy (HE)) who have engaged in chronic opioid use (daily use for 3
months) compared to cirrhotic controls not using opioids (Table 3.1). Faecal samples were
analysed by 16S rRNA sequencing and results showed that opioid use resulted in a shift in beta
diversity, regardless of HE-status. Patients using opioids exhibited reduced abundance of
several bacterial families (Clostridiales XIV, Lachnospiraceae, Bacteroidaceae and
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Ruminococcaceae) compared to non-opioid using patients, reflecting the disruptive effects that
opioid use can have on microbiota, especially native microbes. Opioid users who had a
diagnosis of HE exhibited increased Bifidobacterium abundance compared to patients using
opioids without comorbid HE, whereas opioid users without HE exhibited increased
Peptostreptococcaceae and reduced Parasutterella compared to non-HE patients not using
opioids. In patients with a comorbid diagnosis of NASH, opioid use was not associated with
disruption of the composition of the microbiota, whereas dysbiosis was observed in patients
not using opioids. The functional potential of the altered microbiota was also investigated using
PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved
States; (Acharya et al., 2017) (Table 3.1). Opioid users showed significantly increased potential
for metabolism of branched and aromatic amino acids compared to patients not using opioids,
whereas microbiota of non-opioid using patients had increased potential for functions related
to bioenergetic processes and branched chain amino acid production. When examining the HEpositive subgroup, opioid using patients had increased potential of pathways related to aromatic
amino acid metabolism and branched amino acid degradation, endotoxin synthesis, branched
chain amino acid motility, and nitrogen metabolism compared to non-opioid patients. Finally,
when comparing patients without diagnosis of comorbid HE, there was predicted upregulation
of pathways involved in aromatic acid metabolism in opioid using patients compared to nonopioid using patients. These results suggest an effect of opioid use on amino acid metabolism,
as opioid-using patients repeatedly presented with increased functional potential of pathways
related to metabolism of these molecules compared to non-opioid using patients, even in the
presence of comorbidity. In short, this paper reports shifts in the structure and functional
potential of the microbiota as a result of opioid use in a cohort of cirrhotic patients, with
composition also affected by NASH and HE (Acharya et al., 2017).
Barengolts et al. (2018) investigated a cohort of African American men with a DSM-

77

IV diagnosis of opioid use disorder and co-morbid type 2 diabetes mellitus (T2DM) compared
to controls (Table 3.1). Patient microbiota profiles were analysed through 16S rRNA gene
sequencing of faecal samples. Alpha diversity, determined using the Shannon Index, was not
altered as a result of opioid use but trended towards a higher diversity in the non-opioid T2DM
group treated with metformin compared to all other groups (Table 3.1). Similarly, beta diversity
did not change between groups. When examining specific bacterial populations,
Bifidobacterium abundance was decreased in the T2DM group compared to the non-T2DM
controls, but there was no difference between opioid users and non-opioid users overall.
However, opioid using patients with T2DM had a significant increase in Bifidobacterium
compared to patients not using opioids with T2DM (Table 3.1). The authors also investigated
interactions between metformin (diabetes medication) and opioids in the T2DM subgroup.
Metformin treatment of T2DM in opioid users significantly decreased Bifidobacterium
compared to levels observed in opioid users with T2DM without metformin, and compared to
levels observed in healthy (non-T2DM or opioid) controls (Table 3.1). There was a significant
effect of opioid use on Prevotella, which was decreased in opioid users compared to non-using
controls (Table 3.1); however, Bifidobacterium and Prevotella were not influenced by T2DM
comorbidity in opioid users (i.e., no change in the opioid user group compared to the opioid
and T2DM comorbidity group (Table 3.1). These results suggest that opioids did not shift alpha
or beta diversity in this population, but did influence the genera Bifidobacterium and Prevotella
uniquely in the presence of comorbid T2DM and metformin treatment.
Dysbiosis as a result of methadone was reported in a study by Li et al. (2020a). The
study investigated patients undergoing one or two years of compulsory detention (CD; a
government enforced rehabilitation program) for drug use (n=28, male); patients undergoing
methadone maintenance treatment (MMT; n=16, 12 of which were male); current users of
heroin or methamphetamine (drug using, DU; n=27, all male); and healthy non-drug using
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controls (HC; n=28, 21 of which were male) were examined. Patient faecal samples were
analysed by 16rRNA sequencing. Alpha diversity was not significantly different between
groups (Table 3.1). Beta diversity was significantly different between groups. Community
structure differed significantly between the CD group and controls. MMT and DU groups
showed similar, overlapping community structure. The phyla Actinobacteria and
Cyanobacteria,

and

the

genera

Bifidobacterium,

Fusicatenibacter,

Intestinibacter,

Lactobacillus, Streptobacillus and Veillonella increased abundance in MMT patients.
Aestuariispira was highly abundant in the HC group, while Collinsella, Roseburia,
Ruminococcus and Succinivibrio was increased in the DU group. Finally, Alloprevotella,
Erysipelotrichaceae incertae sedis and Flavonifractor were increased in abundance in CD.
MMT patients had an increased abundance of Actinobacteria compared to the CD group and
genera that were present in significantly different abundance depending on treatment group
included: Anaerostipes (depleted in CD compared to MMT and CD groups), Bifidobacterium
(greatest in MMT), Fusicatenibacter (greatest in MMT), Haemophilus (greatest in DU),
Intestinibacter (greater in MMT compared to CD and control groups), Klebsiella (greatest in
MMT), Lactobacillus (greatest in MMT), Megasphaera, Roseburia (greatest in DU, depleted
in MMT), Ruminococcus (greatest in DU, depleted in CD), Sporobacter and Streptococcus
(greatest in MMT; Table 3.1). In short, these results reflect unique enrichment and depletion
of several bacterial genera as a result of rehabilitation regime, drug use, or absence of use.
These results do not reflect a difference in evenness and richness between individuals
undergoing various rehabilitation programmes, compared to patients undergoing active drug
use and healthy controls, and instead reflects differences in the abundance of specific microbes.
Finally, Xu et al. (2017) investigated the effects of heroin (n=26), methamphetamine
(n=15), ephedrine (n=4) or other drug use (n=5) on the gut microbiota in males patients in
rehabilitation, compared to healthy male controls (n=48). Patient faecal samples were collected
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and analysed by 16S rRNA sequencing. Alpha diversity was altered in SUD compared to
controls. Chao1 increased in SUD, compared to controls; however, no changes were observed
between SUD groups (across substance types). There was also an increase in observed species
diversity index in SUD compared to controls. The report then conducted analyses on a
subgroup of age matched participants (29 SUD patients and 28 controls aged from 19 to 37) to
remove age a potential cofounder. In this age matched subgroup there was an increase in Chao1
in the SUD group compared to controls, with no significant difference between drug use groups
(i.e., regardless of drug type consumed). There was also a significant difference in beta
diversity between the substance use disorder group and controls (Table 3.1). At the genus level
Alistipes, Bacteroides, Barnesiella, Blautia, Clostridium XI, Dialister, Escherichia/Shigella,
Faecalibacterium,

Gemmiger,

Haemophilus,

Megasphaera,

Parabacteroides

and

Paraprevotella, were decreased; and, Alloprevotella, Clostridium XIVa, Megamonas,
Phasolarctobacterium, Prevotella, Roseburia and Ruminococcus were increased in the
substance use cohort. Further analysis revealed an effect of age on Barnesiella, Blautia,
Clostridium XI and Megasphaera. In addition, length of history of substance use had an effect
on the abundance of a number of genera, including Prevotella, Phascolarctobacterium and
Ruminococcus, which were increased while Bacteroidetes and Haemophilus were decreased in
longer term substance use compared shorter term substance use disorder. Xu et al. (2017) also
outlined some potential functional consequences through PICRUSt. Metabolic pathways
associated with cell growth and death, DNA replication and repair, and translation were
upregulated with substance use, and those associated with cellular signalling and processing,
and metabolism were diminished (Table 3.1). This study demonstrates a dysbiotic effect of
substance use, but no differences based on substance type used, compared to controls. Length
of history of substance use had a significant effect on community structure.
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Table 3.1 Clinical studies investigating the effect of chronic opioid use on the commensal gut microbiota

Study
Reference
Acharya et al.
(2017)

Barengolts et
al. (2018)

Li et al. (2020a)

Xu et al. (2017)

Opioids Investigated

Study Participants

Comorbidity

Method of Analysis

Oxycodone (n=42)
Morphine (n=11)
Hydromorphone (n=8)
Tramadol (n=7)
Methadone (n=4)

Opioid positive cirrhotic
patients, opioid negative
cirrhotic patients (n=72 per
group)

Cirrhosis
Opioid Positive
HE (n=40), Diabetes
(n=20), NASH (n=7),
Alcohol Use (n=20);
Opioid Negative
HE (n=38), Diabetes
(n=21), NASH (n=11),
Alcohol Use (n=13)

16S rRNA sequencing

Opioids (Unspecified)

African American Men
OP-/T2DM- (n=24),
OP-/T2DM+/Met- (n=11),
OP-/T2DM+/Met (n=19),
OP+/T2DM- (n=28),
OP+/T2DM+/Met- (n=5),
OP+/T2DM+/Met+ (n=6)
Compulsory Detention (n=28;
all Male),
Drug Users (n=27; all Male),
MMT (n=16; 12 Male),
Healthy Controls (n=28; 21
Male)
(n=101, all male)
Heroin (n=26)
Methamphetamine (n=15)
Ephedrine (n=4),
Others (n=5; Heroin and
Ephedrine,
Methamphetamine, Heroin
and Methamphetamine)
Drug Free Controls (n=48)

Heroin,
Methadone,
Methamphetamine

Heroin,
Methamphetamine,
Ephedrine,

α and β Diversity
β: Δ between opioid and nonopioid groups

β: UniFrac
Functional Potential:
PiCRUST

16S rRNA gene
sequencing of stool
samples

α: Trended ↑ in T2D+/OP-/Met+
vs all other groups
β: ~ between groups

α: Shannon
β: Bray-Curtis

Drug Addiction
Rehabilitation

16S rDNA sequencing

α: ~ between groups

α: ACE, Chao1,
Observed Species,
Shannon, Simpson
β: Jaccard
16S rRNA gene
sequencing

β: Δ between groups.
CD Δ from HC;
~ between MMT, DU CD

α: Chao 1 and
Observed Species
Diversity
β: Unweighted
UNIFRAC

α: ↑ (non-sig) in SUD (Chao1);
↑ but not when age matched
(Observed species index)
β: Δ between SUD and Controls;
~ between substances of abuse

81

Study Reference
Acharya et al.
(2017)

Dysbiotic Strains
↓ Bacteroideaceae, Clostridiales XIV, Lachnospiraceae and Ruminococcaceae in opioid positive patients
compared to opioid negative group
↑ Bifidobacterium in Op+/HE+ vs /OP+/HE↑ Peptostreptococcaceae; ↓ Parasutterella in OP+/HE- vs OP-/HE-

Barengolts et al.
(2018)

↓ Bifidobacterium in T2DM+ vs T2DM↑ Bifidobacterium in OP+/T2DM+ vs OP-/T2DM+
↑ Bifidobacterium in OP+/T2DM+/Met+ vs OP+/T2DM+/Met-, and OP- and T2DM+ groups
↓ Prevotella in OP+/T2DM+/Met- vs OP-/T2DM+/MetTrend between Bacteroides caccae abundance and Op+, Met+
↑ Cyanobacteria and Actinobacteria, and Bifidobacterium, Fusicatenibacter, Intestinibacter,
Lactobacillus, Klebsiella, Streptobacillus, Sporobacter, Streptococcus and Veillonella; ↓
Megasphaera, Roseburia abundance in MMT
↑ Collinsella, Haemophilus, Megasphaera, Roseburia, Ruminococcus and Succinivibrio in DU
↑ Alloprevotella, Erysipelotrichaceae incertae sedis and Flavonifractor; ↓ Anaerostipes, Ruminococcus
in CD
↓ Aestuariispira in all groups compared to HC
Firmicutes ↑ DU, compared to CD
↑ Alloprevotella, Clostridium XIVa, Megamonas, Phasolarctobacterium, Prevotella, Roseburia and
Ruminococcus; ↓ Alistipes, Bacteroides, Barnesiella, Blautia, Clostridium XI, Dialister,
Escherichia/Shigella, Faecalibacterium, Gemmiger, Haemophilus, Megasphaera, Parabacteroides
and Paraprevotella in SUD cohort
Barnesiella, Blautia, Clostridium XI and Megasphaera abundance was influenced by patient age
↑ Prevotella, Phascolarctobacterium and Ruminococcus; ↓ Bacteroidetes and Haemophilus in Longer
term SUD

Li et al. (2020a)

Xu et al. (2017)

Functional Potential
↑ AA Acid metabolism, BCAA
degradation; ↓ BCAA production
in OP+ vs OP↑ AA Acid metabolism, BCAA
degradation, endotoxin synthesis,
BCAA motility, nitrogen
metabolism in HE+/OP+ vs
HE+/OP↑ AA Acid metabolism in HE-/OP+ vs
HE-/OP+
N/A

N/A

N/A

Abbreviations: α=Alpha, β=Beta, Δ =Different, ~=Not Different, N/A=Not Available; OP=Opioids, OP+=Opioid Negative, OP-=Opioid Negative; HE=Hepatic Encephalitis; NASH= NonAlcoholic Steatohepatitis; T2DM=Type 2 Diabetes Mellitus, T2DM+=T2DM Positive, T2DM-=T2DM Negative; Met=Metformin, Met+=Met Positive, Met-=Met Negative; MMT=Methadone
Maintenance Treatment, DU=Drug Users, CD=Compulsory Detention, HC=Healthy Controls; SUD=Substance Use Disorder; AA Acid=Aromatic Amino Acids, BCAA=Branched-Chained
Amino Acids
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Table 3.2 Preclinical studies investigating the effect of chronic opioid use on the commensal gut microbiota

Study
Reference
Banerjee et
al. (2016)

Hakimian et
al. (2019)

Kang et al.
(2017)

Opioid
Investigated
Morphine

Remifentanil,
Oxycodone

Morphine

Treatment
Groups
Morphine,
Morphine and
Naltrexone,
Placebo (n=6
per group)
FMT
Morphine or
Placebo donor
(n=10 per
group);
Morphine or
Placebo
recipient
(n=32)
n-3 PUFA Diet
and Saline
(n=5)
n-3 PUFA Diet
and Opioid
(n=10)
Control Diet and
Saline (n=14)
Control and
Opioid (n=14)

Species/Strain

Morphine,
Morphine and
ABX, Placebo,
Placebo plus
ABX (n=7 per
group)

Male Swiss
Webster

Comorbidity
and Diet

Male
C57BL/6,
NSG,
TLR2KO
and
MORKO,
8-10 week old

Male
C57B16/J,
6-8 weeks old

Experimental Paradigm

Method of Analysis

Morphine, Naltrexone (25mg slow-release pellet
implant) or Placebo, microbiota tested after 5-6
days

16S rDNA
sequencing
α: PD

FMT
Morphine or Placebo pelleted faecal matter
administered to morphine or placebo pelleted
recipient mice, once daily, three times, by oral
gavage, microbiota tested 24h after final FMT.

Anxiety,
Standard lab
chow or n-3
PUFA
supplemented

Acquisition with remifentanil (0.05mg/kg/infusion)
self-administed (i.v.) for 2h sessions or until 50
infusions were administered, paired with
audio/visual reinforcing cues (3 days)
Maintenance with oxycodone (0.25mg/kg/infusion,
10 days),
First extinction (cues with no drug), 5 days
Reinstatement (oxycodone, 2 days)
Reinstatement (oxycodone, 2 days)
Second extinction (cues with no drugs, 5 days)

16S rRNA
sequencing

Antinociception

Antibiotic (ABX) treatment for 10 days with
Vancomycin (5mg/mg), Neomycin (10mg/kg),
Metronidazole (10mg/kg) and Streptomycin
(10mg/kg) by oral gavage every 12 hours, and
Ampicillin (1g/L) in drinking water. Morphine
(75mg pellet, s.c.) or placebo implanted at day 5.
Mice sacrificed at day 10.

16s rRNA
sequencing

α: Faith's
Phylogenetic
Diversity, Chao1,
and Shannon Index
β: Bray-Curtis
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Study
Reference
Banerjee et
al. (2016)

α and β Diversity

Dysbiotic Microbes

Functional Potential

α: Non-sig Δ between groups
β: Δ between morphine and placebo
mice, ~ between naltrexone and
placebo, Placebo-Placebo,
Placebo-Morphine, MorphineMorphine, Morphine-Placebo

↑ Bacillaceae, Enterococcaceae, Erysipelotrichaceae, Staphylococcaceae and
Streptococcaceae;
↓ Bacteroidetes in morphine group vs both other groups

Hakimian
et al. (2019)

α:. n-3 PUFA ↑ species richness
(Chao1, Faiths PD and Shannon
Index) vs control diet
β: Δ between diet groups when
adjusting for study phase; Δ
between OXY maintenance and
both extinction phases; ~
between D1 and D10. ~
between extinction phases

Kang et al.
(2017)

↓ total bacterial abundance in nonABX morphine-treated mice vs
non-ABX placebo mice

During Oxy Maintenance
↑ Allobaculum, Alistipes, Bifidobacterium, Coprobacillus, Coriobacteriaceae,
Dorea, Erysipelotrichaceae, Lactobacillus, Oscillospira, and
Streptococcus;
↓ Akkermansia, Clostridium, Coprococcus, Enterobacteriaceae and
Parabacteroides in n3P vs control diet
During Oxy Extinction
↑Bifidobacterium and Desulfovibrio;
↓ Parabacteroides, and Clostridiaceae, in n3P diet vs control diet
Within n-3P diet treatment
↑ Enterococcus;
↓ Akkermansia, Allobaculum, Bifidobacterium, and Coriobacteriaceae during
extinction phase, compared to maintenance phase
Within control diet treatment
↓ Akkermansia, Coprococcus, family Enterobacteriaceae, Parabacteroides and
Bifidobacterium during extinction phase, compared to maintenance phase
Opioid extinction
↓Akkermansia and Bifidobacterium, regardless of diet, but ↓ Parabacteroides,
within the control diet group.
↓ Bacteroidales, Clostridiales and Lactobacillales;
↑ Enterobacteriales in non-ABX morphine vs non-ABX placebo mice

↑ Coprostanol, Cholesterol;
↓ Cholate, CDCA, DCA, UDCA
and Unconjugated UDCA,
bile salt hydrolase and free
taurine in WT morphine vs
WT placebo and WT
morphine and WT
naltrexone
N/A

N/A
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Study
Reference
Lee et al.
(2018)

Meng et
al. (2020)

Opioid
Investigated
Morphine

Morphine

Treatment Groups

Species/Strain

Morphine Injection (n=4)
Morphine Pellet (n=4)
Saline Injection (n=8)
Vehicle Pellet (n=4)

Male C57BL/6J, 6-8
weeks old

Morphine, HIV only,
HIV and Morphine
and Controls (n=6
per group)

Humanized Bone
Marrow-LiverThymus mice
generated by
implanting xenogenic
Thymus and Liver
tissue into NODSCID IL2R Gamma
Null, from 4 weeks
old
Male C57BL/6 and
TLR2KO, 8-10 weeks
old

Meng et
al. (2015)

Morphine

Morphine, Morphine and
Naltrexone, Placebo
(n=6)

O'Sullivan
et al.
(2019)

Morphine

Morphine, Morphine and
Naltrexone,
Naltrexone, and
Placebo (n=4 per
group)

Sprague-Dawley

Comorbidity
and Diet

HIV

Sepsis

Experimental Paradigm

Method of Analysis

Intermittent morphine sulphate i.p.
escalating dosage (10, 20, 30,
40mg/kg) b.i.d., for 4 days, saline i.p.,
b.i.d.
Continuous morphine sulfate (25mg, s.c.)
or placebo pellet.
HIV infection for 4 weeks,
Combined treatment, morphine
administered 21 days into HIV
infection
Morphine (75mg slow-release implant) or
placebo. Mice sacrificed and
microbiota tested after 7 days.

16S rDNA
sequencing

Caecal Ligation and Puncture 24 prior to
pellet implant
Morphine (25mg slow-release pellet),
morphine and naltrexone (30mg pellet)
or placebo
Morphine (75mg slow release, s.c.) pellet
or placebo for 6 days, then sacrificed
and microbiota analysed, or
Naltrexone (100mg/kg, i.p.) for
Naltrexone and Withdrawal groups at
day 6, then sacrificed and microbiota
analysed.

16S rDNA
sequencing

α: Observed OTUs
β
16S rRNA
sequencing of
caecal contents
α: Oberved
OTUs, Shannon
Index
β: Bray-Curtis

qPCR of caecal
DNA
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Study
Reference
Lee et al.
(2018)

Meng et
al. (2020)

α and β Diversity

Dysbiotic Microbes

Functional Potential

α: ~ between morphine
(sustained and
intermittent) and controls
β: Δ between morphine
(sustained and
intermittent) and controls

Intermittent treatment
↑ Ruminococcus spp.; ↓ Lactobacillus spp. compared to controls.

N/A

α: ↓ Combined morphine and
HIV compared to all other
groups

HIV/Morphine group vs other groups
↑ Firmicutes, Proteobacteria and Enterococcus, Staphylococcus
↓Actinobacteria, Bacteroidetes and Tenericutes, Muribaculaceae, Lachnospiraceae,
Lactobacillus and Ruminococcaceae.

Sustained treatment
↑ Clostridium spp. and Rikenellaceae vs controls
N/A

β: Δ morphine and placebo
HIV infected animals
↑ Proteobacteria, Staphylococcus;
↓ Bacteroidetes

Meng et
al. (2015)
O'Sullivan
et al.
(2019)

N/A
N/A

Morphine facilitated
↑ Enterobacteriaceae in H-BLT mice
↑ Firmicutes, Staphylococcus sciuri, S. cohnii, and S. aureus and Enterococcus durans, E.
casseliflavus, E. faecium, and E. faecalis in morphine-treated mice vs both other groups
↑ Bacteroides thetaiotaomicron, Bacteroides fragilis, Enterococcus faecalis, Enterococcus
gallinarum, and Bacteroides vulgatus;
↓ Bifidobacterium, Clostridium coccoides, Clostridium leptum, Butyricicoccus genus and
Butyricicoccus pullicaecorum, Faecalibacterium prausnitzii in withdrawal group vs
other groups
↑ Anaerotruncus colihominis in morphine vs withdrawal mice
↓ Prevotella in morphine vs placebo mice

N/A
N/A
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Study
Reference
Sharma et
al. (2020b)

Simpson
et al.
(2020)

Sindberg
et al.
(2019)

Opioid
Investigated
Hydromorphone

Oxycodone

Morphine

Treatment
Groups
Hydromorphone
(H), Dextran
Sodium Sulphate
(DSS), or H and
DSS, and Saline
(n=4 per group)

Species/Strain

Oxy, Sal, No
ABX (n=9, 5
female)
Oxy, Sal, ABX
(n=10, 5 female)
Oxy, Nal, No
ABX (n=10, 6
female)
Oxy, Nal, ABX
(n=9, 5 female)
Sal and Nal (n=9,
5 female)
Morphine (n=4)
SIV (n=4)
SIV and
Morphine (n=6)

SpragueDawley

Male PF-WT
C57BL/6 and
IL-10KO
C57BL/6, 10-16
weeks old

Male IndianOrigin Rhesus
Macaques, 3-4
weeks old

Comorbidity
and Diet
Colitis and
IBD

Experimental Paradigm
Hydromorphone (7.5 mg/kg, b.i.d., i.p.) for 7 days.
DSS (to induce colitis) in water from day 3 for 5 days.

Initial ABX (including Vancomycin, 2mg/mL; Bacitracin,
0.5mg/mL; Neomycin, 2mg/mL; Natamycin
1.2µg/mL) in water, or normal water for 2 weeks.
Then, ABX or water with oxycodone (2mg/kg, s.c.
injection, b.i.d., for 5 days) or saline.
Final treatment with naloxone (1mg/kg, s.c. injection) 2h
following final injection, or saline
Faecal samples analysed prior to ABX or water, and at
study conclusion.

Simian
Immunodefici
ency
Syndrome
(SIV)

Morphine (50mg/mL, escalating dose, 2mg/kg to 3mg/kg
first 2 weeks, 4mg/kg 2nd week onwards, i.m., t.i.d.)
SIV infection at day 0 for SIV alone group, or day 70 into
morphine treatment for morphine + SIV group
Faecal samples collected pre-treatment and, day 21, 64
and 84 (from initial treatment in morphine alone
group), 3, 8, 15 and 22 (post-SIV infection in SIV
alone group). For combined SIV and morphine group,
collected day 21 and 64 from initial morphine
treatment, then day 3, 8, 14 and 22 post-SIV infection.

Method of
Analysis
16S rDNA
sequencing
α: Chao1
β: Unweighted
UniFrac
Functional
Potential:
PiCRUST, KEGG
16S rRNA
sequencing
α: Shannon, Chao1
β: Bray-Curtis

16S rDNA
sequencing
α: Shannon Index,
Observed OTUs
β: Weighted
UniFrac
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Study
Reference
Sharma et
al. (2020b)

α and β Diversity

Dysbiotic Microbes

Functional Potential

α: ↓ in H and DSS
compared to H, DSS
and Controls.
β: Δ between DSS and
H and DSS

N/A

Simpson
et al.
(2020)

α: ~ between
Oxy+/ABX- and
saline post-treatment.
↓Oxy+/ABX+ vs
OXY+/ABX-, and
Saline
β: ~ between Saline
and Oxycodone
groups, Δ between
ABX and non-ABX
groups
α: ~ between groups.
β: Δ between
treatments. Δ
between pretreatment and
morphine posttreatment samples.
~ between SIV and
morphine, and
morphine groups

↑ Proteobacteria, Verrucomicrobia, Bacteroidaceae, Enterobacteriaceae, Enterococcaceae,
Peptostreptococcaceae, Porphyromonadaceae, Verrucomicrobiaceae, Akkermansia,
Bacteroides, Bilophila, Enterococcus, Parabacteroides, Ruminococcus, Sutterella and
Turicibacter, Bacteroides acidfaciens, Ruminococcus gnavus and Akkermansia
municiphila
↓ Firmicutes, Lachnospiraceae, Lactobacillaceae, Odoribacteraceae, Rikenellaceae,
Ruminococcaceae, S24-7, Adlercreutzia, Anaerostipes, Odoribacter, AF12, Lacobacillus,
Lactobacillus reuteri and Mucispirillum schaedleri, in H and DSS vs controls
↓ Bacteroidetes in Oxy, and Oxy and ABX (non-sig) post-treatment vs vehicle
↓ Bacteroidetes in Oxy and ABX compared to Oxy
↓ Firmicutes in Oxy, and Oxy and ABX (non-sig) post-treatment vs vehicle
↓ Firmicutes in Oxy and ABX compared to Oxy
↑ Cyanobacteria, Proteobacteria, and Verrucomicrobia in Oxy and ABX post-treatment vs
Oxy and vehicle

↑ Methanobacteriaceae; ↓ Streptococcaceae and Ruminococcaceae post-morphine treatment
↑ Ruminococcaceae post-SIV infection.
↑ Methanobacteriaceae; ↓ Streptococcaceae in morphine and SIV vs pre-treatment samples.
↓ Leuconostocaceae family post-treatment for all groups
↑ Veillonellaaceae, Fibrobacteraceae fibrobacter, Veillonellaceae Megasphaera,
Ersipelotrichaceae RFN20, and BS11; ↓ Order TM7-3, Paraprevotellaceae YRC22 in
Terminal SIV samples (Day 22)
↓ Streptococcaceae streptococcus and Pasteurellaceae Aggregatibacter in Terminal Morphine
samples (Day 84)
↓ Veillonellaceae dialister, Actinobacillus, Pasteurellacea haemophilus and
Methanobacteriaceae Methanosphaera in Terminal SIV and Morphine samples (Day 92)

↓ Primary bile acids, such as cholate and
glycocholate; ↑ ketolithocholate,
dehydrocholate, taurocholenate sulfate
and 3 b-hydroxy-5-cholenoic acid
secondary bile acids in morphine posttreatment vs pre-treatment
↑ sphingolipid metabolites, such as
sphinganine and sphingosine in morphine
↑ Serotonin and N-acetylserotonin in SIV
group
SIV and Morphine treatment altered
serotonin, N-acetylserotonin, Nacetylkynurenine, tricarballylate, and
secondary bile acid deoxycholate

Sindberg
et al.
(2019)

N/A
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Study
Reference
Touw et
al. (2017)

Opioid
Investigated
Loperamide

Treatment Groups

Species/Strain

Loperamide (n=24) or
control (n=27) SPC

Male and
Female SPF
C57Bl/6, 8-10
weeks old
(donors), GF
(recipients),
12-14 weeks
old
Female
C57BL/6J, 810 weeks old

FMT recipients
Loperamide FMT recipients
(n=17) or control FMT
recipients (n=19)
Wang et
al.
(2018a)
Wang et
al.
(2020a)
Zhang et
al.
(2019a)

Morphine

Morphine

Morphine

Morphine, Naltrexone,
Morphine and Naltrexone,
and Placebo (n=4 per group)
Morphine, Placebo, Infection
and Placebo, Infection and
Morphine (n=4 per group)
TLR2KO morphine (n=23)
TLR2KO saline (n=19)
TLR4KO morphine (n=11)
TLR4KO saline (n=8)
WT morphine (n=7)
WT saline (n=6)

Comorbidity
and Diet
Constipation

Experimental Paradigm
Loperamide (0.1%) in drinking water for 7
days. Mice were sacrificed and faecal
samples analysed after 7 days.
FMT (1.5mL, gavaged) caecal homogenate
from donor to recipient mice for 3-4 weeks.
Mice were sacrificed and faecal samples
analysed after 7 days.
Morphine (25mg pellet, s.c.), naltrexone
(30mg pellet, s.c.), morphine and
naltrexone, or placebo for 6 days

Female
Pathogen-Free
C57BL/6J, 810 weeks old

Hospital
Infections

TLR2KO,
TLR4KO, and
C57Bl/6 (WT)
mice

Analgesic
Tolerance

Morphine (25mg pellet, s.c.) or placebo.
C. rodentium infection (200µL oral
gavage) 24h after pellet implantation.
Faecal samples collected daily for 6 days.
Initial pan-ABX for 7-10 days in drinking
water. Morphine sulphate (b.i.d.)
escalating (5, 10, 15, 20, 25, 30, 35,
40mg/kg) or constant dose
(15mg/kg), or saline for 8 days with
pan-ABX

Method of Analysis
16S rRNA gene sequencing
α: Shannon
β: BrayWeighted and
Unweighted UniFrac
Functional Potential: Biolog
Gen III
16S rRNA sequencing of
faecal samples
α: Chao1
β: Unweighted UniFrac
16S rRNA sequencing of
faecal samples
α: Chao1
β: Unweighted UniFrac
16S rRNA sequencing of
faecal samples
β: Bray-Curtis
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Study
Reference
Touw et
al. (2017)

Wang et
al.
(2018a)

Wang et
al.
(2020a)
Zhang et
al.
(2019a)

α and β Diversity

Dysbiotic Microbes

Functional Potential

α: ~ between groups. ~ between
GF recipient mice
β: Δ between groups. Δ
(weighted UniFrac) between
GF recipient mice

↑ Bacteroidetes, Bacteroidaceae,
Porphyromonadaceae, Prevotellaceae,
Bacteroidales S-24-7, Bacteroidales ovatus
and Parabacteroidales distasonis; ↓
Firmicutes, Clostridiales, Lachnospirace and
Ruminococcaceae in loperamide mice vs
controls
↑ Clostridium, Enterococcus, Flavobacterium,
Fusobacterium, and Sutterella in morphine
group vs other groups

↓ Butyrate, Acetate and Propionate in opioid animals compared to
controls.

α: ↓ in morphine-treated group
compared to placebo at Day 3
β: ~ at Day 0. Δ between
morphine and placebo at Day 3.
Naltrexone reduced morphineinduced dysbiosis, but
naltrexone treatment group Δ
from placebo at Day 3
α: ↓ C. rodentium vs placebo,
but not further affected by
morphine
β: Δ between groups
β: Δ between WT morphine and
saline. ~ between morphine and
saline mice in TLR2KO and
TLR4KO

↑ Enterococcus faecalis in morphine group at
Day 3

N/A

↑Allobaculum, Peptostreptococcaceae and
Prevotellaceae; ↓ Actinobacteria,
Firmicutes, Bifidobacteriaceae,
Lactobacillaceae, Bifidobacterium and
Lactobacillus in WT Morphine vs WT
saline

Loperamide community showed ↑ potential for metabolizing amino
acids, carboxylic acids, hexose acids, and various sugars.
↓ bile acids; ↑ phosphatidylethanolamines and saturated fatty acids in
morphine vs placebo
The morphine induced decrease of secondary bile acid, deoxycholic acid,
and phosphatidylethanolamines were reversed by naltrexone
Enterococcus and Erysipelotrichaceae were negatively associated with
cholic and octadecanedioic acid, both of which were conversely
positively correlated with Bacteroidales.
Phosphatidylethanolamines and steric acid were conversely positively
associated with Erysipelotrichaceae and Enterococcus, and negatively
with the order Bacteroidales.
N/A

N/A
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Study
Reference
Zhang et al.
(2021b)

Zhang et al.
(2020a)

Opioid
Investigated
Morphine

Morphine

Treatment
Groups
Morphine (n=10)
Vehicle (n=10)

Morphine (n=24)
Vehicle (n=7)

Species/Strain
Male
C57BL/6J
mice, 8 weeks
old

Male SpragueDawley rats

Comorbidity
and Diet

Experimental Paradigm

Method of Analysis

α and β Diversity

3 stage (acquisition, extinction
and reinstatement) CPP
paradigm.

16S rRNA gene
sequencing of faecal
samples

α: ↑ Observed
OTUs, Chao1, ACE
at morphine
acquisition vs
vehicle group;
↓ Shannon at
extinction stage vs
acquisition; ~
between
reinstatement and
extinction
β: Δ between
groups, Δ between
CPP stages

Morphine (1mL of 10mg/kg, i.p.)
or equal saline, placed inside
A for 45 min, days 3, 5, 7, 9,
11, 13. Saline i.p., placed
inside B, days 4, 6, 8, 10, 12
and 14 for both groups.
Place preference days 15, 22, 29,
36, 43 until PP extinct.
Reinstatement by final morphine
challenge (same conc., i.p.,
and day 44) and final PP test.
Morphine (1mL of 10mg/mL, i.p.)
on days 6, 8 10 and 12, or
saline on days 7, 9, 11, and
13
CPP paradigm. Morphine or saline
i.p. then placing into nonpreferred side (pairing side to
morphine). Saline i.p. for
both groups then placing into
preferred side on alternate
days. Free access to both
compartments on day 14 to
test side preference.

α: ACE, Chao1,
Observed OTUs,
Shannon and
Simpsons
β: Weighted UniFrac
Functional Outcome:
PiCRUST

16S rRNA
sequencing of faecal
samples

α: ~ between groups

α: ACE, Chao1,
Shannon and
Simpsons
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Study
Reference
Zhang et
al. (2021b)

Zhang et
al. (2020a)

Dysbiotic Microbes

Functional Potential

↑ Verrucomicrobia; ↓ Bacteroides in morphine acquisition compared to vehicle group
↑ Bacteroidetes, Bacteroides and Coprobacter; ↓ Verrucomicrobia, Candidatus
Saccharibacteria, Akkermansia, Saccharibacteria genera incertae sedis, Eisenbergiella and
Ruminococcus at extinction compared to acquisition
↑ Bacteroides and Coprobacter; ↓ Candidatus Saccharibacteria, Eisenbergiella,
Saccharibacteria genera incertae sedis and Clostridium XlVa at reinstatement compared to
acquisition
Acquisition was characterised by abundance of Aestuariispira, Alistipes, Akkermansia,
Anaerovorax, Clostridium IV and Ruminococcus
The control group was characterised by abundance of the genera Anaerotruncus, Bacteroides,
Bilophila, Clostridium_XIVb, Eisenbergiella, Parabacteroides and Rhizobium
Extinction was characterised by abundance of Anaerovorax, Corpobacter,
Escherichia_Shigella, Lactobacillus and Parvibacter.
Reinstatement was characterised by abundance of Anaerovorax, Escherichia_Shigella and
Lactobacillus
↑ Coriobacteriaceae, Peptococcaceae_1, Allobaculum and Parasutterella; ↓ Alloprevotella,
Desulfovibrio and Rikenella in Morphine post-treatment compared to morphine pretreatment
↑Clostridium XIVa, Coriobacteriaceae, Corynebacterium and Parasutterella,
Peptococcaceae_1 and Streptococcaceae; ↓ Desulfovibrio in vehicle post-treatment
compared to vehicle pre-treatment
↓ Corynebacterium, Clostridium_XlVa, Enterococcaceae, Staphylococcaceae and
Streptococcaceae in morphine post-treatment compared to vehicle post-treatment
↑ Alloprevotella, Peptostreptococcaceae and Romboutsia; ↓Anaerofilum, Catabacter,
Catabacteriaceae, Christensenella, Christensenellaceae, Clostridium_IV, Dorea,
Elusimicrobium, Elusimicrobiaceae, Roseburia, Schwartzia, Spirochaetaceae and
Veillonellaceae in Hi-CPP compared to lo-CPP
Alloprevotella and Romboutsia postively; Elusimicrobiaceae, Elusimicrobium,
Lachnospiraceae, Roseburia and Ruminococcaceae negatively, correlated with CPP score
↑ Helicobacteraceae, Helicobacter; ↓ Olsenella, Puniceicoccaceae and Rothia
Rothia abundance negatively correlated to CPP score

↑ signal transduction mechanisms and replication; recombination and
repair proteins; ↓ nicotinate and micotinamide metabolism; nitrogen
metabolism and cyanoamino acid metabolism pathways at morphine
acquisition vs controls
↑ Alanine, Aspartate, Glutamate and Histidine Metabolism; Amino Acid
related enzymes; Protein Export; and Ribosome Biogenesis; ↓Two
Component System at morphine extinction vs acquisition
↑ Other ion-coupled transporters; glycolysis/gluconeogenesis; ↓
Phenylalanine, Tryptophan and Tyrosine Biosynthesis; Arginine and
Proline Metabolism; Bacterial Secretion System; and Oxidative
Phorphorylation at morphine reinstatement vs extinction
↑ Ribosome Biogenesis; Purine Metabolism; Cysteine and Methionine
Metabolism; DNA Repair and Recombination Proteins; Amino Acid
Related Enzymes; and, Alanine, Aspartate and Glutamate Metabolism
Pathways; ↓ Two Component Systemat reinstatement vs acquisition
N/A

Abbreviations: α=Alpha, β=Beta, Δ =Different, ~=Not Different, N/A=Not Available; Spp.=several species; FMT=Faecal Matter Transplant; CPP=Conditioned Place Preference; GF=GermFree; PD=Phylogenetic Diversity; SPF=Specific Pathogen free; n3P=n-3 PUFA=n-3 Polyunsaturated Fatty Acids; ABX=antibiotics; OXY=Oxycodone; WT= Wild Type, TLRKO=Toll-Like
Receptor Knockout; BLT=Bone-Marrow, Liver Thymus; i.p.=intraperitoneal, i.m.=intramuscular, s.c.=subcutaneous; b.i.d.=twice daily, t.i.d.=thrice daily
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3.4.2.2 Alterations of the Microbiota by Opioid/Opiate Administration in Preclinical Studies
A) Effect of opioids on gut microbiota
-

Morphine
Dysbiosis of several strains were reported as a result of morphine administration in a

study by Zhang et al. (2020a). Male Sprague-Dawley rats were grouped into either morphine
(n=24) or vehicle (n=7) treatments. Rats were administered morphine (1mL/kg of a 10mg/mL
solution) on days 6, 8, 10, and 12, or saline on days 7, 9, 11 and 13 via intraperitoneal injection.
Faecal samples were collected and analysed via 16S rRNA sequencing. Alpha diversity,
reported as abundance-based coverage estimator (ACE), Chao1, Shannon and Simpson’s
Index, was not significantly different between morphine and saline-treated rats (Table 3.2).
Morphine treatment resulted in dysbiosis of Allobaculum and Parasutterella, which were
increased in abundance, and Alloprevotella, Desulfovibrio and Rikenella, which were depleted
post-treatment. At the family level, Coriobacteriaceae and Peptococcaceae_1 increased in
abundance in post-treatment samples compared to pre-treatment samples. Clostridium_XIVa,
Corynebacterium and Parasutterella increased in post-treatment samples in saline-treated rats,
whereas Desulfovibrio decreased post-treatment. Additionally, at the family level
Coriobacteriaceae, Peptococcaceae_1 and Streptococcaceae increased in abundance posttreatment in the saline group. The study considered the relationship between gut microbiota
and drug associated learning through a model of condition place preference (CPP). In this
paradigm animals are placed in chambers paired or not paired a drug for several sessions,
during a conditioning period. Following this, animals were given free access to either chamber.
Animals that preferred drug paired chambers at this stage were considered to have associated
the chamber with the rewarding effects of the drug. Rats with a high sensitivity to CPP had
increased levels of Alloprevotella, Peptostreptococcaceae and Romboutsia and decreased
levels of Anaerofilum, Catabacter, Catabacteriaceae, Christensenella, Christensenellaceae,
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Clostridium_IV, Dorea, Elusimicrobium, Elusimicrobiaceae, Roseburia, Schwartzia,
Spirochaetaceae and Veillonellaceae compared rats with low sensitivity to CPP. Alloprevotella
and Romboutsia positively correlated with CPP scores, whereas Elusimicrobiaceae,
Elusimicrobium, Lachnospiraceae, Roseburia and Ruminococcaceae correlated negatively
with CPP score, suggesting a role of these microbes in facilitating reward learning (Table 3.2).
Finally, the authors investigated which bacteria may contribute to morphine sensitivity by
investigating baseline composition of high and low CPP score rats (i.e., pre-treatment samples)
and correlating strains to CPP score. At baseline, high CPP rats had increased abundance of
Helicobacteraceae and Helicobacter but decreased Olsenella, Puniceicoccaceae and Rothia.
The abundance of Rothia at baseline was negatively correlated to CPP score. These results
suggest a potential protective effect of Rothia as CPP sensitivity decreased with as the
abundance of this genera increased (Table 3.2). Overall, Zhang et al. (2020a) do not report
changes in alpha diversity, but do report dysbiosis as a result of morphine administration, and
also outline unique patterns of dysbiosis based on sensitivity to CPP, associated with learning
i.e. cognitive function. Finally, sensitivity to CPP was associated with specific strains.
Dysbiosis of the microbiota by morphine hydrochloride administration was reported by
Zhang et al. (2021b). Male C57BL/6 mice were grouped into either morphine hydrochloride
(n=10) or saline (n=10) treatment groups. Morphine hydrochloride (1mL of a 10mg/kg
solution) was administered via i.p. injection. During the acquisition/conditioning phase mice
were administered morphine or saline (controls) on days 3, 5, 7, 9, 11 and 13 and placed into
side A of the apparatus. Both groups received saline on days 4, 6, 8, 10, 12 and 14 and were
placed into side B of the apparatus. Following the final injection, a place preference test was
conducted weekly, until CPP extinction. After achieving extinction, mice received a final
morphine injection and a final place preference test (the reinstatement test). Faecal samples
were collected and analysed by 16S rRNA sequencing. Alpha diversity, reported as ACE,
94

Chao1, Observed Species, Coverage Indices, Shannon and Simpsons Indices, was different
between study stages (Table 3.2). During the acquisition phase, morphine treatment increased
the richness, but not diversity, of the microbiota compared to the controls. The richness and
diversity of the microbiota was decreased during the extinction phase compared to the
acquisition phase, in morphine treated mice. Beta diversity was different in morphine-treated
mice during the acquisition stage compared to morphine-treated mice during the extinction
stage and control group mice. Conversely, beta diversity was similar between morphine-treated
mice during extinction compared to morphine-treated mice during reinstatement and controls.
These results suggests that subsequent morphine challenges following a period of abstinence
do not produce the same effects on the gut microbiota as initial morphine use. Bacteroides was
decreased in the morphine group at acquisition compared to the control group, whereas
Verrucomicrobia was increased (Table 3.2). During the extinction phase, Bacteroides,
Bacteroidetes and Coprobacter were more abundant, whereas Akkermansia, Eisenbergiella,
Ruminococcus,

Candidatus

Saccharibacteria,

Saccharibacteria_incertae_sedis

and

Verrucomicrobia were depleted, compared to the acquisition phase. During the reinstatement
phase, Bacteroides and Coprobacter were more abundant, whereas Clostridium_XIVa,
Eisenbergiella, Candidatus Saccharibacteria and Saccharibacteria_incertae_sedis were
decreased in prevalence, compared to the acquisition phase. The control group was
characterised by abundance of the genera Anaerotruncus, Bacteroides, Bilophila,
Clostridium_XIVb, Eisenbergiella, Parabacteroides and Rhizobium. The acquisition phase of
the morphine group was characterised by Aestuariispira, Akkermansia, Alistipes, Anaerovorax,
Clostridium_IV and Ruminococcus. The extinction phase of the morphine group was
characterised by Anaerovorax, Corpobacter, Escherichia_Shigella, Lactobacillus and
Parvibacter. Finally, the instatement phase was characterised by an abundance of
Anaerovorax, Escherichia_Shigella and Lactobacillus. Next, the authors investigated the
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functional potential of the gut microbiota. During the acquisition phase, the morphine treatment
group had enrichment of pathways involving recombination and repair proteins, signal
transduction mechanisms and replication with a downregulation of pathways involving
metabolism of cyanoamino acid, nitrogen, nicotinate and nicotiamide compared to the control
group. During the extinction phase, pathways involved in metabolism of alanine, aspartate,
glutamate and histidine, protein export, enzymes related to amino acids, and ribosome
production were upregulated, whereas the two-component signal transduction system (a system
bacteria use to respond to external stimuli) was downregulated, compared to the acquisition
phase. During the reinstatement phase pathways involved in glycolysis/gluconeogenesis and
ion-couple transporters were increased, whereas pathways involved in bacterial secretion,
arginine and proline metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, and
oxidative phosphorylation were downregulated, compared to the extinction phase. Finally,
during reinstatement, pathways related to ribosome biogenesis, DNA repair and recombination
proteins, alanine, aspartate and glutamate metabolism, purine metabolism, cysteine and
methionine metabolism and amino acid related enzymes were upregulated, whereas pathways
related to the two-component system was downregulated, compared to the acquisition phase
(Table 3.2). Overall, these results reflect a dysbiotic effect of morphine hydrochloride
treatment. However, cessation from drug administration allowed a shift in community structure
back towards control levels. Finally, a unique community structure arose with each study phase
in addition to unique functional outcomes.
In another study, morphine treatment resulted in dysbiosis of the microbiota when
administered via intraperitoneal injection and pellet implantation (Lee et al., 2018). A group of
male C57BL/6J mice were administered morphine (n=4) or saline (n=8), twice daily, via
intraperitoneal injection at escalating doses (10, 20, 30 and 40mg/kg) with intermittent
withdrawal periods for four days. Another group of mice underwent continuous morphine
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administration (25mg/kg pellet implant, n=4) or saline implant (n=4). Faecal samples were
analysed by 16S rRNA sequencing to determine microbiota composition. Alpha diversity did
not change as a result of drug administration regardless of route of administration (Table 3.2).
Beta diversity was different between morphine-treated mice and controls. Interestingly, the
authors noted different patterns of dysbiosis in the microbiota based on route of administration.
While both saline groups showed overlap in composition, microbiota composition between the
morphine-treated groups were distinct, and did not overlap with each other or the saline groups.
Furthermore, abundance of Lactobacillus was decreased in intermittent morphine-treated mice,
whereas Ruminococcus was increased compared to saline i.p. injected controls. Abundance of
Clostridium and Rikenellaceae was increased in morphine-pelleted mice compared to saline
implanted controls (Table 3.2). Next, the authors investigated the effect of FMT from saline
and morphine-treated mice to drug-naïve recipient animals, reporting no difference in alpha
diversity between saline and morphine recipient groups. In addition to this, intermittent
treatment by injection resulted in increased permeability of the intestinal tract. Compared to
morphine-treated mice, opioid naïve mice displayed preference for cocaine-paired chambers,
a finding replicated in mice receiving FMT from saline-treated mice but not morphine-treated
mice. Furthermore, intermittent, but not sustained, morphine-treatment impaired cocaineinduced CPP. In short, this study identified unique effects of different routes of morphine
administration on the composition of the gut microbiota, and drug-related reward learning.
Treatment with morphine disturbed the commensal gut microbiota in a primate model
with comorbid simian immunodeficiency virus (modelling HIV; Sindberg et al. 2019). Male
Indian-Origin Rhesus Macaques were administered morphine (n=4), SIV (n= 4) or comorbid
morphine and SIV infection (n=6), and faecal samples collected were analysed by mass
spectrophotometry of 16S rDNA. Administration of morphine (50mg/mL) occurred via
intramuscular injection three times daily, at escalating doses; from 2mg/kg to 3mg/kg over first
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two weeks, then 4mg/kg until study endpoint at 12 weeks. Alpha diversity, as determined by
Observed Operational Taxonomic Units (OTUs) and Shannon Index, was not significantly
different between groups (Table 3.2) and no individual treatment group showed alterations in
alpha diversity when comparing post-treatment samples to pre-treatment samples. However,
beta diversity was significantly different between treatments. Ruminococcaceae and
Streptococcaceae

were

increased

in

pre-morphine

treated

samples,

whereas

Methanobacteriaceae was increased in samples from post-morphine treated animals. While
SIV treatment alone did not significantly alter microbiota composition, combined SIV and
morphine treatment did alter composition. Furthermore, combined treatment post-treatment
microbiota structure was similar to structure of primates treated with morphine alone.
Combined treatment also resulted in increased Methanobacteriaceae but decreased
Streptococcaceae in post-treatment samples compared to pre-treatment samples. Next, the
authors compared final samples to initial samples from each treatment (Day 64 for morphine
treatment alone, Day 22 for SIV treatment alone, and Day 92 for combined treatment).
Leuconostocaceae was depleted in all post-treatment samples compared to pre-treatment
samples. Morphine alone resulted in decreased Aggregatibacter and Streptococcus. SIV alone
resulted in increased BS11, Ersipelotrichaceae RFN20, Fibrobacteraceae fibrobacter,
Veillonellaceae, Veillonellaceae Megasphaera, and decreased Paraprevotellaceae YRC22 and
TM7-3 abundance. Combined treatment resulted in decreased Actinobacillus, Dialister,
Haemophilus and Methanosphaera (Sindberg et al., 2019). The authors also report altered
levels of several metabolites in faeces (Table 3.2). For example, morphine treatment resulted
in increased levels of several secondary bile acids including 3 b-hydroxy-5-cholenoic acid, 7ketolithocholate, 12-dehydrocholate, taurocholate sulphate and sphingolipid metabolites
sphinganine and sphingosine; but decreased levels of primary bile acids cholate and
glycocholate compared to pre-treated samples. SIV treatment resulted in increased levels of N-
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acetyl serotonin and serotonin, compared to pre-treatment samples. Compared to samples from
pre-treatment, combined treatment resulted in even greater increases in N-acetyl serotonin and
serotonin than in SIV alone in addition to N-acetyl kynurenine, tricarballylate, and secondary
bile acids such as deoxycholate. In short, unique patterns of dysbiosis on microbial strains are
reported here as a result of morphine administration, SIV infection, or both, though no effect
on alpha diversity is apparent.
Similarly, Meng et al. (2020) reported dysbiosis following morphine pellet implantation
in humanised bone marrow-liver-thymus (BLT) mice with HIV. Treatments included HIV
infection, HIV and morphine (75mg pellet), morphine alone, or controls (n=6). Animals were
sacrificed 7 days after implantation and faecal samples were analysed by 16S rRNA
sequencing. Alpha diversity, analysed as Observed OTUs and the Shannon Index, was
decreased in the HIV and morphine (combined) treatment group compared to controls (Table
3.2). Further, beta diversity was different between morphine and combined treatment mice
compared to placebo-treated mice. The combined treatment group had a significantly greater
relative abundance of Firmicutes and Proteobacteria compared to placebo-treated mice.
Conversely, abundance of Bacteroidetes, Actinobacteria, Tenericutes, Lachnospiraceae,
Muribaculaceae and Ruminococcaceae was depleted in combined treatment mice; the latter
three of which are associated with SCFA production (Meng et al., 2020). Enterobacteriaceae
was enriched in both groups of morphine-treated mice, compared to non-morphine treated
mice. At the genus level, Enterococcus and Staphylococcus were increased in abundance in
HIV-treated mice, whereas relative abundance of Enterococcus was increased and
Lactobacillus abundance was decreased in HIV and morphine-treated mice (Table 3.2).
Dysbiosis of specific bacterial strains due to morphine administration were reported by
Kang et al. (2017) in their study investigating the relationship between chronic morphine
administration, the microbiota and pain tolerance (antinociception). Male Swiss Webster mice
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were assigned to either morphine (75mg pellet), morphine pellet with antibiotics (ABX, an
antibiotic cocktail), placebo (pellet without drug), or a placebo pellet and ABX groups (n=7
per group). Faecal samples were analysed by 16S rRNA qRT-PCR to determine bacterial
abundance. Overall bacterial abundance was depleted in morphine-treated mice (Table 3.2).
Enterobacteriales increased in relative abundance in non-ABX morphine treated-mice
compared to non-ABX controls, whereas Bacteroidales, Clostridiales and Lactobacillales
were depleted. In short, this study reports an overall deleterious effect of morphine
administration on the abundance of the commensal gut microbiota.
In another study by Wang et al. (2020), female C57BL/6J mice were administered
morphine (25mg pellet implant), placebo, morphine with infection (by C. rodentium, modelling
hospital infections), or placebo with infection (n=4 per group) over 6 days. Alpha diversity,
reported as Chao1, was decreased with infection, but further disruption by morphine treatment
was not found. Beta diversity was different between all groups (Table 3.2). Overall, this study
outlines a dysbiotic effect of morphine treatment on the community structure of the microbiota.
Morphine disrupted the commensal microbial community according to a study
conducted by Banerjee et al. (2016). C57B16/J mice were treated with either 25mg morphine,
morphine with naltrexone, or placebo pellet (n=6 per group). Faecal samples were collected 72
hours post-treatment and analysed through 16S rRNA sequencing. There was a non-significant
depletion in alpha diversity, analysed as Phylogenetic Diversity index, in morphine-treated
mice compared to both other groups (Table 3.2). Beta diversity, was significantly different
between morphine-treated mice and both other groups, but not between naltrexone-treated mice
and controls, suggesting a potential remediating effect of naltrexone on the commensal
microbial community structure. Morphine treatment resulted in a significant increase in phyla
Firmicutes, with a concomitant reduction in Bacteroidetes, thus demonstrating a decreased
Firmicutes/Bacteroidetes ratio. Several families belonging to Firmicutes increased in
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abundance after morphine treatment compared to all other groups, including: Bacillaceae,
Enterococcaceae, Erysipelotrichaceae, Staphylococcaceae and Streptococcaceae.
In their study, Meng et al. (2015) investigated the effect of morphine (25mg slowrelease pellet), morphine and naltrexone (30mg pellet), or placebo (n=6 per group) on gut
microbiota in WT or TLR2KO mice modelling sepsis (caecal ligation and puncture). Faecal
samples were analysed by 16S rRNA gene sequencing. Morphine treatment resulted in
increases in several gram-positive species belonging to Firmicutes, including: Enterococcus
casseliflavus,

Enterococcus

durans,

Enterococcus

faecalis,

Enterococcus

faecium,

Staphylococcus aureus, Staphylococcus cohnii and Staphylococcus sciuri (Meng et al., 2015;
Table 3.2), which was reversed by naltrexone treatment.
Several changes in bacterial abundance at the species level as a result of morphine
administration were also reported in rats by O’Sullivan et al. (2019). Sprague-Dawley rats were
divided into four treatment groups (n=4 per group), including morphine pellet (75mg slowrelease implant), placebo (75mg drug free implant), morphine and naltrexone (modelling
withdrawal; morphine pellet and 100mg/kg naltrexone via i.p. injection), or naltrexone
(injection only). Rats implanted with a pellet were sacrificed after 6 days, while the naltrexone
and morphine and naltrexone (withdrawal) groups received injections at day 6 and were
sacrificed 24 hours later. Microbiota was analysed by qPCR of caecal contents. Anaerotruncus
colihominis abundance significantly increased in morphine-treated mice compared to
withdrawal mice, but morphine alone resulted in depletion of Prevotella compared to placebo.
Finally, the authors noted that the abundance of genus Bifidobacterium, and species
Faecalibacterium prausnitzii, both of which possess anti-inflammatory properties (Riedel et
al., 2006, Khokhlova et al., 2012, Quevrain et al., 2016), were decreased in the withdrawal
treatment (Table 3.2). Therefore, in addition to reporting dysbiosis as a result of morphine
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administration, this study also reported dysbiosis of various beneficial bacteria as a result of
naltrexone, after initiation of addiction.
Morphine administration resulted in dysbiosis of the commensal microbiota in a study
by Wang et al. (2018). Female C57Bl/6J mice were randomised into either a morphine (25mg
pellet implant), placebo pellet (25mg implant), naltrexone (30mg pellet implant), or a morphine
and naltrexone group (n=4 per group), for 6 days. Faecal matter was analysed through 16S
rRNA sequencing. Alpha diversity, reported as Chao1, was decreased in morphine-treated
animals compared placebo at Day 3 (Table 3.2). Beta diversity was also different between
morphine-treated and placebo mice at Day 3. Morphine-treated mice had enrichment of
potentially pathogenic bacteria compared to controls from Day 3, including Clostridium,
Enterococcus, Flavobacterium, Fusobacterium and Sutterella. Compared to controls, there
was a significant increase in the species Enterococcus faecalis in morphine-treated mice, but
not naltrexone-treated mice. Metabolites were also disrupted depending on treatment (Table
3.2). Phosphatidylethanolamines and saturated fatty acids were upregulated in the faecal
samples of morphine-treated mice, whereas bile acids were decreased. The secondary bile acid
deoxycholic acid, was decreased with morphine treatment. The authors outlined correlations
between certain microbes and metabolites. The genus Enterococcus and family
Erysipelotrichaceae were negatively associated with cholic and octadecanedioic acid, which
was conversely positively correlated with Bacteroidales. Phosphatidylethanolamines and steric
acid were positively associated with Erysipelotrichaceae and Enterococcus, but negatively
associated with the order Bacteroidales (Table 3.2). In short, this study reports a dysbiotic
effect of morphine treatment, which may include enrichment of harmful bacteria, which was
not observed in naltrexone-treated mice.
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Other Opioids
Dysbiosis of the commensal microbiota as a result of oxycodone administration was

reported by Simpsons et al. (2020), but a protective effect of the receptor antagonist naloxone
was not found. Adult Sprague-Dawley rats were randomly assigned to either; an oxycodone
and saline (n=9, 5 female), oxycodone and saline with antibiotics to deplete the microbiota
(n=10, 5 female), oxycodone and naloxone without antibiotics (modelling withdrawal; n=10,
6 female), oxycodone and naloxone with antibiotics (modelling withdrawal with antibiotics;
n=9, 5 female), or a saline and naloxone (control) group (n=9, 5 female) treatment. The
microbiota was either depleted by antibiotics in drinking water, or kept intact by supplying
normal drinking water (placebo) for two weeks, after which oxycodone (2mg/kg) was
administered every 12 hours, for five days by subcutaneous injection. Depending on treatment
group, withdrawal or intoxication was induced by administration of naloxone (1mg/kg) or
saline, respectively. Faecal samples were obtained and analysed by 16S rRNA sequencing
following each injection. There was no difference in alpha or beta diversity between saline and
naloxone, and oxycodone-treated groups not administered antibiotics suggesting no significant
dysbiotic effect of the opioid administration. Alpha diversity was decreased in the oxycodone
and antibiotic treatment group compared to both the oxycodone without antibiotics and saline
and naloxone treatment groups. Beta diversity was different between antibiotic-treated rats and
rats not treated with antibiotics. Bacteroidetes and Firmicutes were depleted in the oxycodone
compared to the oxycodone plus antibiotics groups and (control) group, but were not
significantly different between the oxycodone without antibiotics group and the saline group.
Cyanobacteria, Proteobacteria, and Verrucomicrobia were increased in oxycodone and
antibiotic-treated rats post-treatment compared to oxycodone and saline and naloxone-treated
rats (Table 3.2).
In their rodent study, Hakimian et al. (2019) report shifts in the commensal microbiota
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as a result remifentanil and oxycodone administration. The authors investigated the effect of
opioid administration on microbiota and behaviour, and the potential remediating effects of n3 polyunsaturated fatty acids (PUFA). Male C57B16/J mice were grouped into four treatments,
including: control diet with saline (n=14), control diet and opioids (n= 14), n-3 PUFA with
saline (n=5), and n-3 PUFA with opioids (n=10). Mice self-administered remifentanil
(0.05mg/kg/infusion) for 3 days during the acquisition phase, then oxycodone
(0.25mg/kg/infusion) for 10 days during the maintenance phase through intravenous catheters
via a lever press. Following this, mice underwent an extinction period of 5 days, then
reinstatement for 2 days with oxycodone, and finally an additional 5 days of extinction. Faecal
samples were analysed by 16S rRNA sequencing at several intervals (baseline, days one and
ten of oxycodone treatment, day five of first extinction period, day one of second extinction
period). Alpha diversity, analysed as Chao1, Faith’s Phylogenetic Diversity, and the Shannon
Index, was enriched as a result of n-3 PUFA supplementation, regardless of opioid status but
was not different between study periods (Table 3.2). The composition of the microbiota was
significantly different between the n-3 PUFA and control diet mice overall when controlling
for drug intervention period, suggesting a significant effect of diet on microbial composition
independent of the influence of opioids. When controlling for diet, microbiota composition was
significantly different between oxycodone maintenance and both extinction periods. The
microbiota composition was not significantly different between days 1 and 10 of the
maintenance phase nor was it significantly different between the two extinction periods. During
oxycodone maintenance, n-3 PUFA supplementation resulted in increases in Allobaculum,
Alistipes,

Bifidobacterium,

Coprobacillus,

Coriobacteriaceae

(family),

Dorea,

Erysipelotrichaceae (family), Lactobacillus, Oscillospira, and Streptococcus, and decreases in
Akkermansia, Clostridium, Coprococcus, Enterobacteriaceae (family) and Parabacteroides
compared to control diet mice (Hakimian et al., 2019). During the extinction phase, n-3 PUFA
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diet resulted in increases in Bifidobacterium and Desulfovibrio, and depletion of
Parabacteroides, and Clostridiaceae (family) compared to control diet animals. Within the n3 PUFA diet subgroup depletion of Akkermansia, Allobaculum, Bifidobacterium and
Coriobacteriaceae, and enrichment of Enterococcus was reported during the extinction phase
compared to the maintenance phase. Similarly, in the opioid-treated control diet group,
depletion of Akkermansia, Coprococcus, family Enterobacteriaceae, Parabacteroides and
Bifidobacterium was reported during the extinction phase compared to the maintenance phase
(Table 3.2). Finally, diet supplementation reduced oxycodone seeking (as determined by
reduced number of lever presses) and anxiety compared to control diet mice. According to
these results, diet and opioids influence the shape of the microbiota community, but diet may
also exert a protective effect on opioid seeking. Structure of the microbiota appears to remain
consistent over the course of addiction, as it did not differ significantly from day 1 and 10. As
abstinence (extinction phase) resulted in a shift in community structure compared to the
maintenance phase, the results suggest that abstinence alone may also have a remediating
effect. Taken together, a targeted diet administered during abstinence may improve the
behavioural symptoms of addiction. Further research should elucidate the biological changes
that underlie these improvements to enhance these targeted treatment options.
The commensal microbiota was disrupted by hydromorphone in a study investigating
opioid use in the context of colitis and inflammatory bowel disease (Sharma et al., 2019). Male
pathogen-free, or interleukin-10 knockout, C57BL/6 mice were assigned to either a
hydromorphone, hydromorphone and dextran sodium sulphate (DSS; which induces colitis),
DSS alone, or placebo group (n=4 per group). Hydromorphone was administered twice daily
at 7.5mg/kg, via i.p. injection for 7 days. Alpha diversity, analysed as Chao1, was significantly
reduced in hydromorphone and DSS treated mice compared to the three other groups (Table
3.2). Beta diversity was different between the four groups. In the combined hydromorphone
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and DSS treatment group there was a decreased abundance of Firmicutes, and an increased
abundance of Proteobacteria and Verrucomicrobia compared to control mice. At the family
level, these included increases in Bacteroidaceae, Enterobacteriaceae, Enterococcaceae,
Peptostreptococcaceae, Porphyromonadaceae and Verrucomicrobiaceae, and decreases in
Lachnospiraceae, Lactobacillaceae, Odoribacteraceae, Rikenellaceae, Ruminococcaceae and
S24-7 (Table 3.2). At the genus level Akkermansia, Bacteroides, Bilophila, Enterococcus,
Parabacteroides, Ruminococcus, Sutterella and Turicibacter were increased in abundance,
whilst Adlercreutzia, AF12, Anaerostipes, Lactobacillus and Odoribacter were depleted in
combined treatment compared to controls. The genus Akkermansia accounted for the family
level increase of Verrucomicrobiaceae, Bacteroides, at the genus level, accounted for the
increase of Bacteroidaceae at the family level; and the genus Sutterella for accounted for
increased abundance of the family Enterobacteriaceae. Finally, compared to controls, the
species Akkermansia muciniphila, Bacteroides acidfaciens and Ruminococcus gnavus were
increased in hydromorphone and DSS mice compared to controls, whereas Lactobacillus
reuteri and Mucispirillum schaedleri were decreased (Table 3.2). Prevalence of opioid use is
high among individuals with colitis (Niccum et al., 2021) and is a risk factor for developing
OUD (Cohen-Mekelburg et al., 2018). As evidenced here, colitis and comorbid opioid use had
a confounding effect on dysbiosis. Controlling the gut microbiota in colitis through FMT shows
promise according to the literature (Mankowska-Wierzbicka et al., 2020, Narula et al., 2017)
and utilising a similar approach may control the additional dysbiosis induced by opioids
reported here. The effect of opioids and colitis on cognition and the course of addiction has yet
to be investigated, however. Other research in similar models of colitis report alterations in
hippocampal microglia (Gampierakis et al., 2021), the morphology of which are influenced by
the gut microbiota. Hence, severe dysbiosis of the gut microbiota by opioids and colitis may
influence cognition through these mechanisms and contribute to the cycle of addiction.
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Administration of the opioid loperamide (used here to induce constipation) resulted in
dysbiosis of the microbiota in a study by Touw et al. (2017). C57BL/6 mice were administered
loperamide (0.1%) in water (n=24), or normal drinking water (controls; n=27) for 7 days.
Faecal samples were analysed by 16S rRNA sequencing. Alpha diversity, reported as
Shannon’s Index, was not different between groups. Beta diversity, was significantly different
between loperamide-treated mice and controls (Table 3.2). In loperamide-treated animals,
Bacteroidetes, Bacteroidaceae, Porphyromonadaceae, Prevotellaceae, Bacteroidales S-24-7,
Bacteroidales ovatus and Parabacteroidales distasonis were increased post-treatment,
whereas Firmicutes, Clostridiales, Lachnospiraceae, and Ruminococcaceae were depleted
compared to controls. Further, a depletion of the SCFAs acetate, butyrate and propionate, was
observed in opioid-treated mice. Analysis of bacterial function showed upregulation of
pathways involved in metabolism of amino acids, carboxylic acids, hexose acids, and various
sugars in loperamide treated mice (Table 3.2). A FMT was conducted next where recipient GF
mice received loperamide (n=17) or control (n=19) faecal samples from donor mice. Beta
diversity was different between GF-loperamide and GF-control recipient mice as determined
by weighted, but not unweighted, UniFrac. In short, loperamide has a dysbiotic effect on
microbiota structure, and influences availability of microbe-produced metabolites and several
key metabolic pathways.

B) Effect of Medications for Opioid Addiction
The literature suggests that medications for opioid addiction may confer some
beneficial effects to the gut microbiota. According to Banerjee et al. (2016), beta diversity was
not significantly different between naltrexone-treated mice and controls, suggesting a
protective effect against dysbiosis. Further, Meng et al. (2015) report the dysbiosis caused by
morphine was reversed by naltrexone administration. In their study, Wang et al. (2018) report
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that beta diversity in both naltrexone-treated groups overlapped but did not overlap with
morphine and placebo-treated mice by Day 3. Further, the enrichment of pathogenic bacteria
observed in morphine-treated mice was not observed in naltrexone-pelleted mice (Table 3.2).
The depletion of deoxycholic acid resulting from morphine treatment was attenuated by
naltrexone, as was the increase in phosphatidylethanolamine by morphine. O’Sullivan et al.
(2019) reported dysbiosis in mice implanted with morphine and naltrexone pellets. The authors
report enrichment in Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides vulgatus,
Enterococcus faecalis and Enterococcus gallinarum and depletion of Butyricicoccus
pullicaecorum, Clostridium leptum and Clostridium coccoides in mice treated with morphine
and naltrexone compared to mice treated with morphine alone, naltrexone alone, or placebo.
Finally, in their study, Simpsons et al. (2020) do not report any beneficial effect of naloxone
as there was no difference in alpha or beta diversity in mice treated with naloxone and saline
compared to those treated with oxycodone.

C) Effect of Receptor Knockout
Banerjee et al. (2016) also investigated the role of opioid receptors in morphine-induced
microbial dysbiosis using toll-like receptor 2 knockout (TLR2KO) mice and µ-opioid receptor
knockout (MORKO) mice treated with morphine or placebo. Microbiota composition of
TLR2KO mice treated with either placebo or morphine overlapped with wild-type placebotreated mice, and morphine and naltrexone-treated mice, suggesting TL2R knockout prevented
dysbiosis. Wild-type morphine-treated mice showed distinct clustering compared to placebo
and both TLR2KO treatment groups. MORKO mice administered morphine or placebo had a
distinct community structure compared to wild-type mice administered morphine or placebo
(controls), indicating unique influence of MORKO on the commensal microbiota (Table 3.2).
In the same study, the potential influence of peripheral immune cells was examined, using
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immunocompromised mice (non-obese, severe combined immune-deficient (NOD-SCID) with
interleukin-2 (IL-2) receptor gamma knockout (NOD SCID Gamma [NSG]) mice). NSG mice
community structure overlapped with MORKO. Furthermore, NSG mice clustered distinctly
from morphine and placebo-treated wild-type mice; however, placebo and morphine-treated
NSG groups overlapped in composition, indicating a unique effect of the mouse model in
community structure, but no additional dysbiotic effect of morphine administration. Following
this, FMT was conducted three times from morphine or placebo pelleted wild-type donor mice
to morphine or placebo pelleted wild-type recipient mice. Transplantation occurred from
placebo-to-placebo, placebo-to-morphine, morphine-to-placebo, and morphine-to-morphine
mice (n=8 per recipient group). Following transplantation, the community structure of recipient
animals shifted towards that observed in donor animals (Table 3.2). Finally, the authors
investigated the faecal levels of metabolites post-morphine treatment in wild-type and
TLR2KO mice implanted with morphine or placebo pellets (Table 3.2). Coprostanol, derived
from cholesterol, was significantly increased in morphine pelleted mice compared to placebo,
and morphine and naltrexone-pelleted mice (Banerjee et al., 2016). Conversely, primary and
secondary bile acids were depleted in the faeces of morphine-treated mice compared to
morphine with naltrexone, and placebo-treated mice, including chenodeoxycholate,
deoxycholate, cholate and tauroursodeoxycholate. These results were not replicated in
TLR2KO morphine-treated mice, suggesting an integral role of the TLR2 receptor mediating
morphine-induced alterations of bile acid and lipid metabolites. Results observed may have
been due to reduced activity of bile salt hydrolase in the gut bacteria (Banerjee et al. 2016).
Overall, these results suggest a dysbiotic effect of morphine administration on beta diversity
only, which may be protected by naltrexone. Additionally, the gut microbiota is able to induce
the phenotype of opioid addiction in FMT recipient mice. Finally, these results suggest a role
of TLR2 and MOR in causing dysbiosis of the microbiota, as knockout prevented dysbiosis.
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While this study reported a protective effect of TLR2KO on the microbiota, this finding may
be in contrast to Meng et al. (2015) who do report dysbiosis of several bacteria in TLR2KO
mice treated with morphine compared to TLR2KO control mice (Table 3.2).
Zhang et al. (2019) investigated the microbiota of TLR2KO mice administered
morphine (n=23), TLR2KO mice administered saline (n=19), TLR4KO mice administered
morphine (n=11), TLR4KO mice administered saline (n=8), and C57BL/6 (wild-type; WT)
administered morphine (n=7), and WT mice administered saline (n=6), following treatment
with antibiotics. Morphine was administered at a constant (15mg/kg) or escalating dose (5,
10, 15, 20, 25, 30, 35, 40mg/kg), twice daily for 8 days alongside antibiotics. Faecal samples
were derived from the small intestine and analysed by 16S rRNA gene sequencing. Beta
diversity was different between morphine tolerant and saline-treated wild-type mice.
However, no significant difference was found between morphine-treated and saline-treated
mice within the TLR2KO and TLR4KO strains, suggesting that these receptors mediated
dysbiosis. Wild-type morphine-treated mice had a reduction in Actinobacteria, Firmicutes,
Bifidobacteriaceae, Lactobacillaceae, Bifidobacterium and Lactobacillus, but expansion of
Allobaculum, Peptostreptococcaceae and Prevotellaceae was also observed in this group,
compared to wild type saline treated animals (Table 3.2). These findings were not found in
TLR2KO or TLR4KO mice. In short, this study reports dysbiosis as a result of morphine
administration, but implicates TLR2 and TLR4 in facilitating these changes.
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Table 3.3 Overview of dysbiosis of the gut microbiota as a result of opioid use in clinical
and preclinical studies
OUTCOME
α – Diversity
β – Diversity
Dysbiotic Microbes

CLINICAL
~ in all studies
Δ in 3; ~ in 1
(Genera) Alloprevotella, Bifidobacterium,
Haemophilus, Megasphaera, Prevotella,
Roseburia and Ruminococcus

Alterations in
Metabolites
Changes in
Functional Potential

↑ Ar. A Acid metabolism
↑ BCAA degradation
↑ Endotoxin production
↑ Functions carried out by the digestive system
Cell health and signalling

PRECLINICAL
↓ in 5; ↑ in 2; ~ in 4; NR in 4
Δ in 9; ~ in 1; NS ~ in 1; NR in 6
Phyla: 7
Class: 1
Families: 14
Genera: 13
Species: 1
↓ Primary bile acids
↑ Secondary bile acids; ↓ in
↓ SCFA, SCFA producing
microbes
↑ Signal transduction
↑ Protein repair
↓ Nicotinamide (Vitamin B3
variant) metabolism
↑, ↓ Amino acids metabolism

Abbreviations: ↑=Increase, ↓=Decrease, Δ =Different/Difference, ~=Not Different, NR=Not Reported,
NS=Non-Significant; SCFA=Short Chain Fatty Acids, Ar. A Acid=Aromatic Amino Acids, BCAA=Branched
Chain Amino Acids

Table 3.4 Bacteria disrupted in clinical and preclinical studies as a result of chronic
opioid use
Dysbiotic Microbes
Actinobacteria
Bacteroidetes
Cyanobacteria
Firmicutes
Bacteroidaceae
Lachnospiraceae
Peptostreptococcaceae
Ruminococcaceae
Clostridium XIVa
Alistipes
Alloprevotella
Anaerostipes
Bacteroides
Bifidobacterium
Dialister
Haemophilus
Lactobacillus
Parabacteroides
Parasutterella
Prevotella
Roseburia
Ruminococcus

Taxonomic Ranking
Phylum
Phylum
Phylum
Phylum
Family
Family
Family
Family
Sub-Family Lachnospiraceae
Genus
Genus
Genus
Genus
Genus
Genus
Genus
Genus
Genus
Genus
Genus
Genus
Genus

Clinical
↑
↓
↑
↑
↓
↓
↑
↓
↑
↓
↑
↑, ↓
↓
↑, ↓
↓
↑, ↓
↑
↓
↓
↑, ↓
↑, ↓
↑, ↓

Preclinical
↓
↑, ↓
↓
↑, ↓
↑
↓
↑
↓
↓
↑
↓
↓
↑, ↓
↑, ↓
↓
↓
↑, ↓
↑, ↓
↑
↓
↓
↑
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3.5 Discussion
The present systematic review aimed to examine the influence of opioids on the gut
microbiota, determine which strains were effected and outline the predicted functional
outcomes of altered microbiota on metabolites and MGB axis signalling pathways. The effect
of opioid use on alpha diversity and beta diversity were investigated, specific microbes that
were enriched or depleted were identified, and the functional potential of the altered microbiota
was examined. Opioid use did not significantly disrupt alpha diversity in clinical studies, while
preclinical results regarding alpha diversity are inconclusive due to seemingly confounding
reports. Depletion in alpha diversity following opioid administration was reported in five
studies, whereas enrichment was reported in two studies; no significant difference was reported
in four studies and the remaining four did not report on this outcome. Depletion in alpha
diversity was generally reported in cohorts with comorbid diseases (Meng et al., 2020; Sharma
et al., 2019; Simpson et al., 2020), as only two studies reported depletion as a result of opioid
treatment alone (Wang et al., 2018; Zhang et al., 2020b). Enrichment of alpha diversity was
found in response to n-3 PUFA diet regardless of opioid status in Hakimian et al. (2019), and
as a result of combined HIV and morphine treatment in Meng et al. (2020). Taken together,
these studies may suggest a minimal influence of opioids on alpha diversity, though more
research is needed to validate this conclusion. In the present review, results were analysed to
determine how the two individual components of alpha diversity, richness and evenness, were
effected by opioids. Richness was increased in four studies, depleted in two and not
significantly different in six; evenness was increased in one and not significantly different in
six. Based on these results, opioid use may facilitate an increase in the number of species
present, reflected by an increased richness; however, confounding result necessitate further
research. In addition, the mechanisms through opioids alter species richness warrants further
investigation, but may involve impaired gut barrier integrity and inflammatory responses,
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which often result from chronic opioid use (Banerjee et al., 2016, Meng et al., 2013). These
results are in line with studies in other substances of abuse. For example, there appears to be
no significant effect of harmful alcohol use on the alpha diversity of the gut microbiota (Mutlu
et al., 2012; Dubinka et al., 2017; Ciocan et al., 2018a; Bjørkhaug et al., 2019). Furthermore,
studies on cocaine report depletion (Scorza et al., 2019) or no change (Volpe et al., 2014) in
alpha diversity. On the other hand, opioid use did impair beta diversity in three clinical studies,
with no difference reported by Barengolts et al. (2018), suggesting that opioid use causes a
shift in the community structure. However, comorbidity may contribute to these results more
than use of opioids. Dysbiosis has been reported in studies examining T2D (Umirah et al.,
2021) and the particular finding of dysbiosis in Bifidobacterium reported by Barengolts et al.
(2018) is reported in numerous other studies in patients with T2D not using opioids (Gurung
et al., 2020). Elsewhere, cirrhosis and hepatic encephalopathy are associated with a dysbiotic
gut microbiota (Dhiman, 2013, Rai, Saraswat and Dhiman, 2015). This comorbidity may
explain the dysbiosis reported in Acharya et al. (2017), who do not report changes in beta
diversity in patients without cirrhosis, suggesting that opioid use worsens dysbiosis with
comorbidity, opioids alone may have a negligible influence on this outcome. Clinical trials
investigating patients with OUD without comorbidity will be necessary to determine how
opioids affect beta diversity, and a lack of such a study is a limitation to enabling clear
conclusions in the present review and literature. Lastly, Li et al. (2020) report differences in
beta diversity between patients undergoing compulsory detention and healthy controls, but
overlap in patients actively engaging in drug use and patients undergoing methadone
maintenance, suggesting a comparable effect of methadone administration and harmful drug
use on beta diversity. Further investigation of such programmes is warranted to determine the
factors that result in the different compositions observed, as they may be clinically significant.
Stronger evidence for an effect of opioid use on beta diversity can be found in preclinical
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research. Beta diversity was significantly different between opioid-treated animals and nonopioid treated animals in nine out ten studies that reported on this outcome. A non-significant
trend towards differences in beta diversity was reported by Hakimian et al. (2019), and the
remaining six studies did not explicitly report on this outcome. In short, chronic opioid use
appears to induce a shift in the composition of the microbiota away from that observed in drug
naïve group though a myriad of other factors may contribute to these results, such as treatment
conditions and comorbidity. Conversely, chronic opioid use does not appear to influence alpha
diversity overall, and may only facilitate an increase in richness. The implications of these
alterations and how they may relate to cognition should be a focus of future research in
addiction, as it a current gap in knowledge.
Specific microbes were altered as a result of opioid administration. In the clinical
studies (Table 3.3), the genera Alloprevotella, Bifidobacterium, Haemophilus, Megasphaera,
Prevotella, Roseburia and Ruminococcus were dysbiotic in more than one study, though the
patterns of dysbiosis were not consistent across these papers. Alloprevotella, Bifidobacterium
and Ruminococcus were generally increased in cohorts administering opioids. In preclinical
studies (Table 3.3), 36 strains were enriched or depleted as a result of opioid use overall. These
included

seven

phyla

(Actinobacteria,

Bacteroidetes,

Cyanobacteria,

Firmicutes,

Proteobacteria, Tenericutes and Verrucomicrobia), one class (Clostridiales), 14 families
(Bacteroidaceae,

Coriobacteriaceae,

Erysipelotrichaceae,
Peptostreptococcaceae,

Lachnospiraceae,

Enterobacteriaceae,
Lactobacillaceae,

Porphyromonadaceae,

Rikenellaceae,

Enterococcaceae,
Methanobacteriaceae,
Ruminococcaceae,

Streptococcaceae, Veillonellaceae), 13 genera (Akkermansia, Allobaculum, Bacteroides,
Bifidobacterium,

Clostridium,

Desulfovibrio,

Dorea,

Enterococcus,

Lactobacillus,

Parabacteroides, Ruminococcus, Streptococcus, Sutterella), and one species (E. faecalis).
Interestingly, there was a high degree of overlap in dysbiotic strains between clinical and
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preclinical studies (Table 3.4), though the pattern of dysbiosis was rarely consistent. This
review identified Lachnospiraceae, Peptostreptococcaceae and Ruminococcaceae (at the
family level), and Dialister (at the genus level) that had a common pattern of dysbiosis between
clinical and preclinical studies. Several of these bacteria are directly or indirectly linked to
cognition according to the literature, and therefore may contribute to cognitive impairments in
OUD. For example, Bacteroidetes was associated with impaired memory in a rodent model of
obesity (Zhang et al., 2019b), a disorder underpinned by neurocircuitry commonly involved in
drug addiction such as dopaminergic reward signalling (Kenny, 2011, Volkow, Wise and Baler,
2017). In addition to this, depletion of Firmicutes was reportedly associated with impaired
visual memory performance in a cohort of older (aged 50 to 85) adults (Manderino et al., 2017),
and evidence from a cohort of depressed patients has linked depletion of Firmicutes to
decreased levels of SCFA (Huang et al., 2018). As discussed previously, SCFA can act on the
CNS, and other preclinical evidence has linked SCFA to performance in memory (Lee et al.,
2020a), suggesting a link between these microbes and cognition. There is a scarcity of literature
reporting on such a link in opioid addiction, but the literature discussed here supports a role of
these specific microbes in the cognitive impairments observed in patients with OUD,
warranting further investigation.
The dysbiosis of the gut microbiota resulting from opioid use was linked to alterations
in various metabolic pathways and metabolic products (Table 3.1, 3.2 and 3.3). In clinical
studies, opioid use was linked to increased potential for aromatic amino acid metabolism, and
branched chain amino acids degradation; endotoxin synthesis, nitrogen metabolism; cell
growth and death; DNA replication and repair, and translation. Downregulation of pathways
involved in cellular signalling and processing, and metabolism were also reported. In
preclinical studies opioid use was linked to potential upregulation of pathways involved in
signal transduction; recombination and repair proteins, and potential downregulation of
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pathways involved in nicotinate and nicotinamide metabolism; nitrogen and cyanoaminoacid
metabolism. Several metabolites important to host health and function were also disrupted. In
opioid-treated animals altered levels of primary and secondary bile acid production,
sphingolipid metabolism, neurotransmitter (serotonin and N-acetylserotonin) levels,
cholesterol levels, and SCFAs levels were reported. According to the literature, bile acids act
as a regulator of the commensal gut microbiota (Ridlon et al., 2015). For example, the
secondary bile acid deoxycholic acid, which was reportedly depleted as a result of morphine
administration by Wang et al. (2018), is a strong antimicrobial compound and is associated
with impaired gut barrier integrity (Stenman et al., 2013). Secondary bile acids can be produced
by several bacterial

strains, including Bacteroides, Bifidobacterium, Clostridium,

Enterococcus and Lactobacillus (Zeng et al., 2019), all of which were found to be dysbiotic in
the present review. As such, these microbes may mediate opioid-induced dysbiosis, impair gut
barrier integrity and facilitate translocation of microbes, metabolites and toxins through
production of bile acids. The role of bile acids in cognition is less explored.
Mahmoudiandehkordi et al. (2019a) reported lower serum levels of primary bile acids, but
increased serum levels of secondary bile acids, including deoxycholic acid, in patients with
Alzheimer’s disease compared to patients with normal cognitive performance. As increased
levels in secondary bile acids, especially deoxycholic acid, are reported in opioid studies, and
are associated with impaired cognition in other disorders, future studies should investigate the
relationship between these key metabolites and cognition in opioid use. Sphingolipids, key
signalling and structural molecules, were increased as a result of morphine treatment by
Sindberg et al. (2019). The literature has outlined a contributing role for sphingolipids in the
development of morphine tolerance, hyperalgesia and antinociception (Kalinichenko et al.,
2018). Bacteroides and Prevotella, noted as being able to produce these molecules (Heaver,
Johnson and Ley, 2018), were dysbiotic as a result of morphine treatment. Altogether, the
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relationship between sphingolipids, gut microbiota, cognition and opioid dependence is under
examined. SCFAs and SCFA-producing microbes, which serve roles in host health, were
disrupted as a result of opioid use. A depletion of SCFAs (butyrate, acetate and propionate)
was reported by Touw et al. (2017), whereas a depletion in SCFA producing strains
(Muribaculaceae, Lachnospiraceae, and Ruminococcaceae) was reported by Meng et al.
(2020). Research has demonstrated the ability of the SCFA butyrate to act as a histone
deacetylase inhibitor (HDACi), in the brain (Bourassa et al., 2016). Specifically, butyrate has
been reported to facilitate the expression of neurotropic factors such as BDNF in several studies
(Lee et al., 2019, Wu et al., 2008). BDNF may facilitate the rewarding aspect of several drugs,
including morphine (Ghitza et al., 2010); BDNF levels increase as a result of drug use, and;
administration of BDNF enhances drug seeking behaviours (Vargas-Perez et al., 2009, Bolanos
and Nestler, 2004). Further, supplementation with beneficial microbes was found to rescue
cognitive performance in a rodent study of vascular dementia, a result associated with increased
butyrate and BDNF (Liu et al., 2015). Therefore, disruption of microbiota metabolites may be
integral to cognitive performance in opioid use through their interaction with BDNF. However,
the role of SCFA in facilitating cognitive impairment in opioid addiction directly (by acting on
the CNS and via epigenetics), or indirectly (by controlling BBB and gut barrier integrity)
requires further investigation as they may serve as an ideal candidate for future novel
treatments.
Innate immune system and opioid receptors appear to be integral in facilitating opioidinduced dysbiosis. Zhang et al. (2019) and Banerjee et al. (2016) reported overlap in microbiota
community structure between morphine-treated TLR2KO, TLR4KO mice and placebo mice,
regardless of route of administration. However, while alpha and beta diversity do not appear to
be affected in receptor knockout mice, Meng et al. (2015) suggest that several species of
bacteria (specifically Gram-Positive species) are susceptible to dysbiosis even with TLR2KO.
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TLR are pattern recognition receptors, part of the innate immune system that are activated by
bacterial components. Specifically, TLR4 is activated by lipopolysaccharides (LPS) and TLR2
by peptidoglycans (PGN), although PGN activation of TLR2 is disputed (Dziarski and Gupta,
2005, Schwandner et al., 1999, Travassos et al., 2004). Regardless, gram-positive bacteria
possess a thicker PGN layer and no outer lipid membrane, compared to gram negative bacteria
which possess a thinner PGN layer but do have lipid outer membrane. The finding that gram
positive bacteria were increased in TLR2KO mice by Meng et al. (2015) suggests that TLR2
may regulate levels of these microbes, potentially through PGN-induced production of IL-17A,
in a TLR2 manner. This interaction is evidenced by the finding that morphine administration
reportedly increased production of IL-17A production, a pro-inflammatory cytokine, by way
of TLR2 activation by translocated microbes, peripherally. Other studies link gram-positive
bacteria such as Firmicutes, which were reportedly enriched by opioids, to the immune system
by way of their metabolites. For example, Firmicutes, able to produce beneficial products such
as SCFA (Dalile et al., 2019), are to facilitate Treg cell generation (Arpaia et al., 2013), which
supress immune responses. Numerous immune system cells, including Treg cells expressed
TLR2 (Sutmuller et al., 2006). Finally, TLR have been linked to synaptic plasticity during
alcohol addiction (Crews et al., 2017), sensitivity to cocaine-induced CPP (Zhu et al., 2018)
and development of morphine tolerance (Eidson et al., 2017). In short, this evidence suggests
a role of TLRs and opioid receptors in mediating gut microbiota dysbiosis and opioid addiction,
most likely through the immune system and inflammation. While there is some evidence
linking these receptors to addiction-related behaviours and brain function, further research is
needed to investigate these relationships.
These results outline a disruption of several metabolic pathways and production of
metabolites that are integral to microbe and host cross-communication and health. There are
several directions for further research, such as determining a) the functional potential of the
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microbes disrupted by opioid use, b) the significance of alterations in metabolites and pathways
in contributing to the cycle of addiction and, c) the mechanisms by which opioids facilitate an
enrichment or depletion of these strains. Addressing this gap may inform a better understanding
of opioid addiction pathology and the development of novel treatments.
There are several limitations to the current literature on opioid use and gut microbiota.
Firstly, the majority of studies utilised 16S rRNA sequencing to profile the commensal
microbiota. A limitation of 16S rRNA sequencing is that it cannot provide accurate species
level identification, nor can it provide accurate prediction of the functional potential of the
microbe’s genome (Ranjan et al., 2016, Johnson et al., 2019). As such, future research should
endeavour to utilise whole genome sequencing when profiling the microbiota. The research
also did not investigate the influence of sex on microbiota composition. Sex influences risk of
opioid misuse (Jamison et al., 2010, Serdarevic, Striley and Cottler, 2017), and also treatment
efficacy (Huhn, Berry and Dunn, 2019), which warrants investigation into how the gut
microbiota may also be effected by opioid use as consequence of gender. The unique effect of
different opioids should also be investigated in future studies. Morphine was the most
commonly investigated substance in the literature, but there has been an alarming rise in the
use of other opioids, including fentanyl, heroin, codeine, oxycodone, and other prescription
opioids. Studies should also examine the effect of opioid addiction medications, particularly
buprenorphine-naloxone (BNX) that is under investigated in the literature, and whether
successful treatment approaches result in restored microbiota balance. Future studies
investigating the effect of opioid use on the microbiota in models without comorbidity are
needed. Several of the studies included in this review included cohorts with comorbid diseases,
many of which are linked to dysbiosis of the commensal microbiota, making it difficult to
assign any results specifically to opioids. Finally, larger sample sizes are needed to give more
power and confidence to the results found.
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In conclusion, the present review has contributed to our understanding of how chronic
opioid use impacts the commensal gut microbiota, and has identified a number of mechanisms
through which this may influence brain function and cognition. The review has found that beta,
but not alpha, diversity is frequently impaired by opioid use. Finally, this review has identified
a panel of microbes that are frequently dysbiotic in the presence of opioids that could serve as
key candidates for future research into novel therapeutics.
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Chapter 4
Overall Discussion and Conclusions
4.1

Overview
An important feature of opioid addiction is cognition due to the role of cognitive

function in the various stages of the addiction cycle and treatment outcomes. The literature
demonstrates cognitive impairment in opioid use; however, results are inconclusive, and little
research has examined particularly sensitive populations, such as individuals commencing
rehabilitation program and pharmacological treatment, particularly in the Australian
population. While existing pharmacological treatments for opioid addiction (such as
methadone and buprenorphine-naloxone) have demonstrated efficacy, there are limitations
including an inability to improve cognitive impairments, or even further enhance cognitive
detriments in some individuals. Hence, there is a need for greater understanding of the effect
of opioid-based pharmacological treatments for opioid addiction on cognition, and to determine
whether other parameters interplay in cognitive outcomes, such as dose, duration of treatment,
length of stay in rehabilitation programs, etc. Furthermore, given the shortfalls of existing
pharmacological interventions, there is a need for novel treatment options. Research is
increasingly demonstrating a role for gut microbiota in host health, including brain
development and functioning; indeed, the gut microbiota engages in bidirectional
communication with the brain through various pathways, termed the microbiota-gut-brain axis.
However, individuals presenting with disorders with cognitive dysfunction, such as
schizophrenia, depression and anxiety also present with an altered gut microbiota. Furthermore,
the existing literature demonstrates alterations in microbiota in studies of addiction (e.g.
cocaine and alcohol), which also frequently present with impaired cognition. There is a body
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of literature that has investigated the effect of chronic opioid use on microbiota; however,
results appear inconclusive and further examination is required. Taken together, the literature
suggests a potential contribution of the microbiota to the cognitive impairment associated with
opioid addiction; however, further research is required. The present thesis aimed to 1) examine
cognition in an Australian population of people undergoing early stages of a rehabilitation
program (incorporating opioid-based pharmacological treatment) for opioid misuse; 2)
investigate the effects of opioid use on the gut microbiota, and; 3) examine the potential
functional outcomes of altered gut microbiota and metabolites with regards to opioid addiction
and cognition by investigating their role in key signalling pathways of the microbiota-gut-brain
axis.

4.1.1

Summary of Findings
In Chapter 2, the results demonstrated cognitive performance that ranged from a low

score in the bottom 19.85 ± 3.65th percentile of the general population for verbal learning
(HVLT-R) to a high score in the 52.85 ± 5.25th percentile of the general population for
processing speed (CF-Animals), demonstrating a level of cognitive dysfunction in this
population compared to the normative data. There was no significant difference in cognitive
performance between patients undergoing treatment with methadone compared to patients
undergoing treatment with buprenorphine-naloxone (BNX). Correlational analyses were
conducted to determine whether cognitive performance was correlated to various treatment
related factors (i.e., dosage (of either BNX or methadone), time since last treatment, life-time
length of pharmacological treatment, length of stay). Dose of methadone or BNX did not
influence cognitive performance. However, there was a strong and positive correlation between
time since last treatment and verbal learning performance (i.e., HVLT-R) in the BNX group,
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demonstrating the importance of considering the immediate effects of opioid treatment on
cognition as a potential confounder across studies in this field. In addition, the BNX group had
a positive correlation between lifetime history of treatment and non-verbal working memory
performance (i.e., WMS III-SS), suggesting a beneficial effect of BNX in this cognitive domain
(albeit, not significantly different to methadone). Neither of these relationships were replicated
in the methadone group. Non-treatment related demographics factors, such as age were
positively correlated to speed of processing (i.e., TMT-A) for each treatment and the whole
cohort, whereas BMI was negatively correlated to reasoning / problem-solving for the BNX
group only (refer to Chapter 2). Interestingly, there was a significant difference in years of
education and length of stay between the two groups, but neither of these factors significantly
affected neurocognitive performance in either group (with no significant correlations observed,
all p > .05). Furthermore, there was a longer length of stay in the BNX treatment group
compared to the methadone group; although length of stay did not correlate to improved
cognitive outcomes; this finding suggests greater adherence to the rehabilitation program (i.e.,
lower drop-out rates) with BNX treatment compared to methadone. Overall, these findings
demonstrate cognitive impairment in individuals undergoing rehabilitation for opioid
addiction; however, an important limitation was the lack of an opioid-free control group and
further, adequately powered, studies are needed. Nevertheless, the results of Chapter 2 suggest
several benefits of BNX over methadone, as well as a role for treatment-related parameters and
demographic factors in the cognitive functioning of patients. Given the importance of cognition
in the addiction cycle and treatment outcomes, further studies investigating the role of factors
that may influence a patient’s course of addiction, treatment response and recovery are
warranted.
The second major aim of the present thesis was to investigate the influence of opioids
on the gut microbiota. This was initially to be addressed using whole genome sequencing
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(WGS) of faecal samples obtained from participants in the cognitive study of Chapter 2;
however, due to COVID lockdown, data sets remained incomplete and WGS was no longer
feasible. Therefore, Chapter 3 addressed this gap in knowledge through a systematic literature
review of the existing literature. The review identified that beta diversity, but not alpha
diversity, was commonly altered as a result of chronic opioid use in both clinical and preclinical
studies; 22 microbes were repeatedly dysbiotic across clinical and preclinical research; several
microbiota metabolites and functional pathways (including those related to immune and
neurotransmitter signalling) were affected by opioids. Hence, the hypothesis that opioid
administration is associated with a dysbiosis of the microbiota and altered metabolites that
could have functional implications was supported. Further research is required to determine the
role (if any) of these dysbiotic strains in addiction, treatment and recovery; however, we
highlight for the first time, key candidate strains of interest for further research. Some of the
other key findings of the review included reports that Toll-Like receptors (TLR) were found to
have a central role in mediating dysbiosis, as knockout of the receptors prevented dysbiosis
from occurring (Banerjee et al., 2016), addiction medications could either recover or induce
dysbiosis (Banerjee et al., 2016, O'Sullivan et al., 2019), and reward learning was influenced
by chronic opioid use (a finding that was associated with microbiota dysbiosis (Zhang et al.,
2021b)). Overall, these findings indicate that dysbiosis of the gut microbiota occurs as a result
of chronic opioid use and highlight several pathways through which the gut microbiota could
be involved in the cycle of addiction. Dysbiosis of the gut microbiota may act as a negatively
reinforcing, interoceptive cue in chronic opioid use (Ren and Lotfipour, 2020).
The third aim was to outline the potential functional outcomes of an altered gut
microbiota and metabolites by investigating their role in key signalling pathways of the
microbiota-brain-gut (MGB) axis, which was also addressed in Chapter 3 through functional
data extracted from the existing literature. The final hypothesis was that opioid use would result
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in changes in the functional potential of the gut microbiota, and that these changes may involve
the MGB axis to potentially influence cognition. The systematic literature supported this
hypothesis, as dysbiosis of the microbiota by chronic opioid use led to disruption of various
metabolites involved in MGB axis signalling. For example, short chain fatty acids (SCFAs)
were reportedly disrupted by chronic opioid use, which is an important finding given the ability
of microbiota-derived SCFAs to influence neuronal and microglial function, learning and
memory (reviewed in Silva, Bernardi and Frozza (2020)). The results reported lends support to
the notion that dysbiosis of the gut microbiota may influence cognition and the cycle of
addiction, which could be relevant to the clinical observations reported in Chapter 2. The
following sections will further discuss the integration of the gut microbiota in the addiction
cycle and cognitive dysfunction during opioid use and potential mechanisms.

4.2

Gut Microbiota and the Immune System in OUD
The systematic literature review (Chapter 3) highlighted several mechanisms by which

the gut microbiota may influence cognition during opioid use via the immune system,
summarised in Figure 4.1. These include depletion of metabolic products (such as SCFA) that
help maintain gut homeostasis and epithelial integrity, and enrichment of metabolic products
(such as secondary bile acids and endotoxins) that disrupt this homeostasis and trigger the
immune system through activation of local receptors such as TLR (Table 4.1).
Depletion of SCFA and SCFA-producing bacteria as a result of chronic opioid
administration may contribute to increased permeability of the gastrointestinal tract. Research
has demonstrated that SCFAs improve gastrointestinal barrier function and can protect against
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•

GM may influence cognition
via mechanisms including:
• SCFA modulation of
BBB and GI integrity
• Modulation of NT
levels e.g. 5-HT,
catecholamine
production e.g. DA

•

Negatively reinforcing
internal cues:
• Altered GM
• GM indirectly through
other pathways e.g.
inflammation
• Increased endotoxins
• Increased GI
permeability

Figure 4.1 Proposed mechanisms through which dysbiosis of microbiota by chronic opioid
use may influence cognition and contribute to the cycle of addiction. Chronic opioid use
results in dysbiosis of the gut microbiota. This dysbiosis may contribute to several negative
outcomes, such as: a) altering gut homeostasis, b) impairing the gastrointestinal tract allowing
for translocation of microbes and products, c) altering the composition of the microbiota and
output of metabolic products. Such outcomes may trigger the immune system, one of the many
pathways of the MGB axis. Dysbiosis in the gut, an altered microbiota, translocation of
products may influence the brain by acting as interoceptive cues processed by structures such
as the insula. In the context of addiction, these cues may drive addiction-related behaviours as a
patients seeks to alleviate these issues. Alternatively, cognition may be influenced by some of
the many other products of the microbiota involved in other pathways of the MGB axis that
were reportedly altered in Chapter 3. For example, SCFAs, which were altered in chronic
opioid users, can influence BBB and GI barrier integrity. The GM also produces modulates or
produces precursors to many neurotransmitters such as serotonin and dopamine, which are
integral to brain function. Hence, the microbiota may also influence cognition through other
pathways such the neuroendocrine pathway. Linking to the role of cognition in the model of
addiction introduced in Chapter 1, these opioid induced alterations may altogether perpetuate
the cycle of opioid dependence. Abbreviations: GM=Gut Microbiota; BBB=Blood Brain
Barrier; SCFA=Short Chain Fatty Acids; DA=Dopamine; GI=Gastrointestinal.
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Table 4.1 Overview of the potential pathways through which the gut microbiota
may contribute to chronic opioid use and influence cognition and the potential molecules
involved, based on the findings of Chapter 3.
MGB Axis
Pathways
Immune Pathway

Neuroendocrine

Molecules Involved








Short Chain Fatty Acids (Butyrate)
Secondary Bile Acids
Endotoxins, Peptidoglycans and
Lipopolysaccharides
Microbes
Short Chain Fatty Acids (Butyrate)
Neurotransmitters
Amino Acids (Aromatic and
Branched Chain)

Potential Structures Involved





Toll-Like Receptors
Microglia
Vagus Nerve
Insula




Vagus Nerve
Gastrointestinal Tract

ethanol-induced disruption to the gut (Eamin et al., 2013). SCFAs increase barrier integrity
through upregulation of Claudin-1, a tight junction protein, in-vitro (Wang et al., 2012), thus
providing evidence of a mechanistic linking between SCFAs and gut barrier integrity. In the
present context, the opioid-induced depletion of SCFA and SCFA producing bacteria may lead
to disruption in gut barrier permeability; a symptom present in many disorders with impaired
cognition, including Parkinson’s disease (Clairembault et al., 2015), autism spectrum disorders
(de Magistris et al., 2010), schizophrenia (Julio-Pieper et al., 2014, Maes et al., 2019, Yuan et
al., 2019). Reports demonstrate that these disorders also have reported depletion of SCFA or
SCFA-producing bacteria (Aho et al., 2021, Huang et al., 2021, Wang et al., 2020, Zhang et
al., 2020). Together, these studies evidence a link between SCFAs, gut barrier permeability
and potentially, cognition. Similarly, clinical and preclinical studies have reported impaired
gut barrier integrity as a result of chronic alcohol consumption (Leclercq et al., 2014, Lee et
al., 2020, Yang et al., 2019). In the systematic review conducted in Chapter 3, one preclinical
study reported the depletion of SCFAs as a result of opioids (Touw et al., 2017), whereas the
majority of studies reported dysbiosis of SCFA-producing bacteria, such as Firmicutes. SCFAs
may contribute to cognitive impairments in OUD through their ability to act on the CNS, and
to maintain not only GI tract permeability, but also BBB permeability (discussed later); thus
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impacting brain function and perpetuating the cycle of addiction. Future studies should focus
on SCFAs when investigating the relationship between the gut microbiota and cognition in
OUD as a potential mechanism by which microbiota dysbiosis can cause a functional effect on
behavioural outcomes.
In addition to SCFAs, the studies investigated in Chapter 3 reported alterations in bile
acids (BA), though secondary BAs (SBA) were observed to both increase (Sindberg et al.,
2019) and decrease (Banerjee et al., 2016) as a result of chronic opioid use. Study design is
likely to explain these inconsistencies as Sindberg et al. (2019) utilised morphine injections in
a primate model, whereas Banerjee et al. (2016) utilised morphine pellet implants in a mice
model. Studies in alcohol, however, consistently report increases in SBA in addicted patients
(Bajaj, 2019, Kakiyama et al., 2014). Much like SCFAs, BAs influence gut barrier integrity
but do so through farnesoid X receptors (FXR). These receptors are located in various tissues
(e.g., intestinal tissues) and cells (e.g., CD4, CD8 immune cells), and are activated by primary
(PBA) and secondary BA (SBA), such as deoxycholic acid and ursodeoxycholic acid (Shaik,
Prasad and Narala, 2015, Tripathi et al., 2018). Upon activation by BAs, the receptors can
induce the production of antimicrobial agents, exert anti-inflammatory action and improve gut
barrier integrity (Gadaleta et al., 2011, Inagaki et al., 2006, Shaik et al., 2015). Therefore,
disruption of bacterial products (such as SCFAs and BAs) may contribute to the increased
permeability of the intestinal barrier observed in opioid addiction (Gicquelais et al., 2020, Kang
et al., 2017, Rueda-Ruzafa et al., 2020, Salavrakos et al., 2021).
Mechanisms by which disruption of these metabolites and increased permeability of the
gut epithelium may contribute to the cycle of addiction appear to converge on the immune
system, one of the major pathways of the microbiota-gut-brain (MGB) axis (Figure 4.2). As
noted previously, SCFAs and BAs regulate intestinal permeability and a depletion of these
metabolites may impair permeability and allow for translocation of microbes and endotoxins
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Figure 4.2 Proposed mechanisms through which opioid induced perturbations in the gut may influence the course of opioid addiction and
cognition through neuroinflammation. Chronic opioid use induces disruption of the gastrointestinal tract causing dysbiosis, and impaired barrier
integrity, facilitating translocation of microbes and endotoxins outside of the gut lumen. This translocation induces a neuroinflammatory response via CNS
components such as TLRs on microglia, which are involved in various cognitive processes. Thus, chronic neuroinflammation resulting from persistent
opioid use, impaired gut health and microbiota dysbiosis may potentially lead to impaired cognition, perpetuating the cycle of addiction.
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from the gut lumen to induce a systemic immune response. TLR are activated by bacterial
constituents (such as peptidoglycans (PGN) and lipopolysaccharides (LPS)), playing a vital
role in immune responses by activating transcription factors such as nuclear factor kappa B
(NF-κB) (Kawasaki and Kawai, 2014), and are evidently central to opioid addiction
(Hutchinson et al., 2007). For example, a preclinical study by Hutchinson et al. (2012) found
that either TLR4 knockout or antagonism by naloxone diminished oxycodone-induced place
preference (place preference is a model of drug-associated learning that also reflects the
development of addiction). In another study, Zhang et al. (2011) found TLR2 knockout
diminished the development of tolerance to morphine, and morphine-induced microglia
activation. Furthermore, research demonstrates a relationship between SCFAs (Huuskonen et
al., 2004), BAs (Jena et al., 2018), and microglia, outlining a more direct relationship by which
microbially derived metabolites may influence the CNS. Microglial activation is a component
of neuro-inflammation, which itself is common in opioid addiction (Bachtell et al., 2017,
Eidson et al., 2017). Neuro-inflammation in the context of opioid addiction contributes to the
development of tolerance via TLR4 activation (Wang et al., 2021). In studies of alcohol abuse,
neuro-inflammation is linked to poorer cognitive performance (Coppens et al., 2019), and in
preclinical opioid research, perinatal exposure to methadone increased TLR4 and microglial
activation in Sprague-Dawley pups and resulted in poorer cognitive function during adulthood
(Jantzie et al., 2020). These findings seem to not only place TLRs and neuroinflammation as a
potential component in the development of opioid addiction, but also to cognitive function. The
findings of Chapter 3 also suggested a role of TLRs in opioid-induced microbiota dysbiosis.
Knockout of these receptors prevented dysbiosis according to Banerjee et al. (2016) and Zhang
et al. (2019), and in another study by Meng et al. (2013), TLR2KO and TLR4KO prevented
morphine-induced bacterial translocation due to impaired barrier integrity. This converging
line of evidence suggests a role for TLRs in mediating dysbiosis of the gut microbiota, and in
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contributing to opioid addiction through microglial activation (Figure 4.2). Interestingly, the
results of Chapter 2 demonstrated an overweight phenotype in the cohort of participants tested,
based on the average BMI. Existing literature demonstrates that visceral adipose tissue is
associated with an upregulation of inflammatory markers (e.g., C-reactive protein, interleukin6), and is linked to impaired cognition function through this state of systemic inflammation
(Cannavale et al., 2021). This coincides with the finding of the present study that BMI
negatively correlated to cognitive performance. Importantly, taken together with the literature,
our findings of cognitive impairment in Chapter 2 could be related to microbiota dysbiosis and
systemic inflammation in this overweight population; however, further research is required to
confirm. This thesis highlights a necessity to investigate cause and effect relationships between
diet, adiposity, BMI, gut microbiota, inflammation and brain function and opioid use.

4.2.1

The Three Stage Model of Addiction, Neuro-inflammation and Interoception
As suggested above, the gut microbiota may contribute to the cycle of opioid addiction

through its role in neuro-inflammation, which serves as a negatively reinforcing interoceptive
cue (Figure 4.1). Interoception is the awareness of the internal state of the body (VerdejoGarcia, Clark and Dunn, 2012), and in the context of opioid use this may include sensitivity to
pain and other symptoms associated with tolerance and withdrawal. Inflammation and
increased intestinal permeability (Ganci et al., 2019), the enrichment of certain microbes that
upregulate intestinal permeability, enrichment of pathogenic bacteria and translocation of
microbes by chronic use of opioids may contribute to these internal sensations, as suggested
by Ren and Lotfipour (2020), thereby outlining a role of the microbiota in the three stage model
of addiction. Research suggests a central role for the insula, which processes internal cues, in
addiction. For example, one imaging study reported stronger connections between the insula
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and amygdala, and increased impulsivity in abstinent heroin users (Xie et al., 2011). Clinical
studies have reported that interoception is impaired in patients with OUD (Stewart et al., 2020),
and in abstinent males (Subay and Sonmez, 2021) compared to healthy controls. Furthermore,
damage to the insula interrupts addiction related behaviours, as outlined in a review by
Droutman, Read and Bechara (2015). More recent research even posits the gut microbiota as
directly exerting interoceptive cues (Critchley and Garfinkel, 2017, Mayer et al., 2014). The
current thesis proposes that disruption of the gut microbiota by chronic opioid use contributes
to the cycle of addiction, in-part by acting as, or contributing to negatively reinforcing
interoceptive cues. The systematic literature review of Chapter 3 suggested that neuroinflammation, induced by changes in the gut microbiota, may be one such cue that leads to
impaired cognition, thereby further potentiating harmful opioid use. Hence, through the
immune system, the gut microbiota may be involved in the withdrawal/negative affect stage
and preoccupation/anticipation stage of addiction in the context of chronic opioid use.

4.3

Gut Microbiota and Neurotransmitters in OUD
Disruption of the gut microbiota by chronic opioid use may also affect the brain through

the neuroendocrine pathway (Table 4.1). The microbiota and products such as SFCAs influence
the production of neurotransmitters and neuropeptides by enteroendocrine (EEC) and
enterochromaffin cells (ECC; refer to Chapter 1). This is evidenced through a study by Yano
et al. (2015), who reported decreased levels of serotonin in germ-free compared to control mice,
and another by Reigstad et al. (2015), who reported increased ECC production of serotonin in
mice colonised with a human microbiota, in comparison to GF mice. Furthermore, compared
to germ-free mice, humanised gut microbiota mice had increased levels of colonic Tph1 protein
and mRNA, which codes for tryptophan hydroxylase 1, the rate limiting enzyme of serotonin
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production in the gut (Reigstad et al., 2015). The same study also reported promotion of TPH1
transcription in a model of human ECCs following treatment with microbiota metabolites,
acetate (10-50mM) and lower concentrations (0.5mM and 1mM) of butyrate (Reigstad et al.,
2015). In the context of opioid use, there is evidence to suggest that opioids can increase
serotonin by inhibiting serotonin reuptake from the synaptic cleft (reviewed in Baldo and Rose
(2020)). In addition, compared to controls, chronic opioid users exhibit increased metabolism
of aromatic amino acids (Acharya et al., 2017), such as tyrosine and tryptophan that are
precursors to dopamine and serotonin, respectively. Furthermore, recent studies have
discovered the presence of tyrosine hydroxylase coding genes in microbes such as
Lactobacillus and Enterococcus (van Kessel et al., 2019), which were identified in Chapter 3
as dysbiotic in OUD through numerous studies (Hakimian et al., 2019, Meng et al., 2020,
Sharma et al., 2020). Therefore, microbiota metabolites could modulate precursors to
neurotransmitters that are implicated in brain function, including cognition (Jenkins et al.,
2016, Jongkees et al., 2015). As such, there is cause to further investigate the contribution of
the gut microbiota to cognitive impairment via neurotransmitter dysfunction in OUD.

4.4

Limitations and Future Directions
The present thesis identified cognitive dysfunction in individuals undergoing treatment

for chronic opioid addiction in an Australian rehabilitation setting, demonstrated imbalances
in the gut microbiota associated with opioid use and a potential role for the gut microbiota in
the mechanisms of cognitive dysfunction associated with opioid use. However, considering the
complexity of interactions between the microbiota-gut-brain axis, further research is needed to
understand the relevance of microbiota alterations in addiction and cognition in people with an
opioid use disorder. Future studies may examine the functional outcomes (i.e., effects on
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cognition, the addiction cycle, treatment response and recovery) of treatment with bacterial
supplements containing key species identified as dysbiotic in Chapter 3.
The findings of cognitive impairment in the population examined in Chapter 2 are
important; however, further studies could consider an increased sample size, collecting data
from multiple sites, examining participants longitudinally (i.e., at the start of treatment,
throughout the rehabilitation cycle and post-recovery), and utilise a demographically-matched
(e.g. age, sex, education) opioid-naïve control group. Chapter 2 was limited by the use of
correlational analyses and future research should include a more robust statistical approach.
Data sets containing self-reported parameters could be matched to medical records in order to
identify and manage some aspects of under/over-reporting. Future studies could also examine
the role of diet on cognitive parameters and the gut microbiota.
Despite uncovering important findings in the systematic literature review of Chapter 3,
research into the relationship between the gut microbiota and OUD have several limitations.
Firstly, studies frequently investigate cohorts presenting with comorbidity such as diabetes
(Barengolts et al., 2018), HIV (Sindberg et al., 2019) or bowel disorders (Sharma et al., 2020),
which themselves can result in microbiota dysbiosis. As such, it is hard to parse out the
individual contribution of chronic opioid use. The research frequently utilised 16 rRNA
sequencing and more robust whole genome sequencing (WGS) methods exist. 16S rRNA
sequencing gives has lower taxonomic resolution and is limited in providing species level
identification (Ranjan et al., 2016, Rizal et al., 2020). For example, a study by Ranjan et al.
(2016) reported that 16S rRNA sequencing detected 1800 species whereas WGS detected over
3000 when analysing the same sample. Due to the superior capacity for WGS to also describe
the genomic content of the microbiota, it may also provide functional data to give insight into
how the microbiota is causally related to disease. As such, future research into OUD should
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transition to WGS methods, enabling clearer understanding of potential impacts on brain
function and identify potential microbial targets for intervention.
There are several further research questions that succeeding studies could address,
including whether different opioids, such as morphine and codeine, or buprenorphine-naloxone
and methadone, uniquely affect the composition of the gut microbiota. As limited studies in
the present in the review of Chapter 3 suggest that medications for opioid use protect and
reverse dysbiosis, it would be important to examine the mechanisms by which this occurs to
enhance understanding of disease pathogenesis. The role of the treatment- and non-treatmentrelated parameters examined in Chapter 2 (such as length of treatment, dosage, BMI, age etc.)
on dysbiosis and cognitive performance during opioid use is another potential question for
future research.

4.5

Conclusions
In conclusion, the results of this thesis have demonstrated: a) cognitive impairment in

an Australian cohort undergoing early stages of treatment compared to a general population, b)
that opioid use impairs balance of the gut microbiota, and c) alterations to the microbiota by
opioid use involves key signalling pathways of the microbiota-gut-brain axis and thus may
influence brain functioning in individuals engaging in opioid use. Importantly, while there was
no significant difference between performance between participants treated with methadone
and BNX, results suggested BNX treatment may confer some benefits to cognitive functioning
over methadone treatment. The study also highlighted the importance of key treatment (time
since last dosage and lifetime history of treatment) and non-treatment (e.g., age and BMI)
related factors in cognitive performance of individuals undergoing opioid-assisted therapy in
early stages of rehabilitation treatment. Although further research is needed, these are key
147

findings that may inform the future of opioid-based pharmacological treatment. The result of
this thesis also demonstrates for the first time that opioid use caused dysbiosis of specific
microbes; and also disrupted key signalling pathways of the microbiota-gut-brain axis that may
be involved in cognition. These are significant results that support the potential to address not
just opioid misuse, but addiction more broadly, through targeting the microbiota. Overall, the
findings of this thesis will potentially inform future studies and the development of novel
therapies that could improve the lives of individuals with opioid addiction.
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